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 The work presented herein focuses on the study of novel metallodrugs (transition 
metal-based drugs) and their interaction with different biomolecules in the form of 
peptides, proteins, and cellular components via the use of ultra-high resolution Fourier 
Transform-Ion Cyclotron Resonance Mass Spectrometry (FT-ICR MS). 
 A LC-MS/MS methodology with a specialised peak picking algorithm was 
developed for automatic detection of metallated species and information of metallodrug-
binding was successfully elucidated.  An alternative digestion method for bottom-up 
study was examined, however, standard tryptic digestion showed better and more 
predictable results.  Further, the performance and efficiency of two distinct disulfide 
bond reduction methods: electrochemical reduction and radical-induced reduction were 
investigated.  Results showed that both techniques can effectively reduce disulfide 
bonds of model proteins, opening the protein structure and enhancing fragmentation 
efficiency during MS/MS experiments to different controllable degrees; Better protein 
identification and characterisation was therefore afforded using these methods. 
 A range of octahedral iridium-(III)-based anticancer complexes were found to be 
capable of generating toxic singlet oxygen upon irradiation of visible blue light (463 
nm), as evidenced by the production of a specific oxidised form of tryptophan, 3-
hydroxykynurenine, on a model peptide. Proteomics studies of human lung cancer cells 
(A549) revealed the photoactivation of the iridium complex caused selective oxidative 
damage to specific histidine residues in key cellular proteins; Heat shock protein 70 kDa 
and aldose reductase.   
 The overall effects of an osmium-based anticancer drug against A2780 human 
ovarian cancer cells and an iridium-based antimicrobial complex against Staphylococcus 
aureus were studied using quantitative nLC-FT-ICR-MS/MS.  The osmium-based 
anticancer complex affected the energy production pathway of the cancer cell, whereas 
the iridium-based antimicrobial complex was found to be capable of triggering a series 
of secondary responses from bacterial cells by inducing a vast amount of stress, 
including oxidative stress.   
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Chapter 1 Introduction  
1.1 Introduction of Mass Spectrometry 
 Mass spectrometry (MS) is an important analytical technique to study different 
molecules/species based on their masses.  For molecules/species to be detected, they 
need to be charged, and therefore, MS measures their mass-to-charge ratios (m/z). 
 The first study based on charged ions of a molecule was achieved by Sir J. J. 
Thompson on O2, N2, CO, CO2, and COCl2 in 1912.  MS since then has developed 
rapidly for the last 100 years and has become one of the most employed analytical 
techniques to study a wide range of research areas, including proteomics,1 
metabolomics,2 and petroleomics.3  The mass spectrometer consists of three major 
components, which are ionisation source, mass analyser, and detector.  An introduction 
of ionisation techniques, mass analysers and fragmentation methods will be presented in 
this chapter. 
 
1.1.1 Ionisation Techniques in Mass Spectrometry 
 As only charged gas state molecules can be detected in a mass spectrometer, it is 
important to ionise the molecules prior to detection.  In general, ionisation techniques 
can be grouped into two categories: hard ionisation and soft ionisation.  Hard ionisation 
refers to the ionisation processes being energetic, and fragments from the molecular ions 
are generated during the process.4  Fragments generated during the hard ionisation 
process are useful and can be used for structural elucidation of the analytes.  On the 
other hand, due to the generation of multiple fragments per molecular ion, hard 
ionisation is not the best option if a mixture of analytes is involved as it can introduce 
more challenges to the data analysis.  Soft ionisation, on the other hand, is milder as an 
ionisation technique compared to hard ionisation.  Mostly molecular ions are preserved 
during the ionisation process, avoiding the complication of data analysis if complex 
mixture of analytes is involved, and enabling the detection of more labile/fragile species. 
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1.1.1.1 Electron Impact/ Ionisation 
Electron impact/ ionisation (EI) is one of the hard ionisation techniques in MS 
and was introduced by Sir A. J. Dempster in 1918.5  In EI ionisation, electrons are 
generated from a heated filament which has electric current running through it.  
Electrons are accelerated to 70 eV (1 eV= 96.485 kJmol-1) and attracted towards an 
anode in an ionisation chamber (see Figure 1.1).  Vaporised/gaseous molecules are 
introduced from the inlet which is placed orthogonally to the heated filament and collide 
with the high energy electron beam to displace a bound electron from the analyte 
species, forming a radical cation (M+•). The overall EI ionisation process can be 
represented by the equation below: 
𝑀 + 𝑒−𝑓𝑎𝑠𝑡 → 𝑀
+• + 2𝑒−       [Eq. 1] 
M represents the gaseous molecule, e- fast represents the high energy electron, and M
+• 
represents the radical cation. 
The radical cations generated by the EI ionisation process are usually unstable 
and can undergo a series of dissociation reactions and generate more stabilised fragment 
ions. The extensive fragment ions generated can be used for structural elucidation of the 
analytes. Gas chromatography (GC) is commonly used to couple with EI ionisation to 
separate a mixture of analytes based on the difference in boiling points of the 
components in the mixture. EI ionisation is generally employed to volatile small 
molecules, thus suitable for clinical, pesticides, food/drug analysis, and other 
applications.6,7  The low volatility of most biomolecules is also a limiting factor in EI 
ionisation of biomolecules.  




Figure 1.1 Schematic representation of an electron ionisation source (Reproduced 
from De Hoffmann et al. 2007 with permission).4 
 
1.1.1.2 Chemical Ionisation 
 Chemical ionisation (CI) was introduced by Talrose in 19528 and further 
developed extensively by Munson and Field.9,10  Unlike EI ionisation, CI was designed 
to be a proton-transfer based ionisation source, instead of an electron based method.  
Highly reactive protonated gas/reagent gas is used to promote proton transfer from the 
reagent gas to the analyte species thus creating protonated ions as a result compounds 
with extremely low proton affinity are desired, i.e. extremely reactive Brønsted acids, 
meaning the capability of donating their extra proton effectively.  The formation of gas-
phase proton-transfer reagent gas is usually achieved through a glow discharge 
source/chamber.  A high energy spark converts methane (CH4) into an extremely 
reactive Lewis acid, sometimes referred as superacid, CH5
+, this process is represented 
by the equations below: 
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Step 1: CI reagent gas – methane (CH4) 
𝐶𝐻4 + 𝑒
− → 𝐶𝐻4
+• + 2𝑒−       [Eq. 2] 
𝐶𝐻4
+• + 𝐶𝐻4 → 𝐶𝐻5
+ + 𝐶𝐻3
•      [Eq. 3] 
Step 2: Proton transfer to analyte  
𝑀 + 𝐶𝐻5
+ → 𝑀𝐻+ + 𝐶𝐻4       [Eq. 4] 
Compared to EI ionisation, CI is a milder/softer ionisation technique, meaning 
CI causing less/little to no fragmentation to analyte species, generating predominantly 
MH+ ions.  However, CI only produce singly charged ions and is a gas phase reaction, 
imparting volatility requirements, limited its use to smaller analyte species only and 
preventing the study of larger biomolecules, such as peptides and proteins. 
 
1.1.1.3 Electrospray Ionisation 
Electrospray ionisation (ESI) was first introduced by John Fenn in 1985 who 
was later awarded a Nobel Prize in Chemistry in 2002. 
 
Figure 1.2 Schematic representation of an ESI ionisation source.  Droplets undergo 
desolvation, reach their Rayleigh limits, explode into smaller daughter droplets, 
eventually form naked charged ions. 
The analyte solution is first exposed to a high potential difference (typically 3-6 
kV) between the solution and the mass spectrometer inlet.  The charged analyte solution 
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is then passed through an ESI needle, mixed with an inert gas (often nitrogen) and form 
a Taylor cone, which then leads to the formation of highly charged droplets.  The 
charged droplets within the plume will be attracted towards the mass spectrometer inlet.  
As the charged droplets move towards to mass spectrometer inlet under the electric 
field, desolvation of the droplet occurs.  When the solvent surrounding the charges in the 
droplet evaporates, the number of charges in the droplet stays approximately constant, 
and the droplets eventually approach the Rayleigh limit of instability.11  When a droplet 
approaching its Rayleigh limit (see Eq. 5 below), it will fission into two or more species 
(daughter droplets), average of 13 daughter droplets per coulombic explosion was 
observed in some cases.12  The daughter droplets will continue to move towards the 
mass spectrometer inlet under the electric field like before and desolvation continues, 
until reaches their Rayleigh limits, and fission happens again.  The process repeats until 
eventually producing desolvated ions.  The desolvated ions can be manipulated and 
detected by the mass spectrometer and analysed.  
𝑧𝑟𝑒 = √8𝜋(𝜖𝛾𝑟3)        [Eq. 5] 
where zr represents the charge of electrospray droplet at Rayleigh limit, r is the radius of 
the electrospray droplet at Rayleigh limit, ε represents permittivity of free space, and γ is 
the surface tension of the solute. 
 ESI is a very soft ionisation technique, meaning the ionisation process only 
produces molecular ions of the analytes, [M+nH]n+ for positive ion mode or [M-nH]n- 
for negative ion mode, without inducing modifications or fragmentation to the analytes.  
The ability of producing multiply charged analyte species by ESI allows the feasibility 
of analysing large biomolecules, e.g. large proteins or deoxyribose nucleic acid (DNA), 
by increasing the charges on the molecules, lowering the resulting m/z ratio into a more 
achievable mass range for most mass spectrometers.  However, the mechanism of 
analyte charging, generating naked charged ion from solvated-analyte droplets is still 
under debate despite the fast development of MS in the past century.  Several models 
have been proposed;  the ion ejection model (IEM), the charged residue model (CRM), 
and the chain ejection model (CEM), are the most widely accepted models (Figure 
1.3).13 
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 Konermann et al. suggested that IEM is mainly applicable for small molecules, 
usually getting charged via proton/salt ions already present in the solution.  CRM is 
mainly employed by large molecules such as folded proteins and protein complexes 
which require a lot of energy to overcome the energy barrier for IEM to occur.  CEM is 
mainly applicable for unfolded proteins (disordered/extended chain structure), such as 
denatured biomolecules and polymers.  
 
Figure 1.3 Summary of the three most widely accepted models for ESI ion 
formation. From left to right, the Ion Ejection Model, the Charge Residue Model, 
and the Chain Ejection Model. (Reproduced from Konermann et al. 2013 with 
permission).13 
1.1.1.4 Nano Electrospray Ionisation 
Nano electrospray ionisation (nESI) has been developed to decrease sample 
consumption, while retaining a stable, reliable ion signal, i.e. higher sensitivity.  The 
orifice diameter of the nESI emitter (~0.5-5 µm) is much smaller than that of a standard 
ESI emitter (~10-100 µm).14  Therefore, the initial droplet size forming from nESI is 
inherently smaller than those forming from ESI.  Unlike ESI, nESI does not require a 
nebulising inert gas to achieve an effective ESI plume.  Due to the advantage of smaller 
initial droplet size, nESI emitters are generally placed a lot closer to the MS inlet 
compared to ESI as the process does not require as much time and space for the droplet 
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to expand and produce naked charged ions.  nESI typically uses much lower voltages to 
achieve effective ionisation (~500-1500 V) compared to ESI, which usually requires 
3000-6000 V.  As initial droplet size is smaller in nESI, lower source temperature can 
also be used for effective desolvation, providing a more suitable option for native MS of 
biomolecules, where excess heat from desolvation may cause denaturation.  nESI 
emitters are generally pulled borosilicate glass capillaries, which can be easily made 
using a heated capillary puller.  The shape of the capillaries (orifice diameter, tapering 
etc) can be optimised using different parameters, such as temperature of the heated 
filament, pulling velocity etc.  nESI emitters generally require optimisation depending 
on the sample nature or different solvent system.  A schematic representation of nESI is 
in Figure 1.4. 
 
Figure 1.4 Schematic representation of a nESI experiment setup. 
 
1.1.1.5 Matrix Assisted Laser Desorption Ionisation 
 Matrix assisted laser desorption ionisation (MALDI) was invented by Karas and 
Hillenkamp in 1985.15,16  Tanaka et al. later showed species over 100,000 m/z can be 
analysed by MALDI MS.17  MALDI uses a solid sample, which is ionised inside a 
chamber under vacuum.  Desorption and ionisation are the two most important steps in 
MALDI.  To achieve effective desorption in MALDI, matrices are required.  Matrices 
are composed of aromatic rings and a functional group that could provide a proton for 
the analyte (see examples of matrices below in Figure 1.5). 




Figure 1.5 Examples for 3 common matrices used in MALDI-MS. 
Analytes are first mixed effectively with matrix solution. Then the mixed sample 
is spotted onto a stainless steel MALDI target plate and allowed to dry.  When the 
sample is irradiated with laser, aromatic groups on the matrix molecules in the mixed 
sample will absorb a large amount of energy and deprotonate.  The released protons 
hopefully transfer to the neutral analyte molecules and ionise them. The analyte ions can 
then be manipulated and detected with a mass analyser.  Like ESI and nESI, MALDI is 
also a soft ionisation technique, meaning the ionisation process does not induce 
excessive fragmentation.  However, the excess laser energy can still lead to 
fragmentation of the analyte molecular ions in certain cases.  Usually only singly 
charged ions are generated from MALDI, which restricts the optimal detection from 
many instruments.  Low shot-to-shot reproducibility is also a main disadvantage 
compared to ESI and nESI.  A schematic representation of MALDI is shown below. 
(Figure 1.6). 
  




Figure 1.6 Schematic representation of MALDI ionisation process.  N2 laser 
activates and ionises matrix molecules into ions, which then undergo proton 
transfer with nearby analyte molecules, generating detectable analyte ions. 
 
1.1.2 Mass Analysers 
 After the generation of ions, they can be manipulated and transmitted down to 
the mass analyser using electric potential differences.  Ions are separated according to 
their corresponding m/z, and finally getting detected by the mass analyser.  There are 
many types of mass analysers, for brevity the following three are discussed, quadrupole, 
time-of-flight (ToF), and Fourier transform-ion cyclotron resonance (FT-ICR) MS.  
Mass accuracy and resolving power are often measured to evaluate the performance of a 
mass analyser. 
Mass accuracy measures the deviation of the measured m/z value of a certain 
analyte species from its theoretically calculated m/z.  Mass accuracy of a mass analyser 
is expressed in parts-per-million (ppm), and can be represented by the equation below: 
𝑀𝑎𝑠𝑠 𝐴𝑐𝑐𝑢𝑟𝑎𝑐𝑦 (𝑝𝑝𝑚) =  
(𝑀𝑒𝑎𝑠𝑢𝑟𝑒𝑑 𝑚/𝑧−𝑇ℎ𝑒𝑜𝑟𝑒𝑡𝑖𝑐𝑎𝑙 𝑚/𝑧)
𝑇ℎ𝑒𝑜𝑟𝑒𝑡𝑖𝑐𝑎𝑙 𝑚/𝑧
× 1,000,000 [Eq. 6] 
 Resolving power is a measure of how effectively a mass spectrometer can 
separate mass spectral peaks, the higher the resolving power, the more effective the 
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instrument is at resolving closely spaced peaks.  The resolving power of a mass 




      [Eq. 7] 
m represents the m/z of the peak in question, and Δm represents the width of the peak at 
half of its own height, i.e. its Full Width Half Maximum (FWHM). 
 
1.1.2.1 Quadrupoles Mass Analyser 
The quadrupole analyser was introduced by Paul and Steinwedel in 1953.18  A 
quadrupole is generally made of 4 circular rods which are placed parallel to each other.  
Ions travel along the z-axis and oscillate in the x and y planes.  The electric field 
generated by the direct current (DC), voltage (V), and radio frequency (RF) amplitude 
(V) on the 4 rods dictates the oscillation of the ions.  The 4 rods are electronically 
connected oppositely in pairs and the potential on the different pairs of rods are set to be 
completely out of phase, i.e. 180o and rapidly oscillate between the pairs of rods (see 
Figure 1.7).4  
 
Figure 1.7 Schematic representation of a quadrupole, 4 parallel rods are paired up 
electronically with the rod opposite to each other. 
Ions are accelerated down the electric gradient before entering the quadrupole, 
then retain the same velocity in the z axis during transmission. The trajectory stability of 
ions can be represented by the two equations below (Eq. 8 and Eq. 9).19 
  










         [Eq. 9] 
where a and q are directly proportional to V and A respectively, z represents charge of 
the ion, m represents mass of the ion, r0 is the field radius, and ω is the angular 
frequency.  
Only ions with stability at certain V and A values can be transmitted and 
detected, while all other unstable ions will be discharged, e.g. onto the rods, getting 
neutralised, i.e. cannot be detected.  The principle of ion stability in a quadrupole can be 
represented via the Mathieu stability diagram (see Figure 1.8).  
 
Figure 1.8 Mathieu Stability Diagram.  The intersection of the scan function with 
the stability diagram is directly related to the width of the spectral peak.  The areas 
under the curve is corresponding to the spectral peak area.  By altering the DC 
voltages (V) and RF frequency (f) applied to the quadrupole, the scan function 
changes, thus the regions of stability of each species changes. 
The resolving power of a quadrupole is approximately 2000 at 1000 m/z.4  
Quadrupole are well known for their robustness and reliability, therefore it has been 
employed in many different research fields.20  Quadrupoles can also be coupled to other 
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mass analysers, acting as an ion guide, mass filter, or a collision cell, which will be 
discussed further in section 1.1.3. 
 
1.1.2.2 Time-of-flight Mass Analyser 
 The principle of the time-of-flight instrument was first proposed by Stephens 
back in 1946.21  In ToF-MS, ions are accelerated through a flight tube by an electric 
field, induced by the potential difference between the electrodes and the extraction grid.  
In theory, all ions gain the same amount of kinetic energy, however different ions have 
different masses, therefore travel with different velocity and reach the detector at 
different times.  
 
Kinetic energy gained by ions: 
𝐾𝑖𝑛𝑒𝑡𝑖𝑐 𝑒𝑛𝑒𝑟𝑔𝑦 (𝐾𝐸) =
1
2
𝑚𝑣2 = 𝑞𝑉     [Eq. 10] 




         [Eq. 11] 
where m is the mass of the ion, v is the velocity of the ion, q = ze is the charge of the 
ion, and V is the electric potential generated from the potential difference between the 
electrodes and the extraction grid. 
 From equation 11, it shows that the ion velocity gained from the electric field is 
inversely proportional to the mass of the ion, i.e. heavier ions travel slower and vice 
versa.  In theory all ions get the same amount of kinetic energy, however the kinetic 
energy gained by each ion is slightly different to each other in reality, leading to 
spreading of ions drift time, even ions with the same m/z, causing peak broadening and 
low peak resolution.  To overcome this, multiple solutions have been developed.  The 
reflectron is a common technique employed to correct the difference in kinetic energy 
between ions.  The idea of reflectron in ToF was first introduced by Mamyrin et al. in 
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1973.22  The reflectron acts like a mirror which reflects the ions travelling from the 
ionisation source to the detector (seen Figure 1.9). 
 
Figure 1.9 Schematic representation of a reflectron ToF.  Ions with higher kinetic 
energy (solid sphere) travel faster and penetrate deeper into the reflectron while 
ions with lower kinetic energy (striped sphere) travel slower and penetrate not as 
deep into the reflectron compared to ions with higher kinetic energy.  The time 
difference of the ions spending in the reflectron corrects the spreading of kinetic 
energy, resulting in ions with the same m/z arriving the detector as the same time. 
 Ions with higher kinetic energy travel faster and penetrate deeper into the 
reflectron compared to ions with less kinetic energy, meaning ions with higher kinetic 
energy will spend a longer time in the reflectron than that of ions with lower kinetic 
energy. Therefore, ions with the same m/z, even with different initial kinetic energy after 
leaving the source can arrive the detector at the same time. With the application of 
reflectron in ToF-MS, the mass accuracy can be enhanced significantly from 200 ppm to 
10 ppm (depending on the calibration), and resolving power at 1000 m/z can be 
improved greatly from 5,000 to 20,000 or higher, resolving power of 100,000 can be 
achieved with some commercial setups now.4 
 
1.1.2.3 Fourier Transform-Ion Cyclotron Resonance Mass Analyser 
Fourier transform-ion cyclotron resonance (FT-ICR) mass analyser was first 
developed by Marshall and Comisarow in 1974.23,24  FT-ICR is well-known for its high 
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mass accuracy and resolving power, therefore it has been widely applied to many 
scientific researches.3,25–27  The major principles of FT-ICR will be discussed below. 
 
1.1.2.3.1 Cyclotron Motion 
 Cyclotron motion describes the ion motion in the presence of a magnetic field.  
The ICR cell is placed in the centre of a superconducting magnet which creates a 
homogenous magnetic field across the ICR cell.  When the ions are transmitted into the 
ICR cell, with the motion perpendicular to the existing magnetic field, the ions 
experience a force called the “Lorentz force” (see Figure 1.10).  The Lorentz force can 
be expressed by the equation below: 
𝐹 = 𝑞𝑣 × 𝐵         [Eq. 12] 
where F is the calculated Lorentz force experienced by the ion of interest, q is the charge 
of the ion, v is the velocity of the ion, and B is the magnetic field strength created by the 
superconducting magnet. 
 
Figure 1.10 Cyclotron motion of a positively charged ion (left) and a negatively 
charged ion (right) in the presence of magnetic field (B). (Reproduced from 
Marshall et al. 2002 with permission).28 
 With the effect from the Lorentz force experienced by the ions under the 
magnetic field, the ions orbit around the centre axis of the magnetic field (z-axis), and 
this motion is referred as the “cyclotron motion”.  The theoretical cyclotron frequency of 
an ion orbiting the centre of the magnetic field can be represented with the equation 
below: 
  






         [Eq. 13] 
where ωc is the cyclotron frequency of the ion in Hertz (Hz), q is the charge of the ion, B 
is the magnetic field strength, and m is the mass of the ion. 
In equation 13, it is shown that the cyclotron frequency of an ion is inversely 
proportional to the m/z of the ion, meaning higher m/z ions orbits the centre axis of the 
magnetic field at a lower frequency and vice versa.  Based on the difference in cyclotron 
frequencies of ions, ions with different m/z can be separated.  In theory, if cyclotron 
motion is the only contributing factor of the ion movement, the cyclotron frequency of 
an ion can be accurately measured, then by applying a calibration function, the 
measured cyclotron frequency can be expressed in m/z value.  However, to measure the 
cyclotron frequencies of the ions in the ICR cell, they must be trapped in the cell.  
1.1.2.3.2 Trapping Motion 
An ICR cell consists of four main components; trapping electrodes, excitation 
electrodes, detection electrodes, and an amplifier to amplify small magnitude signals up 
to a transmittable level (see Figure 1.11).29 
 
Figure 1.11 Schematic representation of a cubic ICR cell, showing the four major 
components; trapping electrodes, excitation electrodes, detection electrodes and an 
amplifier (Reproduced from Marshall et al. 1998 with permission).29 
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Without a trapping motion, ions will escape the FT-ICR cell along the z-axis. To 
avoid the ions from escaping the cell, a low electric potential of equal polarity can be 
applied to the two trapping electrodes of the cell, creating a “potential wall”.  When the 
energies of the ions are lower than the trapping voltages, the ions will be confined 
axially within the limits of the ICR cell, oscillating back and forth between the 
electrodes.  The trapping motion frequencies of ions are around several kHz and can be 




        [Eq. 14] 
where ωz is the trapping oscillating frequency induced by the trapping motion, q is the 
charge of the ion, Vtrap is the trapping potentials applied to the trapping electrodes, m is 
the mass of the ion, α is geometry factor of the ICR cell, and a is the plate-to-plate 
difference of the ICR cell. 
1.1.2.3.3 Magnetron Motion 
 Introducing an electric potential to the trapping plates can effectively confine the 
ions in the ICR cell, however, this also induces an electric field between the trapping 
plates.  The combination of the electric and magnetic forces on the ions produces a 
motion called the “magnetron motion”.  The magnetron motion acts along the same axis 
as the cyclotron motion but at a much lower frequency (<100 Hz), and can be 




         [Eq. 15] 
where ωm is the magnetron frequency in Hz, Vtrap is the trapping potentials applied to the 
trapping plates, α is the geometry factor of the ICR cell, a is the distance between the 
two trapping plates, and B is the magnetic field strength. 
 Since the cyclotron motion and magnetron motion are acting along the same 
axis, the frequency of the ion measured by an ICR cell, known as the “reduced cyclotron 
frequency” can be represented with the equation below: 
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𝜔𝑚𝑒𝑎𝑠𝑢𝑟𝑒𝑑 = 𝜔𝑐 − 𝜔𝑚       [Eq. 16] 
 The summarised ion motions (cyclotron motion, trapping motion, and magnetron 
motion) in a penning trap is shown below (see Figure 1.12)29 
 
Figure 1.12 Overall ion trajectory with the contribution of the cyclotron motion 
(vC), the trapping motion (vT), and the magnetron motion (vM) in a penning trap 
(Reproduced from Marshall et al. 1998 with permission).29 
 Motion of ions discussed above assumes an ideal vacuum, which is 
unachievable.  Damping of the three principle ion motions can be caused by ion-ion 
interactions and ion-background gas collision, with the cyclotron motion being 
particularly susceptible by these effects.  The damping of cyclotron motion is 
represented below in Figure 1.13, showing with collision of excessive background gas 
can lead to loss of ions from the ICR cell.  Therefore, the use of ultra-high vacuum 
conditions is crucial for measurements in FT-ICR MS. 
  




Figure 1.13 Representation of damping of an ion’s cyclotron motion with excessive 
background gas (pressure= 0.01 Torr). The ion is quickly lost from the ICR cell. 
(Reproduced from Amster et al. 1996 with permission).30 
1.1.2.3.4 Excitation and Detection in FT-ICR Cell 
When ions enter an ICR cell, the cyclotron radii of the ions are generally too 
small to generate a detectable signal and are incoherent between each other, i.e. ions 
with the same frequency are not travelling together thus net image current is zero.  A 
radio frequency (RF) can be applied to the two excitation electrodes (see Figure 1.11) to 
excite the ions.  The RF pulse applied on the excitation electrodes, thus resonant 
excitation, will transfer energy to the ions trapped in the ICR cell.  From equations 13-
16, it is shown that the cyclotron frequency of an ion is independent of its kinetic 
energy, therefore added energy from the RF pulse will allow the ions to travel faster and 
be excited to achieve a larger cyclotron radius, while the cyclotron frequency remain the 
same around the ICR cell.  The excitation event in an ICR cell is summarised in Figure 
1.14 below: 




Figure 1.14 Representation of an ion cloud being excited by a RF pulse, showing 
acceleration with a spiral trajectory (left) into a large, detectable orbit (right) 
(Reproduced from Marshall et al. 1998 with permission).29 
 To excite a wide range of frequencies, thus a wide m/z range, approaches of 
different excitation profiles have been proposed.  Frequency-sweep excitation (chirp) 
and stored waveform inverse Fourier transform (SWIFT) are the two most common 
approaches applied in FT-ICR MS.  The chirp was first introduced by Marshall in 
1974,24 which excites ions over a broad frequency sweep with a low excitation 
voltage.31  The chirp provides a wide frequency excitation in a straight forward fashion.  
However, it also exhibits excitation frequency profiles which are not completely 
uniform/flat in the region of interests, especially at the beginning and end of each pulse 
(horns) (see Figure 1.15c).  Over-excitation of ions in these regions influences the 
observed relative abundance of the ions with those frequencies.  To overcome the non-
uniform excitation profile by the chirp, a flat consistent excitation profile would be 
ideal.  SWIFT was proposed by Marshall later in 1985 to overcome the short-comings of 
chirp excitations.32  Instead of applying a frequency sweep to a wide frequency range, 
SWIFT predicts the perfect excitation profile (rectangular excitation) then uses an 
inverse Fourier transform to calculate the time domain signal required obtain a perfect 
rectangular excitation profile (see Figure 1.15d).  SWIFT can further be applied to 
isolate the m/z of interest in an ICR cell by over exciting the ions with undesired m/z by 
over-exciting them into larger orbits towards the electrodes in the ICR cells, getting 
neutralised and lost, while only the ions of interest are retained in the ICR cell (see 
Figure 1.15e).29 




Figure 1.15 Different excitation pulses used to excite ions into a larger orbit in an 
ICR cell and enable detection. a) and b) show rectangular pulses with different 
magnitudes and durations, c) represents a standard frequency-sweep excitation 
(chirp) used in most FT-ICR MS instruments, d) Stored Waveform Inverse 
Fourier Transform (SWIFT), and e) SWIFT isolation/ejection excitation profile 
(Reproduced from Marshall et al. 1998 with permission).29 
 Once ions are excited to a large enough orbit, and thus become detectable inside 
the ICR cell, the RF pulse applied to the excitation electrodes is turned off.  Then the 
ions continue to orbit around the ICR cell at the excited radius (Figure 1.14, right).  The 
excited ion packet induces a current when it orbits pass the detection plates. The induced 
current can be represented by the equation below:33 
  











         [Eq. 17] 
where Q is the induced image current, q is the charge of the ion, y is the position of the 
ion on the y-axis, and d is the distance between the ion and the detection plate. 
 From equation 17, it is worth to note that the induced image current is 
independent to the magnetic field strength created by the superconducting magnet. Also, 
the position of the ion in the y-axis (y) is directly proportional the induced image 
current, meaning the detected ion signal increases with the cyclotron post-excitation 
radius. Moreover, the detected signal is also proportional to the charge of the ion (q), as 
a result FT-ICR MS (like all other MS platforms) is more sensitive to multiply charged 
ions.  
 As described by equation 13, the cyclotron frequency is inversely proportional to 
the m/z ratio of the ion, therefore ions with lower m/z ratio orbit at higher speed inside 
the ICR cell.  The consequence of such fast-moving ions is the need to scan fast enough 
to detect the high frequency species.  Ions having higher frequency than the sampling 
rate will not be detected because they will make multiple revolution between each 
sample event.  As a result, the sampling rate has always needed to be set fast enough to 
keep up with the high frequency species.  To determine the sampling rate of the 
detection event, it is important to determine the highest frequency desired, also known 
as the “Nyquist frequency” and to avoid aliasing effect and obtain an accurate detected 
signal of the ions, the sampling rate has to be at least twice as fast as the Nyquist 
frequency. 
1.1.2.3.5 FT-ICR Cells 
The FT-ICR cell is the mass analyser in all FT-ICR MS based experiments.  
However, there are different designs of FT-ICR cells and each of them is optimised to 
provide more consistent performance or to overcome challenges during FT-ICR MS 
experiments. 
Cubic ICR cells were the first ever design for FT-ICR cells and have been used 
for many successful platforms over the years.34  A cubic ICR cell consists of two 
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excitation plates, two detection plates, and two trapping plates, all identical in 
dimensions, able to fit effectively between the poles of permanent magnets (Figure 
1.16a).  However, cubic ICR cells possess limited ion capacity and were not optimised 
for cylindrical bore superconducting magnets which are more used in recent decades.  
Different cell geometries have been investigated over the years for better performance 
and cylindrical geometry is found to enhance the sensitivity of the experiment. 
 
Figure 1.16 ICR cells configurations. E = excitation, D = detection, and T = 
trapping. a) Cubic ICR cell, b) Cylindrical ICR cell, c) Segmented end cap 
cylindrical ICR cell (Infinity Cell), d) Open cylindrical ICR cell, e) Open 
capacitively-coupled cylindrical ICR cell (Beu Cell), f) Dual cubic ICR cell, and g) 
“Matrix-shimmed” ICR cell. (Reproduced from Marshall et al. 1998 with 
permission).29 
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 Cylindrical ICR cells can be classified into two main groups, closed and open. 
They both share a similarity of consisting rounded, quarter-circumference 
excitation/detection plates. Closed cylindrical ICR cells (Figure 1.16, b and c) use 
circular end cap trapping electrodes, while open cylindrical ICR cells (Figure 1.16, d 
and e) use cylindrical trapping plates for confining ions inside the ICR cells for 
measurement. The rounded/curved shape of the detection electrodes allow a more 
prolonged interaction with the ion-packets when they are excited, thus improving 
sensitivity (Figure 1.17).  The end capped cylindrical ICR cells (Figure 1.16, b) suffer 
from more electric field permeation throughout the ICR cell and disruption of the ion 
orbit away from the centre of the ICR cell.35 
 
Figure 1.17 Ion packet interacts with the detection plate in the cubic ICR cell (left), 
less interaction when the ion packet is near the corners of the cubic cell while there 
is a more consistent interaction between the ion packet and the detection plate in 
the cylindrical ICR cell (right). 
 To overcome the problem caused by the end cap electrodes and a cylindrical cell 
of finite dimensions, Caravatti et al.35 introduced the idea of a closed-cylindrical cell 
with special resistively-coupled trapping electrodes wire which was designed to simulate 
an infinitely long trapping electrode (Infinity cell, Figure 1.16, c), to eliminate axial 
excitation and ejection events.  The capacitively-coupled open cylindrical cell (Beu cell, 
Figure 1.16, e) was introduced by Beu et al. in 1992.36 Beu cell was designed to 
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capacitively-couple the excitation and detection electrodes during ion excitation to 
eliminate z-axis ejection of ions along the magnetic field. 
1.1.2.3.6 Resolving Power of FT-ICR 








     [Eq. 18] 
where m is the m/z ratio of the ion, q is the charge is the ion, B is the magnetic field 
strength, and Taqn is the transient length. 
 From equation 18, the resolving power in a FT-ICR instrument is directly 
proportional to the magnetic field strength and the transient length.  Ions inside the ICR 
cell ideally can orbit indefinitely, i.e. transient lasting indefinitely.  However, practically 
ions experience ion-ion interactions and ion-background gas molecule collisions, 
disrupting the cyclotron frequency of the ions, and eventually ejected from the ICR cell, 
as discussed above.  Therefore, it is important the pressure in the region where the FT-
ICR cell sits remain as low as possible, ideally < 10-10 mbar.  The magnetic field 
strength created by the superconducting magnet also contributes linearly to the resolving 
power too, e.g. from a 12 T FT-ICR mass spectrometer to a 21 T FT-ICR mass 
spectrometer, the resolving power should be able to increase by a factor of 1.75, for ions 
with the same m/z. 
1.1.3 Tandem Mass Spectrometry 
Mass spectrometry is a powerful tool which provides an insight into the mass 
information of the analyte, but it only provides an overall picture of which component is 
present in the sample mixture.  Although elemental composition analysis, also known as 
fine structure, can be achieved by FT-ICR MS with the aid of its ultra-high resolution 
and high mass accuracy, it is often limited to small molecules. As the mass of the 
analyte increases, e.g. large biomolecules (proteins, DNA, etc.), fine structure analysis 
becomes extremely difficult as the mass increase can be a result of having different 
combinations of elements/components.  Techniques such as electron impact ionisation 
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(EI, discussed in section 1.1.1.1) induce fragmentation during the ionisation process, 
which has its own advantages and disadvantages.  With the fragments EI ionisation 
generates, structural information of the analyte can often be obtained, however, 
fragmentation during ionisation relies on pure/pre-separated samples to avoid overlap of 
fragment species from different analytes.  To overcome this, selected fragmentation of 
species can be applied.  Ions/precursors of interest can be selected/isolated by multipole 
mass selection (e.g. quadrupole mass selection/isolation), followed by applying different 
fragmentation techniques to yield important information from the fragment ions 
generated. This process is known as tandem mass spectrometry (MS/MS). 
 
Figure 1.18 Standard acquisition in an MS/MS experiment. a) full mass spectrum 
of all species presents in a sample, b) isolation spectrum of a selected ion using a 
quadrupole mass filter, and c) tandem mass spectrum of the selected ion achieved 
by applying fragmentation. Sample shown in the MS/MS example is myoglobin 
from equine heart (a 16.9 kDa protein). 
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A wide range of fragmentation techniques have been developed over the years. 
These fragmentation techniques can be classified into three categories: collision-based, 
photon-based, and electron-based.  Common fragmentation techniques include: 
collisionally activated dissociation/collisionally induced dissociation (CAD/CID),38 
infrared multiphoton dissociation (IRMPD),39 ultraviolet photodissociation (UVPD),40 
electron capture dissociation (ECD),41 electron induced dissociation (EID),42 electron 
detachment dissociation (EDD),43 electron transfer dissociation (ETD),44 etc.  In this 
section, three of the most common fragmentation methods, CAD, IRMPD, and ECD 
will be discussed.  Peptides and proteins are the main focus in this thesis, a 
nomenclature system, also known as the “Roepstorff nomenclature”, of fragments 
generating from a peptide/protein is summarised below (Figure 1.19):45 
 
Figure 1.19 Roepstorff nomenclature of fragments generated from 
peptides/proteins. 
1.1.3.1 Collisionally Activated Dissociation/Collisionally Induced Dissociation 
 Collisionally activated dissociation tandem mass spectrometry (CAD MS/MS) 
was first introduced by Jennings in 1968.38  An inert collision gas (often Ar, Ne, He, or 
N2) is involved in the fragmentation process.  Analyte ions are usually accelerated into a 
cloud of collision gas by using an opposite polarity voltage.  By forcing the ions of 
interest to collide with a cloud of neutral inert gas, it causes energy transfer and 
vibrationally heat up the ions of interest.  Often a single collision event is not enough to 
heat up the ions of interest to fragment, but each ion will undergo many collision events, 
which allows the build-up of energy within ions. Eventually, the deposited energy will 
Chapter 1 Introduction 
27 
 
exceed the bond strength of a bond within the analyte ion and it will dissociate and 
cause fragmentations.  In peptides and proteins, the fragmentation often occurs at the 
kinetically weakest amide bond of the ion and generate b and y ions (see Figure 1.20).46  
CAD MS/MS does not only generate b and y ions in the fragmentation process, but also 
produces the loss of a wide range of small neutral molecules, e.g. H2O, NH3, CO2 etc, 
which often increases the complexity of the mass spectrum and makes the data analysis 
more challenging. 
 
Figure 1.20 Diagram to show the breakage of the amide bond and generates b and 
y ions in CAD MS/MS.46 
 CAD MS/MS has been very effective at sequencing peptides, and has limited 
success at large peptides/small proteins, however, fragments are often only observed 
near the termini regions (N- and C- termini); rarely showing informative backbone 
coverage across the centre/the core regions of the protein.47  As discussed above, CAD 
MS/MS breaks the weakest bond available in the analyte ion with slow heating 
generated from many collision events (ergodic process), therefore labile 
interactions/modifications, such as non-covalent interactions or phosphorylation will be 
dissociated during the CAD MS/MS fragmentation process and lose their location 
information in the analyte before backbone fragmentation, due to their inherently weak 
bond strength compared to the peptide backbone.48 




Figure 1.21 Representation of peptide backbone showing the bonds cleaved in CAD 
MS/MS and the types of fragment generated (highlighted). 
1.1.3.2 Infrared Multiphoton Dissociation 
Infrared multiphoton dissociation tandem MS (IRMPD MS/MS) is also a 
common technique that been used to study biomolecules, such as peptides and 
proteins.49  Laser-based dissociation techniques have been shown to fragment the 
analyte ions effectively and achieving sequence information.  Carbon dioxide (CO2) 
laser is one the most common lasers used in IRMPD MS/MS because it is relatively 
cheap, continuous wave, and low maintenance.  CO2 laser emits photons at a wavelength 
of 10.6 µm which can readily be absorbed by many biomolecules and small molecules.39  
In an IRMPD MS/MS experiment,  a 10.6 µm continuous-wave CO2 laser is used to 
irradiate the trapped ions of interest (Figure 1.22), often in an ICR cell. Like CAD 
MS/MS, b and y ions are often generated upon IRMPD irradiation, often with losses of 
small neutral molecules, such as H2O and CO2 (Figure 1.23). 




Figure 1.22 Schematic drawing showing the IRMPD MS/MS in the ICR cell.  IR 
photons generated by the CO2 laser irradiates the precursor ion packet which 
travels on the z-axis and getting fragmented in the b and y ions. 
 
Figure 1.23 Representation of peptide backbone showing the bonds cleaved in 
IRMPD MS/MS and the types of fragment generated (highlighted). 
 Unlike CAD MS/MS, which fragments the analyte ions by colliding them with a 
cloud of stationary inert collision gas, IRMPD induces fragmentation by exciting the 
analyte ions into a higher energy state (excited state), overcoming the energy barrier of 
breaking the peptide backbone.  Each photon generated by the CO2 laser (~25 W) 
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provides only ~ 0.1 eV of energy, therefore, a dissociation event often requires an 
absorption of multiple photons.  The level of fragmentation of CAD MS/MS can be 
optimised by the amount of collision energy applied, i.e. the amount of voltage applied 
to accelerate ions into the cloud of collision gas, while IRMPD MS/MS can often be 
optimised by the laser power and the pulse length of irradiation. The higher the power 
and the longer the pulse length of irradiation, the more the energy transfer to the analyte 
ions.  Usually a careful balance between the laser power and pulse length of irradiation 
is required for an IRMPD MS/MS experiment, to avoid a complete dissociation of the 
analyte ions and a wide range of neutral losses. 
1.1.3.3 Electron Capture Dissociation 
Electron capture dissociation tandem MS (ECD MS/MS) was introduced by Zubarev et 
al. in 1998 to fragment multiply charged proteins.41  ECD is usually implemented in FT-
ICR MS while CAD and IRMPD are more commonly found implemented in other 
instruments as well.  ECD MS/MS was believed to be a non-ergodic process where the 
precursor ions isolated (often by a quadrupole) is dissociated before the energy is 
distributed in the ions.50  ECD is based on the emission of low energy electrons (~ 1 – 3 
eV) and interacts with the trapped precursor ion packet.  The electrons can be captured 
by positively charged analyte ions, creating a radical cation species (also known as the 
charge reduced species, CRS).  The CRS are often energetically unstable and dissociates 
into multiple fragmentation pathways (discuss below). ECD MS/MS often results in the 
breakage of the N-Cα bond on the peptide/protein backbone and generates c and z
• ions 
as major products (Figure 1.24, a).  Apart from c and z• ions, a and y ions can also be 
generated as minor products in ECD MS/MS (Figure 1.24, b). 
The electron capture event and the generation of the CRS can be represented by 
the equation below:51 
[𝑀 + 𝑛𝐻]𝑛+ + 𝑒−(~ 1 − 3 𝑒𝑉) → [𝑀 + 𝑛𝐻](𝑛−1)+•   [Eq. 19] 
where [M+nH]n+ is the molecular ion with n protons. 




Figure 1.24 Reaction scheme to show a) the generation of c and z• ions as major 
products, b) the generation of a and y ions as minor products in ECD MS/MS.46 
Chapter 1 Introduction 
32 
 
 Often a hollow cathode is implemented behind the ICR cell to generate the low 
energy electrons for ECD MS/MS.  In theory, ions are transmitted along the z-axis of 
the instrument, which unfortunately cannot interact with the cloud of electrons emitted 
by the hollow cathode as the cloud of electrons will be emitted as a “doughnut” shape, 
i.e. having no electron density in the middle, and most electron density form an outer 
circular ring (Figure 1.25).  ICR cell optimisation (e.g. side kick voltages, trap plate 
voltages) is often needed to manipulate the selected precursor ion packet into the most 
electron-dense region to maximise the interaction between the precursor ions and the 
low energy electrons, thus yield more effective fragmentation from ECD MS/MS. 
 
Figure 1.25 Schematic drawing showing the ECD MS/MS in the ICR cell (top).  
Low energy electrons are emitted from a hollow cathode. Ions are initially having 
no interaction with the cloud of electron, often cell parameters need to be optimised 
to drift the ion packet into the electron density to yield effective fragmentation, 
forming c and z ions. 
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 The mechanism of ECD MS/MS in peptides/proteins has been under debate for 
many years, and there are a few more commonly accepted mechanisms in the field, 
below are the two major reaction mechanisms proposed for ECD MS/MS. 
1.1.3.3.1 Cornell Mechanism 
 
Figure 1.26 The Cornell mechanism of ECD MS/MS. a) electron capture at the C-
terminal donor amine group, causing the breakage of N-Cα and generates c+ and z• 
ions, b) electron capture at the N-terminal donor amine group, causing the 
breakage of N-Cα and generate c fragment and z+• ions.51 
The Cornell Mechanism was first introduced by McLafferty et al. in 1998.41  
Electron capture event occurs at a positively charged site (protonated N-terminus or on 
the side chains of basic amino acids (lysine (Lys), arginine (Arg), histidine (His))), 
forming a hypervalent N-species, inducing a hydrogen transfer to the amide oxygen, 
resulting in the formation of a carbon-centred aminoketyl radical. The breakage of the 
N-Cα bond is then induced by being physically next to an unstable radical species and 
forming c- and z- ions (Figure 1.26).51 
1.1.3.3.2 Utah-Washington Mechanism 
 The Utah-Washington mechanism is a combination of two previously proposed 
mechanisms: the Utah mechanism by Simons et al. in 2003,52 and the Washington 
mechanism by Turecek et al. in 2005.53  The two mechanisms focused on different steps 
in the dissociation event: Utah focused on the electron capture steps while Washington 
focused on the subsequent dissociation.  However, the two mechanisms proposed the 
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formation of same products (c- and z•- fragments from the breakage of the N-Cα bond in 
peptides/proteins).  Therefore, the two mechanisms are combined and known as the 
Utah-Washington mechanism and is the most accepted mechanism for ECD MS/MS 
(Figure 1.27). 
 
Figure 1.27 The Utah-Washington mechanism of ECD MS/MS, showing the two 
possible pathways to dissociate the N-Cα bond after the electron capture event. 




Figure 1.28 Representation of peptide backbone showing the bonds cleaved in ECD 
MS/MS and the types of fragment generated (highlighted). 
1.1.3.3.3 ECD of Disulfide Bonds 
 In CAD and IRMPD MS/MS, fragmentation effectiveness is often hindered by 
the number of disulfide bonds present in the sample, the number of possible cleavages 
along the peptide/protein backbone is less with CAD and IRMPD MS/MS as often the 
disulfide bonded region is protecting the backbone to be cleaved (Figure 1.29). While 
ECD MS/MS is shown to preferentially cleave disulfide bonds in a sample and allow 
more possible cleavages.54 
 
Figure 1.29 Example of the effectiveness of different fragmentation techniques on a 
disulfide bonded sample. a) limited possible cleavages (shown in red) with CAD or 
IRMPD MS/MS due to the protected region by the disulfide bond in the sequence 
(shown in orange), b) disulfide bond is getting cleaved by ECD, opening the 
protected region, c) more possible cleavages (shown in green) without the 
protection by the disulfide bond. Example was shown using Lys8 – vasopressin. 




Figure 1.30 Reaction scheme showing the capture of electron to the a disulfide 
bond and results in S-S bond cleavage.46 
1.1.3.3.4 Fragmentation Efficiency of ECD MS/MS 





     [Eq. 20] 
where ƩAfragments is the sum of the peak areas of fragment ions after MS/MS and 
ƩAprecursor is the sum of peak areas of precursor ions before MS/MS. 
 The fragmentation efficiency of ECD MS/MS is ~ 20% for a doubly charged 
peptide ion, however, a lot higher fragmentation efficiency, as high as 80% efficiency 
can be achieved with some highly charged protein ions.55  To enhance the efficiency of 
ECD MS/MS in some highly structured proteins, often IRMPD is applied to aid the 
fragmentation process.  The IRMPD applied is often tuned to induce as minimal 
fragmentation effect as possible, it is mainly to warm up the precursor ions, activating 
the structure to become more accessible by electrons during ECD MS/MS.  This process 
is known as infrared-activated electron capture dissociation tandem mass spectrometry 
(IR-ECD MS/MS).56,57  
1.1.3.3.5 Applications of ECD MS/MS 
 ECD MS/MS has shown very promising fragmentation in top-down analysis, 
produces extensive cleavages along the protein backbone.41 Therefore, ECD MS/MS is 
an excellent tool to perform de novo sequencing, i.e. to determine the peptide/protein 
sequence by using fragment ion information from a tandem mass spectrum.  De novo 
sequencing is extremely useful if an unknown sample is involved, by determining the 
identity of the unknown component in the sample, often expanding the knowledge to the 
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study significantly.  Multiple fragmentation techniques can be applied to a sample to 
maximise the backbone cleavages, by combining them together, they contribute hugely 
into the de novo sequencing of biomolecules. 
 CAD and IRMPD MS/MS cleave the peptide/protein backbone by slowly 
heating up the precursor ions by energy transfer via multiple collision events and 
exciting the ions to their excited states using IR photons, respectively, which are ergodic 
processes. Therefore, these fragmentation techniques tend to lose the important labile 
post-translational modifications (PTMs), such as phosphorylation58 and glycosylation59, 
and non-covalent interactions60 before breaking the peptide/protein backbone.  This 
restricts the possibility of studying the modification/binding locations on biomolecules.  
While ECD MS/MS is a radical-based process, which is capable to preserve these labile 
modifications and non-covalent interactions, allowing the precise modified locations or 
binding sites to be derived. 
1.1.3.3.6 Other Electron-Based Dissociation Techniques 
Apart from ECD, there are other electron-based dissociation techniques (ExD) 
that are employed to work on different sample natures.  Electron transfer dissociation 
(ETD) was introduced by Syka et al. in 2004.44  Unlike ECD using a cathode to generate 
electrons, ETD relies on a carrier molecule/ion to transfer the electron to the analyte 
species.  Negative anion radicals, generated by a negative chemical ionisation (nCI) 
source (Figure 1.31), and the precursor ions are transferred to the ion trap MS where 
ion-ion interaction takes place.  During the ion-ion interaction process, electrons could 
transfer to the analyte species and create CRS, and eventually produce c- and z- 
fragment ions like ECD. 
Instead of using low energy electrons to induce fragmentation like in ECD, 
higher energy electrons can also be used.  Electrons with energy (~ 6-10 eV) can interact 
with the precursor ions, not only generating the c- and z- ions, but also special side chain 
losses from amino acid residues.  Some of these side chain losses are diagnostic, with 
observation of these side chain losses, revealing the presence of specific residues.  The 
use of electrons within this energy range is referred as hot-ECD (hECD).51 
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ECD has proved to be a very effective fragmentation technique, however its use 
is limited to multiply charged precursor ions.  Small molecules are often observed as 
singly charged ions, and they cannot be fragmented with ECD due to the charge 
limitation.  Therefore, electron induced dissociation (EID) was developed by Budnik 
et.al. in 2000.61  Electrons within the energy range of ~ 9-25 eV can be used to perform 
EID, generating fragment ions similar to those from EI. 
ECD is an exclusively positive-mode technique, meaning it cannot be used on 
negatively charged ions. Therefore, electron detachment dissociation (EDD) was 
introduced by Budnik and Zubarev et al. in 2001.62  Electrons within energy range of 
15-20 eV could induce electron detachment on the negative target analyte, therefore, 
EDD is a common fragmentation technique to study DNA/ribonucleic acid (RNA) 
systems.43 
1.1.4 A Hybrid FT-ICR Mass Spectrometer  
 All MS data presented in this thesis are acquired using a Bruker 12 T SolariX 
FT-ICR MS (Figure 1.31).  Ions can be generated using ESI, nESI, or MALDI in a 
SolariX FT-ICR MS. Ions produced by ESI and nESI are orthogonally induced via a 
glass capillary into the vacuum region and accelerated towards to ion funnels by 
applying an equal polarity voltage to the incoming ions onto the deflector plate, this 
allows neutral molecules to be taken away from the vacuum while ions are transmitted 
further down into the FT-ICR MS.  Ions produced using MALDI are generated under 
vacuum under a MALDI extraction lens, which accelerates the ions through the 
deflector plate and getting repelled towards the ion funnels. 
Ions can be focused using ion funnels set at the entrance of the multipoles.  
Focused ions are then transmitted into the Qh (quadrupole-hexapole) region of the MS.  
The quadrupole can be used for transmission purpose only or for mass filtering if 
MS/MS experiment is required.  Ions of interest can be selected in the quadrupole 
(discussed in section 1.1.2.1) and transmitted further down into the hexapole collision 
cell for ion accumulation.  CAD or ETD can also be performed in the hexapole collision 
cell if needed. 
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Ions are then transferred into the ICR cell through a hexapole transfer optic.  
Once the ions entered the ICR cell, which sits in a homogenous magnetic field region 
within the superconducting magnet, by applying a voltage to the front trap plate (equal 
polarity to the ions) and a similar magnitude to the back trap plate (usually 0.35-1 V for 
infinity cell), ions can be confined in the ICR cell. 
Once ions are confined in an ICR cell, IRMPD and ExD can be performed if 
necessary. The hollow cathode and CO2 laser are located at the opposite side of the ion 
entrance in the ICR cell with lenses positioned between the cathode and the ICR cell.  
All ions can be excited and detected inside the ICR cell as discussed above. 
 
Figure 1.31 Schematic representation of the Bruker 12T SolariX mass 
spectrometer. Courtesy of Bruker Daltonics, Bremen, Germany. 
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1.2 Introduction to Anti-Cancer Metallodrugs 
1.2.1 Cancer 
 Uncontrolled/excessive cell proliferation (growth and replication) is detrimental 
to individual cell function and is a common fundamental symptom of cancer.  Growth 
and replication are often carefully controlled and limited by cellular proteins and 
biological mechanisms to sustain a healthy condition of a living organism.  Inside the 
nucleus of cells, there are DNA coding information for cell growth and replication.  
Cancer often arises because of damages/mutations/coding problems within the DNA of 
the cell itself.  Apart from chemical-induced damages (e.g. host exposure to 
carcinogens), radiation-induced damage (e.g. prolonged exposure to UV light),63 or 
problem arising during DNA replication/transcription.64  Damage to the host cell DNA 
can lead to an accelerated proliferation rate, demanding more resources from the host 
organism and creating asymmetric cell growth in that area/region of the host, often 
forming a large collection of cancerous cells, also known as a tumour (Figure 1.32)  
Cancerous cells can often migrate from the creation area/primary site to other areas of 
the host, creating secondary tumours, a process known as metastasis (Figure 1.33).  The 
spread of cancerous cells can put a huge amount of pressure/strain on biological 
processes, both from resources competition between the healthy cells and cancerous 
cells due to the accelerated proliferation and physical stresses from the cancerous cells/ 
the tumour to the cells nearby, disrupting normal cell functions.  Unfortunately, the 
probability of developing cancer is unavoidable as there is always a possibility of DNA 
damage whenever a cell undergoes division, creating damaged DNA.65  The 
development of cancer and its biological causes have been the subject of detailed studies 
over many years.66 




Figure 1.32 Normal and uncontrolled cell growth after DNA damage.  An 
unbalanced growth of cancerous cells (tumour) is competing for resources and 
putting stress on normal cells nearby. Reproduced from 
http://www.mun.ca/biology/desmid/brian/BIOL2060/BIOL2060-24/24_01.jpg, 
accessed 20/05/2019. 




Figure 1.33 Primary tumour migrates from the creation point to distant sites by the 
circulatory system, forming a secondary tumour. Reproduced from 
http://www.mun.ca/biology/desmid/brian/BIOL2060/BIOL2060-24/24_04.jpg, 
accessed 20/05/2019. 
1.2.2 Cancer Treatment 
 Different forms of treatment have been developed and chemotherapy is one of 
the most commonly used approaches to attack cancer cells.  An ideal cancer treatment 
would have high selectivity towards cancerous cells and extremely low or no selectivity 
towards normal healthy cells.67  Potencies of anti-cancer drugs can be measured by their 
half-maximal inhibitory concentration (IC50) values. The IC50 value is a measure of how 
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much drug is needed to inhibit a biological process by half, thus the smaller the IC50 
value of a drug, the more potent the drug is for that process.68 These treatments are often 
designed to target DNA as cancer is intrinsically DNA-related.  Different DNA-
targeting reagents have been designed over years, and are usually small molecule-
based,64 macromolecule-based,69 and transition metal-based.70,71 
 Ideally, these metal-based anti-cancer complexes target cancerous DNA within 
the cancer cells and induce a chemical change, often via covalent bonding, crosslinking, 
or deformation of structure.72,73  The “modified” DNA will no longer able to be 
interpreted by transcription proteins; preventing the cancerous cell from further 
replicating, and eventually leading to cell death.  However, because of the highly similar 
cell content and cell function between the normal host cell and cancerous cells, a perfect 
anti-cancer drug is extremely difficult to design, i.e. high selectivity to cancerous cells 
and non-potent to normal cells.  Metal-based anti-cancer drugs are the most commonly 
used chemotherapy. Over the past few decades, platinum based anti-cancer drugs made 
a huge impact on cancer therapy.  The first Food and Drug Administration (FDA) 
approved platinum-based drug was cisplatin (cis-diaminodichlorido-platinum, CDDP).74  
Cisplatin is shown to attack cancerous DNA by physically binding to the exposed 
guanine nucleobases, causing DNA deformation, disrupting its tertiary structure, 
preventing transcription and proliferation and leading to cell death (Figure 1.34). 
  




Figure 1.34 Mechanism of action of cisplatin on DNA.  Cisplatin is activated inside 
the host’s body and bind to the DNA, which causing DNA deformation and fail to 
be transcribed. 
 Cisplatin has shown its effectiveness against various different cancers, especially 
testicular, cervical, and bladder cancers. Cisplatin has high potency, having IC50 of 1.2 
µM (± 0.2) against A2780 ovarian cancer cells.75  However extensive use of cisplatin on 
cancer patients has results in an array of side effects, including liver failure, kidney 
damage, dramatic weight loss etc.76  With the widespread cisplatin treatment, cisplatin 
resistant strains of cancer have also been observed unfortunately. Due to the self -
protection system of the host, any “toxic” treatments, including the use of cisplatin to 
attack cancer cells, the host will attempt to adapt and remove the active complexes from 
the host body, lowering the effectiveness of the drug.  To overcome this, other platinum-
based anti-cancer drugs, including oxaliplatin, carboplatin etc. have been developed.74 
 
Figure 1.35 Examples of the traditional platinum-based anti-cancer drugs. 
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 Studying the mechanism of action (MoA) of a drug is important because it 
allows researchers to understand better how the drug works and provides insight into 
future drug development.  For instance, cisplatin has shown that one of more of the 
chlorido ligands in the structure can be displaced while inside the host body/cell, 
producing a more active aqua-Pt(II) complex (Cl- displaced by H2O), and this aqua/di-
aqua species can bind to cancerous DNA to cause structural deformation, preventing 
further cell growth and replication of cancerous cells, inducing cell death (Figure 
1.34).77,78  However, even cisplatin has proven to be very effective against certain 
cancers, only a very small percentage of the cisplatin actually makes its way to the DNA 
target in the cancerous cells.79,80  There are far more species/molecules in the host body 
which could bind to cisplatin before the drug makes its way to the DNA target despite 
the guanine nitrogen N7 presenting a very reactive ligands for cisplatin.  Studies have 
shown 90-98% of cisplatin actually becomes protein-bound with just one day of 
injection.79,80  It is believed that the undesired side effects experienced by patients are 
due to the off-target interactions.  Therefore, the design of novel metallodrugs which 
have fewer side effects and can overcome resistance to current platinum drugs has 
attracted significant attention. 
1.2.3 Novel Metallodrugs 
 In-depth studies of novel metallodrugs have been a popular research topic, 
including rational drug design and further development of the existing drugs. Below are 
a series of new metallodrugs, categorised according to their structure and functions, each 
with the own target/mechanism of action, designed to cause either cell death or 
prevention of them from proliferation. 
1.2.3.1 Piano-Stool Complexes 
 In older metallodrug designs, multiple binding sites are often found on 
complexes by losing/displacing the different initial ligands in the complex structure, 
making the study of mechanism of action difficult.  Therefore, slight alternations in drug 
designs have been proposed to restrict the loss of multiple ligands by introducing large 
chelating ligands (using more than one pair of electrons to bind to the metal ion centre).  
These large chelating ligands can be π-bonded aromatic rings as in arenes and 
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cyclopentadienyls (Figure 1.36), which bind to the metal ion centre in an η6 or η5 
fashion, i.e. using 6 electrons and 5 electrons, respectively. 
 
Figure 1.36 Examples of piano-stool complexes.  a) [(η6-bip)Os(en)Cl]PF6,43 b) [(η6-
p-cym)Os(NMe2-azpy)I]PF6,81 and c) [(η5-Cp*)Ir(2-(CHO-phenyl)-(CHO-
pyridine))Cl].60,82 
 With using an η5 or η6-arene and a bidentate ligand, it was shown to greatly 
enhance activity at the monodentate site, making these piano-stool complexes excellent 
candidates to be active anti-cancer agents.83–85  A recent study by Sadler and co-workers 
has reported an osmium-based piano-stool complex which was 49-times more potent 
than cisplatin towards A2780 ovarian cancer cells.81  Though piano-stool complexes can 
be more active than cisplatin towards target cancerous cells, they are still often 
transformed in vivo from the initial complex to a more active species.  This process 
often is involved in intelligent drug design: by introducing a relatively inactive species 
(pro-drug) to the host and only transform/activated when the pro-drug has travelled to 
the target area, this can be induced by a change in micro-environment (e.g. pH, 
temperature etc.).70,73 
 Selectivity is a key factor of drug design and development, to reduce side effects 
to patients during treatment and more importantly to enhance the drug selectivity 
towards the correct target and this can be achieved by employing functionalised ligands.  
The functionalised ligands are designed to bind to specific targets, leading to 
accumulation of drugs in certain areas, not only enhancing the selectivity of the drug but 
also make the drug more potent.86 
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1.2.3.2 Photoactivatable Complexes and Photosensitisers 
 As discussed above, high selectivity is a key factor for anti-cancer drug 
development.  Therefore, a variety of metallodrugs have been designed to be activated 
by external stimulus.  Apart from changes in micro-environment (pH and temperature), 
light can also be used as a trigger to transform the pro-drug to its active form.26,87  
Ideally, before light irradiation/activation, the pro-drug should possess little to no 
cytotoxicity (the quality of being toxic to cells), which means the pro-drug will not 
bind/interact with any molecule or cells, and upon irradiation, the pro-drug can be 
activated directly to have high cytotoxicity near/in the cancer cells/tumour.  Obviously, 
if a pro-drug can be activated by light at all wavelengths, it will easily be activated 
before the drug reaching the desired target, losing the aim of being an effective 
photoactivatable drug.  Therefore, it is important for a pro-drug only be activated at a 
specific wavelength, so that it can transform into its active form, creating an effective 
and controlled chemotherapy treatment, also known as photoactivated chemotherapy 
(PACT).87  These photoactivatable complexes are usually activated by higher-energy 
wavelengths (e.g. blue visible light, ~ 450-490 nm), resulting in metal-ligand bond 
cleavages, leaving a metal complex of different geometry (e.g. octahedral to square 
planar),26 which is often more active than the pro-drug, allowing it to attack the 
cancerous cells more effectively. 
 
Figure 1.37 Light penetration measurements in millimetres through human tissue.  
(Reproduced from Wang et al. with permission).88 
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One of the leading PACT agents, trans, trans, trans-[Pt(N3)2(OH)2(pyridine)2], 
also known as FM190, has shown to be an effective PACT agent by having very low 
cytotoxicity of > 212.3 µM in the dark towards OE19 (oesophageal cancer) and upon 
irradiation with 420 nm, IC50 of FM190 is 8.4 µM.
89  Wootton et al. have recently 
shown FM190 is able to perform a dual attack on peptide amino acids, either by 
oxidation (induced by hydroxyl radicals), or platination (binding to the platinum centre), 
or both.26 
 
Figure 1.38 Examples of PACT agents.  a) trans, trans, trans-
[Pt(N3)2(OH)2(pyridine)2],26 b) a methylated cis-[Rh(phen)2Cl2]Cl,90 and c) 
[Pt(terpy)Cl]Cl.91 
Photosensitisers (photodynamic therapy agents, PDT agents) for cancer therapy 
usually function by absorbing a convenient wavelength of light, often a good 
transmission/penetration through skin/tissue, but at the same time cannot be harmful to 
the host, e.g. visible light.  Energy absorbed is then transferred to nearby cellular 
components, e.g. mitochondria, where oxygen molecules can be excited to become 
singlet oxygen (1O2).  Singlet oxygen a type of reactive oxygen species (ROS) and is a 
much more reactive form of molecular oxygen.  Having a high concentration of singlet 
oxygen within the target cell, can induce oxidative stress leading to cell 
death/apoptosis.92  Zhang et al. have shown that the photosensitiser, 
[Ir(phenylquinoline)2(diketonate)2], also known as PZ6, being extremely potent towards 
A549 lung cancer cell line upon irradiation.93  PZ6 is non-toxic in the dark, having IC50 
value > 100 µM, while upon blue light (465 nm) irradiation, PZ6 is extremely potent 
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(IC50 = 0.23 µM).  PZ6 has shown the ability to generate singlet oxygen upon 
irradiation, supporting by the observation of 3-hydroxykynurenine when a model 
peptide (Lys3-Bombesin) was treated with PZ6.94  Zhang et al. have also shown specific 
oxidative attack on specific cellular proteins when A549 are treated with PZ6.93 
 
Figure 1.39 Examples of PDT agents.  a) [Ir(phenylquinoline)2(diketonate)2],93 b) 
Zinc phthalocyanine,95 and c) [(2-(phenyl)(pyridine))2Ir(2-(pyridine)2)]Cl.96 
1.3 Introduction to Proteomics 
 The terms “proteome” and “proteomics” were first introduced by Marc Wilkins 
in 1995.97 Proteome is a combination of the words “protein” and “genome”, meaning the 
total protein complement of a genome. Proteomics is the study of the proteome (a large 
scale of proteins generated by living organisms). 
 MS is a common analytical technique used in proteomics.  By measuring the 
masses of proteins and peptides, information such as protein identities, modifications, 
including PTMs, or even structures of proteins can be revealed.  Proteomics is important 
because it provides an insight into the mechanisms and inner working of cells,98 which 
helps us to understand how the anti-cancer drugs are affecting cells, e.g. change in 
protein quantity or even a change in protein content.  Proteomics research is hugely 
involved in various areas: biomarker discovery for diseases,99 protein 
quantification,100,101 PTMs study on proteome scale,93,102 monitoring the interactions of 
potential drugs with proteins in living organisms.93,103  MS-based proteomics can 
generally be classified into three different types: top-down proteomics, bottom-up 
proteomics, and middle-down proteomics, which will be discussed more below. 
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1.3.1 Top-Down Proteomics 
 Top-down proteomics is a study of intact proteins, it preserves the most 
information of the initial biological system, including intact protein sequence 
information and chemical modifications (e.g. PTMs) as less chemical alternation is 
needed to be induced to analyse the samples, which could disrupt labile modifications 
and interactions in-between or within proteins.  Therefore, top-down proteomics 
analysis is normally used for structural analysis, PTM, and de novo sequencing studies 
of proteins.57,101,104,105  Because of the huge number of proteins present in a proteomics 
sample and the possible fragments generated by tandem mass spectrometry (MS/MS), 
the performance requirement of the MS instrument is also the highest.  Ultra-high 
resolving power is generally needed because of the overlapping distributions of peaks 
throughout the whole mass range which reduces the type of MS which can be used.  FT-
ICR MS and orbitrap MS are the two most common MS system required to fulfil the 
extremely high demand in resolving power.  However, such instruments are very 
expensive and therefore top-down proteomics is not as commonly seen as the other two 
types of proteomics studies; bottom-up proteomics and middle-down proteomics. 
1.3.2 Bottom-Up Proteomics 
 Bottom-up proteomics is the study of digested proteins. Proteases such as 
trypsin, pepsin, and chymotrypsin are used to break large proteins into manageable size 
peptides.  Trypsin cleaves proteins at the carboxyl side of arginine and lysine while 
pepsin and chymotrypsin prefers cleaving at amino acids containing an aromatic ring, 
such as phenylalanine, tryptophan, and tyrosine.106  Proteins that underwent digestion 
will be chemically cut into smaller pieces of peptides.  However, before protein 
digestion takes place, chemicals such as reducing and alkylating reagents are commonly 
mixed with the protein samples to break disulfide bonds and help achieve a better result 
of digestion.107  Dithiothreitol (DTT), and tris(2-carboxyethyl)phosphine (TCEP) are 
commonly used to reduce the disulfide bonds, opening the protein structure.  Disulfide 
bonds will be reformed from the free thiols on cysteine residues though, therefore, 
alkylating reagents, such as iodoacetamide (IAA), N-ethylmaleimide (NEM) are used to 
react with the free thiols and block them off, preventing disulfide bonds from reforming.  
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After the reduction and alkylation steps, there should not be any cross-linking by 
disulfide bonds left in proteins, and the proteases can perform a more effective 
digestion.  Digestion is often carried out under 37 oC, to simulate the body temperature, 
therefore, incubation is needed.  Digestion time is often around 12-16 hours, with the 
long incubation time, PTMs such as oxidation and deamidation are often artificially 
induced into the sample and fragile PTMs could be lost during the process too.  The 
bottom-up approach is relatively easier than top-down analysis because peptides 
produced from the digestion steps are easier to be detected and analysed compared to 
large proteins. 
1.3.3 Middle-Down Proteomics 
 Middle-down proteomics is an approach which sits between top-down and 
bottom-up.  Intact proteins are still being digested, but the product peptides are larger.  
Proteins are usually enzymatically digested with a shorter incubation time compared to 
the bottom-up approach (2-4 hours), this helps to reduce the loss of fragile modifications 
(e.g. PTMs) and decrease the amount of modification artificially induced into the 
samples.  Middle-down digestion can also be achieved by employing different proteases.  
Endoproteinase Lys-C is often used because in theory it only cleaves proteins on the C-
terminal side of lysine residues, meaning, there will be fewer cleavages, yielding larger 
product peptides.  With middle-down, peptides after the digestion process usually 
contain more possible protonation sites, which favours MS/MS processes (discussed 
above). 
 
1.3.4 Proteomics Using Liquid Chromatography-Mass Spectrometry 
 One of the advantages of MS-based experiments is the ability to use hyphenated 
techniques, e.g. liquid chromatography (LC), gas chromatography (GC), etc.  A single 
proteomic study involves thousands and thousands of proteins, making direct analysis 
extremely difficult.  By coupling a separation technique, e.g. LC prior to the MS 
analysis, also known as LC-MS, it “simplifies” the complexity of the protein/peptide 
mixtures, making the analysis more feasible. 




Figure 1.40 Schematic drawing of a LC-MS experiment. 
 Different valves can be used in a LC set-up. Figure 1.40 shows a common set up 
using a 6-port valve.  Each position is connected to the two neighbouring positions (e.g. 
position 1 connecting with positions 2 and 6) via two different channels (indicated with 
blue and red lines).  Only one channel can be used at a time while the other will be 
blocked.  While using a 20 µL sample loop, usually a maximum of 18 µL of sample, are 
drawn by the solvent pump into the sample loop through the blue channel (1→2→5→6).  
After that, the rotor rotates (activating the red channel), water from position 4 pushes the 
sample into the trapping column (shown in green) via silica-fused capillary (shown in 
orange), 4→5→2→3.  The trapping column has a wider dimension, allowing a higher 
flow rate to shorten the trapping time.  Packing material (same as those using in the 
analytical column, e.g. C18) that packed in a trapping column which can also act as a 
desalting purpose by retaining the proteins/peptides and washing away the salt content.  
Trapping columns are generally very short (~ 2-3 cm) to avoid peak broadening due to 
separation at this stage.  Depending on the sample, if there is a lot of salt present, 
samples can be trapped in the trapping column and washed for a longer time.  Salts are 
washed out from position 1 of valve W via the red channel.  After trapping, the valve 
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rotors of valve S and valve W rotate and activate the blue channel, allowing a shorter 
distance for the solvent mixture to push the sample through the trapping column into the 
analytical column (~ 20 cm) via a silica-fused capillary. The complex proteomics 
sample can be separated in the analytical column according to the type of column is 
employed (e.g. reversed phase (RP) column separates the mixture mainly due to the 
hydrophobicity of the species).  Separated samples can then finally be ionised by 
ESI/nESI and sprayed towards the MS inlet via an emitter.  Ions generated can also be 
manipulated and fragmented with the techniques mentioned above. 
1.3.5 Separation Methods in LC-MS 
Stationary and mobile phases are two important elements in LC. Stationary 
phase is an immobile material inside a column, which analyte molecules adsorbed onto 
according to their properties, e.g. hydrophobicity, charge etc.  Mobile phase refers to the 
solvents flow through the stationary phase of the column, eluting the analytes by 
reducing the interaction between the adsorbed molecules and the stationary phase. 
1.3.5.1 Separation According to Hydrophobicity of Analytes 
 Hydrophobicity values of different amino acids have been compiled by Fauchere 
in 1983 (Table 1.1).108  The hydrophobicity values range from -1.01 (arginine, most 
hydrophilic) to 2.25 (tryptophan, most hydrophobic).  Proteins and peptides are made up 
with a combination of different amino acids, therefore, each protein and peptide will 
have a different hydrophobicity value, which can be calculated by the sum of the 
corresponding hydrophobicity values of each amino acid involved.108 
Side Chain of Hydrophobicity (πr) Side Chain of Hydrophobicity (πr) 
Alanine (A) 0.31 Leucine (L) 1.70 
Arginine (R) -1.01 Lysine (K) -0.99 
Asparagine (N) -0.60 Methionine (M) 1.23 
Aspartic Acid (D) -0.77 Phenylalanine (F) 1.79 
Cysteine (C) 1.54 Proline (P) 0.72 
Glutamine (Q) -0.22 Serine (S) -0.04 
Glutamic Acid (E) -0.64 Threonine (T) 0.26 
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Glycine (G) 0 Tryptophan (W) 2.25 
Histidine (H) 0.13 Tyrosine (Y) 0.96 
Isoleucine (I) 1.80 Valine (V) 1.22 
Table 1.1 Hydrophobicity values of the 20 naturally occurring amino acids.108 
 Reversed phase (RP) chromatography is the most common separation method 
used in LC studies based on the hydrophobicity of the proteins/peptides.  The stationary 
phase of RP columns consists of alkyl chains (C4/C8/C18). Different length of the alkyl 
chains favours the separation of different samples.  The shorter alkyl chains are more 
suitable for larger analytes, therefore C4 RP columns are commonly used for intact 
protein separation, while longer alkyl chains are more suitable for smaller analytes, so 
C18 RP columns are commonly used for small molecule/peptide separation.  The alkyl 
chains on an RP column provide a hydrophobic interaction surface for the incoming 
analyte molecules.  Hydrophobic analytes are adsorbed strongly on the surface while the 
hydrophilic analytes travel through the column without much adsorption (Figure 1.41, 
a).  The red spheres represent highly hydrophobic analyte molecules, which adsorbed 
strongly with the stationary phase of the RP column and eluted at last, while the green 
spheres represent less hydrophobic analytes and adsorbed less strongly to the alkyl 
chains.  The blue spheres represent the least hydrophobic analyte molecules, which 
shows no interaction with the stationary phase and eluted immediately without any 
retention. The more hydrophobic an analyte is, the higher concentration of organic 
solvent is required to elute the analyte from the column.  RP is the most suitable LC 
column to couple with MS as the buffers used in RP are salt-free, therefore the LC-MS 
studies presented in this thesis were carried out using RP columns. 




Figure 1.41 Schematic drawing of the two most commonly employed separation 
techniques based on the hydrophobicity of analytes. a) reversed phase column, b) 
hydrophilic interaction liquid chromatography column. 
 Hydrophilic interaction liquid chromatography (HILIC) is an alternative method 
to separate analyte molecules according to their hydrophobicity.  One of the most 
commonly used stationary phases in HILIC contains zwitterionic sulfobetaine ligands.  
Unlike RP columns, the stationary phase of HILIC column provides a hydrophilic 
interaction surface for the incoming analyte molecules.  Hydrophilic analytes adsorb 
strongly to the stationary phase while hydrophobic analyte molecules show little to no 
interaction to the zwitterionic stationary phase.  Therefore, hydrophilic molecules are 
retained for longer on the column and eluted with a later retention time.  HILIC has been 
shown to achieve a better separation on protein/peptide containing fragile PTMs, such as 
phospho- or glyco- peptides or proteins.109,110  Acetonitrile is often used as a loading 
buffer for HILIC separation while water/methanol is used as an elution buffer due to 
their high polarity.  Ammonium formate (HCOONH4) buffer solution is often used to 
control the pH to maintain the analytes at a single ionic form for better separation. 
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1.3.5.2 Separation According to Charge of Analytes 
 Under different solvent conditions, proteins and peptides present with different 
charge according to the pH of the environment.  Proteins and peptides can be separated 
based on the polarity in LC. 
 Strong cation exchange (SCX) relies on the interaction between the analytes and 
the negatively charged stationary phase (sulfonate, -SO3
-) on the column.  Positively 
charged species interact and retain on the column more effectively while negatively 
charged species and neutral molecules travel through the column with little to no 
interaction and elute before the positive species.  The higher the magnitude of positive 
charge, the stronger the electrostatic interaction and the longer it takes for the species to 
be eluted from the column.  Strong anion exchange (SAX) is the opposite to SCX, by 
having positively charged stationary phase (quaternary amine, -N(CH3)3
+), negatively 
charged species are attracted and retained on the column while the positively charged 
species and neutral molecules are eluted with limited retention.  Extremely high salt 
concentration, e.g. 350 mM of KCl or NaCl, is often used to elute the analytes from the 
column, therefore extra purification steps are needed prior to MS analysis.  The 
schematic representations of SCX and SAX are shown below (Figure 1.42). 
  




Figure 1.42 Schematic representations of a) strong cation exchange (SCX), and b) 
strong anion exchange (SAX). 
 
1.3.6 Quantification in Proteomics 
 A main aspect of proteomics research is to identify and quantify the 
concentration ratios of protein expressed in cells or tissues in different states/conditions, 
e.g. healthy cell and cancerous cells.111  The ability to quantify the concentrations/levels 
of proteins prevent provides an extra dimension of information and this information can 
often be critical to drug development studies.112  There are different quantification 
methods developed by researchers and the three most commonly used techniques are 
discussed below. 
1.3.6.1 Quantification Using Label-Free Analysis 
 Label-free quantification is one of the most commonly used methods to achieve 
a relative abundance of proteins/peptides between two samples.  Assumptions are taken 
that under well controlled conditions with sufficient data redundancy, identical peptides 
across different LC-MS/MS experiments can be compared directly.112  Sample 
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preparation and data acquisition usually have to be performed very carefully to minimise 
external influences on the observed protein quantity.  Samples to be compared and 
quantified should be prepared using identical reagents by a single researcher, to 
eliminate variations induced be different bottles of reagents and human errors.  All 
analysis should also be performed in a single batch to minimise intra-analysis variations.  
To quantify proteins/peptides across samples, an internal control is usually added to the 
sample at known concentrations to evaluate the reproducibility of the experiment.112  
There are different ways to perform a label-free quantification experiment, and they are 
discussed below. 
Ion Abundance 
Number of ions can be reflected by the height or the peak area of a peak at a particular 
m/z.  Quantity can be measured by directly comparing the ratio of ion abundances 
between two identical peaks (Figure 1.43, i).  However, variations induced by difference 
in experimental set up will not be accounted for. 
Ion Abundance Ratios 
Quantification can also be performed by measuring the ratio between the extracted ion 
chromatogram (EIC) peak area of the ion of interest and the EIC peak area of the 
internal control in sample 1 and compare to that in sample 2, variations induced between 
the experimental set up or ionisation efficiency can be accounted for (Figure 1.43, ii).  
The assumption is made that the internal control is not reacting with the sample and the 
detection of one does not affect detection of the other and vice versa. 




Figure 1.43 Representations of the two label-free quantification methods.  i) Ion 
abundance, ii) Ion abundance ratio.  (A) is the peak of interest in sample 1, (B) is 
the peak of interest in sample 2, and (IS) is the internal standard induced in the 
corresponding sample. 
Spectral Counting 
The spectral count for a protein/peptide refers to the number of MS/MS spectra acquired 
during a LC-MS/MS experiment.  Assumption being the more abundant a 
protein/peptide is, the more likely it is will be selected for MS/MS analysis.  However, 
this method is also limited to runs where no active inclusion can be used for the MS/MS, 
meaning MS/MS of the same peptide will be acquired repeatedly, lowering the possible 
number of protein identifications.  The total spectral count should be the same across 




         [Eq. 21] 
where s is the spectral count for species n, 1 and 2 are the sample numbers and i is the ith 
species. 
1.3.6.2 Quantification Using iTRAQ/TMT 
 Isobaric tag for relative and absolute quantification (iTRAQ) and tandem mass 
tag (TMT) have also been commonly used for quantification in proteomics studies.111  
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Quantification is performed by tagging a cleavable molecule in each sample onto the 
peptides. The chemical tag is made up by three components, a reporter group, a balance 
group, and an amine specific peptide reactive group (N-hydroxysuccinimide, NHS) 
(Figure 1.44, a).  Different reporter groups with varying isotope encoding, usually with a 
substitution of a 12C for a 13C (neutromer),113,114 are paired up with their corresponding 
balancing groups, therefore, all of the tags will be exactly the same in mass (Figure 1.44, 
b).  These chemical tags attach to all peptides in a protein digest via free amines at the 
peptide N-terminus and on the side chain of lysine residues.115  Different samples with 
different tags induced into will be mixed together. The peptide of interest from all 
samples will appear as a single species because masses of all tags are the same.  Upon 
fragmentation, e.g. CAD, the reporter group will be dissociated, and their intensities is 
directly proportional to the peptide quantities (Figure 1.44, c). 
 
Figure 1.44 Quantification using iTRAQ/TMT. a) Schematic representing of the 
reaction between the chemical tag and peptides (iTRAQ and TMT), b) chemical 
structures of iTRAQ reporter groups, c) quantification of peptides by reporter 
groups upon CAD MS/MS.111 
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1.3.6.3 Quantification Using SILAC 
 Addition of stable isotope amino acids into the cell culture (SILAC) is another 
method that commonly used for quantification studies in proteomics.  The principle of 
SILAC is based on inducing stable isotope labelled amino acids, such as 13C or 15N-
labelled arginine or lysine, into the entire proteome during protein metabolism.116  Two 
populations of cells are grown in two different culture media, “light” or “heavy”, where 
the light medium contains amino acids with natural isotopes, and the heavy medium 
contains amino acids with heavy isotopes.  Proteins from cells grown in the heavy 
medium will be made of amino acids with heavy isotopes after enough cell division 
events (also known as the adaption stage),117 while the proteins from cells grown in the 
light medium will have natural amino acids. After the adaption stage, in the 
experimental stage, cells from the two culture mediums will be mixed together, the 
mixture will often be analysed by LC-MS/MS, the quantification of SILAC is based on 
calculating the ratio of the heavy isotope labelled peptide and the natural isotope 
peptide.  The change in signal intensities from the light sample to heavy sample allow a 
quantitative comparison of their relative abundance in the mixture to be made.  This 
method assumes the kinetic isotope effect has a negligible impact on the biological 
system. 
1.4 Post-Translational Modifications 
 Post-translational modifications (PTMs) refer to the modification of proteins 
after the protein biosynthesis event.  PTMs are covalently bound and induced 
enzymatically.118  Proteins are synthesised by ribosomes using translation messenger 
RNA (mRNA) into polypeptides, which may then undergo a modification process and 
form mature protein.  PTMs play a fundamental role in regulating the folding of proteins 
and other important cellular functions, such as cell signalling,119 regulating cell 
proliferation,120 etc.  There are many different types of PTMs, and PTM discovery is a 
very popular research topic.  One of most commonly studied PTMs, oxidation, by MS is 
discussed below. 
  




 Oxidation is a commonly observed PTM in proteins; consisting of the inclusion 
of oxygen at groups into species and often induced by reactive oxygen species (ROS).  
Cancer cells are known to produce more ROS compared to healthy cells,121 however, an 
excessive amount of ROS can lead to a redox imbalance (oxidative stress), triggering 
cell death/apoptosis. Therefore, by studying the location of the oxidation site, this may 
provide more information about the cancer cells, and developing more effective anti-
cancer agents, ideally by selectively inducing oxidative stress in cancerous cells only.93  
However, in order to target the possible oxidised species by MS and include these 
oxidation modifications in the database searches, it is important to study oxidation of 
different amino acids first as not all amino acids can be oxidised.  It is worth noting that 
some oxidised products can be used to diagnose the source of oxidation/the identity of 
the ROS.  With the aid of the ultra-high mass accuracy by FT-ICR, the mass difference 
causing by oxidation can be measured and help localise the oxidation site in the 
protein/peptide. 
 Generation of ROS is a commonly used technique in PACT and PDT (discussed 
above) to induce oxidative stress near or in cancerous cells.  ROS is often produced after 
the energy transfer from the excited sensitiser to molecular oxygen (Figure 1.45), to 
yield singlet oxygen (1O2) and oxidises the surrounding targets (e.g. proteins).
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Figure 1.45 Schematic representation of protein modifications in the mitochondria 
(Mito) and endoplasmic reticulum (ER) by a photoactivable Ir(III) complex. 
(Reproduced from Nam et al. 2016 with permission).96 




(1)  Aebersold, R.; Mann, M. Mass Spectrometry-Based Proteomics. Nature 2003, 
422 (6928), 198–207. 
(2)  Dettmer, K., Aronov, P.A., Hammock, B. D. Mass Spectrometry-Based 
Metabolomics. Mass Spectrom. Rev. 2007, 26, 51–78. 
(3)  Rodgers, R.P., Marshall, A. G. Petroleomics: Advanced Characterization of 
Petroleum-Derived Materials by Fourier Transform Ion Cyclotron Resonance 
Mass Spectrometry (FT-ICR MS); 2007, Springer, New York, USA. 
(4)  Hoffmann, E. De; Stroobant, V. Mass Spectrometry Principles and Applications 
Third Edition; 2007, Wiley, Hoboken, New Jersey, USA. 
(5)  Dempster, A. J. A New Method of Positive Ray Analysis. Phys. Rev. 1918, 11, 
316–325. 
(6)  Dongre, V. G.; Karmuse, P. P.; Nimbalkar, M. M.; Singh, D.; Kumar, A. 
Application of GC-EI-MS for the Identification and Investigation of Positional 
Isomer in Primaquine, an Antimalarial Drug. J. Pharm. Biomed. Anal. 2005, 39 
(1–2), 111–116. 
(7)  Li, Y.; Zhang, H.; Hu, J.; Xue, F.; Li, Y.; Sun, C. A GC-EI-MS-MS Method for 
Simultaneous Determination of Seven Adulterants in Slimming Functional Foods. 
J. Chromatogr. Sci. 2012, 50 (10), 928–933. 
(8)  Nikolaev, E. Victor Talrose: An Appreciation. J. Mass Spectrom. 1998, 33 (6), 
499–501. 
(9)  Munson, M. S. B.; Field, F. H. Chemical Ionization Mass Spectrometry. I. 
General Introduction. J. Am. Chem. Soc. 1966, 88 (12), 2621–2630. 
(10)  Field, F. H.; Munson, M. S. B. Chemical Ionization Mass Spectrometry. V. 
Cycloparaffins. J. Am. Chem. Soc. 1967, 89 (17), 4272–4280. 
(11)  Rayleigh, Lord. XX. On the Equilibrium of Liquid Conducting Masses Charged 
with Electricity. London, Edinburgh, Dublin Philos. Mag. J. Sci. 1882, 14 (87), 




(12)  Smith, J. N.; Flagan, R. C.; Beauchamp, J. L. Droplet Evaporation and Discharge 
Dynamics in Electrospray Ionization. J. Phys. Chem. A 2002, 106 (42), 9957–
9967. 
(13)  Konermann, L.; Ahadi, E.; Rodriguez, A. D.; Vahidi, S. Unraveling the 
Mechanism of Electrospray Ionization. Anal. Chem. 2013, 85 (1), 2–9. 
(14)  Wilm, M.; Mann, M. Analytical Properties of the Nanoelectrospray Ion Source. 
Anal. Chem. 1996, 68 (1), 1–8. 
(15)  Karas, M.; Bachmann, D.; Bahr, U.; Hillenkamp, F. Matrix-Assisted Ultraviolet 
Laser Desorption of Non-Volatile Compounds. Int. J. Mass Spectrom. Ion 
Process. 1987, 78 (C), 53–68. 
(16)  Karas, M.; Bachmann, D.; Hillenkamp, F. Influence of the Wavelength in High-
Irradiance Ultraviolet Laser Desorption Mass Spectrometry of Organic 
Molecules. Anal. Chem. 1985, 57 (14), 2935–2939. 
(17)  Tanaka, K.; Waki, H.; Ido, Y.; Akita, S.; Yoshida, Y. Protein and Polymer 
Analyses up to m/z 100 000 by Laser Ionization Time-of-Flight Mass 
Spectrometry. Rapid Commun. Mass Spectrom. 1988, 2 (8), 151–153. 
(18)  Wolfgang, P.; Steinwedel, H. Notizen: Ein Neues Massenspektrometer Ohne 
Magnetfeld. Zeitschrift für Naturforsch. A 1953, 8 (7), 448–450. 
(19)  March, R. E.; McMahon, A. W.; Londry, F. A.; Alfred, R. L.; Todd, J. F. J.; 
Vedel, F. Resonance Excitation of Ions Stored in a Quadrupole Ion Trap. Part 1. 
A Simulation Study. Int. J. Mass Spectrom. Ion Process. 1989, 95 (2), 119–156. 
(20)  Hopfgartner, G.; Varesio, E.; Tschäppät, V.; Grivet, C.; Bourgogne, E.; Leuthold, 
L. A. Triple Quadrupole Linear Ion Trap Mass Spectrometer for the Analysis of 
Small Molecules and Macromolecules. J. Mass Spectrom. 2004, 39 (8), 845–855. 
(21)  Wolff, M. M.; Stephens, W. E. A Pulsed Mass Spectrometer with Time 
Dispersion. Rev. Sci. Instrum. 1953, 24 (8), 616–617. 
Chapter 1 Introduction 
65 
 
(22)  Mamyrin, B. A.; Karataev, V. I.; Shmikk, D. V.; Zagulin, V. A. The Mass-
Reflectron, a New Nonmagnetic Time-of-Flight Mass Spectrometer with High 
Resolution. Sov. Phys. - JETP 1973, 37 (1), 45–48. 
(23)  Comisarow, M. B.; Marshall, A. G. Fourier Transform Ion Cyclotron Resonance 
Spectroscopy. Chem. Phys. Lett. 1974, 25 (2), 282–283. 
(24)  Comisarow, M. B. B. M. B.; Marshall, A. G. G. A. G. Frequency-Sweep Fourier 
Transform Ion Cyclotron Resonance Spectroscopy. Chem. Phys. Lett. 1974, 26 
(4), 489–490. 
(25)  Walker, L. R.; Tfaily, M. M.; Shaw, J. B.; Hess, N. J.; Paša-Tolić, L.; Koppenaal, 
D. W. Unambiguous Identification and Discovery of Bacterial Siderophores by 
Direct Injection 21 Tesla Fourier Transform Ion Cyclotron Resonance Mass 
Spectrometry. Metallomics 2017, 9 (1), 82–92. 
(26)  Wootton, C. A.; Sanchez-Cano, C.; Lopez-Clavijo, A. F.; Shaili, E.; Barrow, M. 
P.; Sadler, P. J.; O’Connor, P. B. Sequence-Dependent Attack on Peptides by 
Photoactivated Platinum Anticancer Complexes. Chem. Sci. 2018, 9 (10), 2733–
2739. 
(27)  Lam, Y. P. Y.; Wootton, C. A.; Hands-Portman, I.; Wei, J.; Chiu, C. K. C.; 
Romero-Canelon, I.; Lermyte, F.; Barrow, M. P.; O’Connor, P. B. Does 
Deamidation of Islet Amyloid Polypeptide Accelerate Amyloid Fibril Formation? 
Chem. Commun. 2018, 54 (98), 13853–13856. 
(28)  Marshall, A. G.; Hendrickson, C. L. Fourier Transform Ion Cyclotron Resonance 
Detection: Principles and Experimental Configurations. Int. J. Mass Spectrom. 
2002, 215 (1–3), 59–75. 
(29)  Marshall, A. G.; Hendrickson, C. L.; Jackson, G. S. Fourier Transform Ion 
Cyclotron Resonance Mass Spectrometry: A Primer. Mass Spectrom. Rev. 1998, 
17 (1), 1–35. 
(30)  Amster, I. J. Fourier Transform Mass Spectrometry. J Mass Spectrom 1996, 31 
(September), 1325–1337. 
Chapter 1 Introduction 
66 
 
(31)  Marshall, A. G.; Roe, D. C. Theory of Fourier Transform Ion Cyclotron 
Resonance Mass Spectroscopy: Response to Frequency-Sweep Excitation. J. 
Chem. Phys. 1980, 73 (4), 1581–1590. 
(32)  Marshall, A. G.; Wang, T. C. L.; Ricca, T. L. Tailored Excitation for Fourier 
Transform Ion Cyclotron Mass Spectrometry. J. Am. Chem. Soc. 1985, 107 (26), 
7893–7897. 
(33)  Comisarow, M. B. Signal Modeling for Ion Cyclotron Resonance. J. Chem. Phys. 
1978, 69 (9), 4097–4104. 
(34)  Marshall, A. G. Milestones in Fourier Transform Ion Cyclotron Resonance Mass 
Spectrometry Technique Development. Int. J. Mass Spectrom. 2000, 200 (1–3), 
331–356. 
(35)  Caravatti, P.; Allemann, M. The ‘Infinity Cell’: A New Trapped‐ion Cell with 
Radiofrequency Covered Trapping Electrodes for Fourier Transform Ion 
Cyclotron Resonance Mass Spectrometry. Org. Mass Spectrom. 1991, 26 (5), 
514–518. 
(36)  Beu, S. C.; Laude, D. A. Elimination of Axial Ejection during Excitation with a 
Capacitively Coupled Open Trapped-Ion Cell for Fourier Transform Ion 
Cyclotron Resonance Mass Spectrometry. Anal. Chem. 1992, 64 (2), 177–180. 
(37)  Scigelova, M.; Hornshaw, M.; Giannakopulos, A.; Makarov, A. Fourier 
Transform Mass Spectrometry. Mol. Cell. Proteomics 2018, 10 (7), 1–19. 
(38)  Jennings, K. R. Colllision-Induced Decompositions of Aromatic Ions. Int. J. 
Mass Spectrom. Ion Phys. 1968, 1 (3), 227–235. 
(39)  Little, D. P.; Speir, J. P.; Senko, M. W.; O’Connor, P. B.; McLafferty, F. W. 
Infrared Multiphoton Dissociation of Large Multiply Charged Ions for 
Biomolecule Sequencing. Anal. Chem. 1994, 66 (18), 2809–2815. 
(40)  Ly, T.; Julian, R. R. Ultraviolet Photodissociation: Developments towards 
Applications for Mass-Spectrometry-Based Proteomics. Angew. Chemie - Int. Ed. 
2009, 48 (39), 7130–7137. 
Chapter 1 Introduction 
67 
 
(41)  Zubarev, R.; Kelleher, N. L.; McLafferty, F. W. Electron Capture Dissociation of 
Multiply Charged Protein Cations. A Nonergodic Process. J. Am. Chem. Soc 
1998, 120 (16), 3265–3266. 
(42)  Kalli, A.; Grigorean, G.; Håkansson, K. Electron Induced Dissociation of Singly 
Deprotonated Peptides. J. Am. Soc. Mass Spectrom. 2011, 22 (12), 2209–2221. 
(43)  Wootton, C. A.; Sanchez-Cano, C.; Liu, H.-K.; Barrow, M. P.; Sadler, P. J.; 
O’Connor, P. B. Binding of an Organo-Osmium(II) Anticancer Complex to 
Guanine and Cytosine on DNA Revealed by Electron-Based Dissociations in 
High Resolution Top-Down FT-ICR Mass Spectrometry. Dalton Trans. 2015, 44 
(8), 3624–3632. 
(44)  Syka, J. E. P.; Coon, J. J.; Schroeder, M. J.; Shabanowitz, J.; Hunt, D. F. Peptide 
and Protein Sequence Analysis by Electron Transfer Dissociation Mass 
Spectrometry. Proc. Natl. Acad. Sci. U. S. A. 2004, 101 (26), 9528–9533. 
(45)  Roepstorff, P. Proposal for a Common Nomenclature for Sequence Ions in Mass 
Spectra of Peptides. Biomed. Mass Spectrom. 1984, 11 (11), 601. 
(46)  Cooper, H. J.; Hakansson, K.; Marshall, A. G. The Role of Electron Capture 
Dissociation in Biomolecular Analysis. Mass Spectrom. Rev. 2005, 24 (2), 201–
222. 
(47)  Li, H.; Lin, T. Y.; Van Orden, S. L.; Zhao, Y.; Barrow, M. P.; Pizarro, A. M.; Qi, 
Y.; Sadler, P. J.; O’Connor, P. B. Use of Top-down and Bottom-up Fourier 
Transform Ion Cyclotron Resonance Mass Spectrometry for Mapping Calmodulin 
Sites Modified by Platinum Anticancer Drugs. Anal. Chem. 2011, 83 (24), 9507–
9515. 
(48)  Xu, F.; Xu, Q.; Dong, X.; Guy, M.; Guner, H.; Hacker, T. A.; Ge, Y. Top-down 
High-Resolution Electron Capture Dissociation Mass Spectrometry for 
Comprehensive Characterization of Post-Translational Modifications in Rhesus 
Monkey Cardiac Troponin I. Int. J. Mass Spectrom. 2011, 305 (2–3), 95–102. 
(49)  Zhang, X.; Li, H.; Moore, B.; Wongkongkathep, P.; Ogorzalek Loo, R. R.; Loo, 
Chapter 1 Introduction 
68 
 
J. A.; Julian, R. R. Radical-Directed Dissociation of Peptides and Proteins by 
Infrared Multiphoton Dissociation and Sustained off-Resonance Irradiation 
Collision-Induced Dissociation with Fourier Transform Ion Cyclotron Resonance 
Mass Spectrometry. Rapid Commun. Mass Spectrom. 2014, 28 (24), 2729–2734. 
(50)  Breuker, K.; Oh, H. B.; Lin, C.; Carpenter, B. K.; McLafferty, F. W. Nonergodic 
and Conformational Control of the Electron Capture Dissociation of Protein 
Cations. Proc. Natl. Acad. Sci. 2004, 101 (39), 14011–14016. 
(51)  Zhurov, K. O.; Fornelli, L.; Wodrich, M. D.; Laskay, A.; Tsybin, Y. O. Principles 
of Electron Capture and Transfer Dissociation Mass Spectrometry Applied to 
Peptide and Protein Structure Analysis. Chem. Soc. Rev. Chem. Soc. Rev 2013, 42 
(42), 5014–5030. 
(52)  Sawicka, A.; Skurski, P.; Hudgins, R. R.; Simons, J. Model Calculations Relevant 
to Disulfide Bond Cleavage via Electron Capture Influenced by Positively 
Charged Groups. J. Phys. Chem. B 2003, 107 (48), 13505–13511. 
(53)  Syrstad, E. A.; Tureček, F. Toward a General Mechanism of Electron Capture 
Dissociation. J. Am. Soc. Mass Spectrom. 2005, 16 (2), 208–224. 
(54)  Li, H.; O’Connor, P. B. Electron Capture Dissociation of Disulfide, Sulfur-
Selenium, and Diselenide Bound Peptides. J. Am. Soc. Mass Spectrom. 2012, 23 
(11), 2001–2010. 
(55)  Zubarev, R. A.; Horn, D. M.; Fridriksson, E. K.; Kelleher, N. L.; Kruger, N. A.; 
Lewis, M. A.; Carpenter, B. K.; McLafferty, F. W. Electron Capture Dissociation 
for Structural Characterization of Multiply Charged Protein Cations. Anal. Chem. 
2000, 72 (3), 563–573. 
(56)  Mikhailov, V. A.; Cooper, H. J. Activated Ion Electron Capture Dissociation (AI 
ECD) of Proteins: Synchronization of Infrared and Electron Irradiation with Ion 
Magnetron Motion. J. Am. Soc. Mass Spectrom. 2009, 20 (5), 763–771. 
(57)  Ge, Y.; Lawhorn, B. G.; ElNaggar, M.; Strauss, E.; Park, J. H.; Begley, T. P.; 
McLafferty, F. W. Top down Characterization of Larger Proteins (45 KDa) by 
Chapter 1 Introduction 
69 
 
Electron Capture Dissociation Mass Spectrometry. J. Am. Chem. Soc. 2002, 124 
(4), 672–678. 
(58)  Shou, W.; Verma, R.; Annan, R. S.; Huddleston, M. J.; Chen, S. L.; Carr, S. A.; 
Deshaies, R. J. Mapping Phosphorylation Sites in Proteins by Mass Spectrometry. 
Methods Enzymol. 2002, 351, 279–296. 
(59)  Chamot-Rooke, J.; van der Rest, G.; Dalleu, A.; Bay, S.; Lemoine, J. The 
Combination of Electron Capture Dissociation and Fixed Charge Derivatization 
Increases Sequence Coverage for O-Glycosylated and O-Phosphorylated 
Peptides. J. Am. Soc. Mass Spectrom. 2007, 18 (8), 1405–1413. 
(60)  Wootton, C. A.; Millett, A. J.; Lopez-Clavijo, A. F.; Chiu, C. K. C.; Barrow, M. 
P.; Clarkson, G. J.; Sadler, P. J.; O’Connor, P. B. Structural Analysis of Peptides 
Modified with Organo-Iridium Complexes, Opportunities from Multi-Mode 
Fragmentation. Analyst 2019, 144, 1575–1581. 
(61)  Haselmann, K. F.; Budnik, B. A.; Zubarev, R. A. Electron Capture Dissociation 
of B2+ Peptide Fragments Reveals the Presence of the Acylium Ion Structure. 
Rapid Commun. Mass Spectrom. 2000, 14 (23), 2242–2246. 
(62)  Budnik, B. A.; Haselmann, K. F.; Zubarev, R. A. Electron Detachment 
Dissociation of Peptide Di-Anions: An Electron-Hole Recombination 
Phenomenon. Chem. Phys. Lett. 2001, 342 (3–4), 299–302. 
(63)  Narayanan, D. L.; Saladi, R. N.; Fox, J. L. Ultraviolet Radiation and Skin Cancer. 
Int. J. Dermatol. 2010, 49, 978–986. 
(64)  Shannon, A. M.; Bouchier-Hayes, D. J.; Condron, C. M.; Toomey, D. Tumour 
Hypoxia, Chemotherapeutic Resistance and Hypoxia-Related Therapies. Cancer 
Treat. Rev. 2003, 29 (4), 297–307. 
(65)  Circu, M. L.; Aw, T. Y. Reactive Oxygen Species, Cellular Redox Systems, and 
Apoptosis. Free Radic. Biol. Med. 2010, 48 (6), 749–762. 
(66)  Moreno, P. M. D.; Pego, A. P. Therapeutic Antisense Oligonucleotides against 
Cancer: Hurdling to the Clinic. Front. Chem. 2014, 2 (October), 1–7. 
Chapter 1 Introduction 
70 
 
(67)  Bednarski, P.; Mackay, F.; Sadler, P. Photoactivatable Platinum Complexes. 
Anticancer. Agents Med. Chem. 2008, 7 (1), 75–93. 
(68)  Aykul, S.; Martinez-Hackert, E. Determination of Half-Maximal Inhibitory 
Concentration Using Biosensor-Based Protein Interaction Analysis. Anal. 
Biochem. 2016, 508, 97–103. 
(69)  Yang, J.; Kopeček, J. Macromolecular Therapeutics. J. Control. Release 2014, 
190, 288–303. 
(70)  Reedijk, J. Platinum Anticancer Coordination Compounds: Study of DNA 
Binding Inspires New Drug Design. Eur. J. Inorg. Chem. 2009, No. 10, 1303–
1312. 
(71)  Ndagi, U.; Mhlongo, N.; Soliman, M. E. Metal Complexes in Cancer Therapy – 
An Update from Drug Design Perspective. Drug Des. Devel. Ther. 2017, 11, 
599–616. 
(72)  Pizarro, A. M.; Sadler, P. J. Unusual DNA Binding Modes for Metal Anticancer 
Complexes. Biochimie 2009, 91 (10), 1198–1211. 
(73)  Sava, G.; Bergamo, A.; Dyson, P. J. Metal-Based Antitumour Drugs in the Post-
Genomic Era: What Comes Next? Dalton Trans. 2011, 40 (36), 9069–9075. 
(74)  Wong, E.; Giandornenico, C. M. Current Status of Platinum-Based Antitumor 
Drugs. Chem. Rev. 1999, 99 (9), 2451–2466. 
(75)  Hearn, J. M.; Romero-Canelón, I.; Qamar, B.; Liu, Z.; Hands-Portman, I.; Sadler, 
P. J. Organometallic Iridium(III) Anticancer Complexes with New Mechanisms 
of Action: NCI-60 Screening, Mitochondrial Targeting, and Apoptosis. ACS 
Chem. Biol. 2013, 8 (6), 1335–1343. 
(76)  Ivanov, A. I.; Christodoulou, J.; Parkinson, J. A.; Barnham, K. J.; Tucker, A.; 
Woodrow, J.; Sadler, P. J. Cisplatin Binding Sites on Human Albumin. J. Biol. 
Chem. 1998, 273 (24), 14721–14730. 
(77)  Pillaire, M. J.; Hoffmann, J. S.; Defais, M.; Villani, G. Replication of DNA 
Chapter 1 Introduction 
71 
 
Containing Cisplatin Lesions and Its Mutagenic Consequences. Biochimie 1995, 
77 (10), 803–807. 
(78)  Alderden, R. A.; Hall, M. D.; Hambley, T. W. The Discovery and Development 
of Cisplatin. J. Chem. Educ. 2009, 83 (5), 728. 
(79)  Zayed, A.; Shoeib, T.; Taylor, S. E.; Jones, G. D. D.; Thomas, A. L.; Wood, J. P.; 
Reid, H. J.; Sharp, B. L. Determination of Pt-DNA Adducts and the Sub-Cellular 
Distribution of Pt in Human Cancer Cell Lines and the Leukocytes of Cancer 
Patients, Following Mono- or Combination Treatments, by Inductively-Coupled 
Plasma Mass Spectrometry. Int. J. Mass Spectrom. 2011, 307 (1–3), 70–78. 
(80)  Centerwall, C. R.; Tacka, K. A.; Kerwood, D. J.; Goodisman, J.; Toms, B. B.; 
Dubowy, R. L.; Dabrowiak, J. C. Modification and Uptake of a Cisplatin 
Carbonato Complex by Jurkat Cells. Mol. Pharmacol. 2006, 70 (1), 348–355. 
(81)  Hearn, J. M.; Romero-Canelón, I.; Munro, A. F.; Fu, Y.; Pizarro, A. M.; Garnett, 
M. J.; McDermott, U.; Carragher, N. O.; Sadler, P. J. Potent Organo-Osmium 
Compound Shifts Metabolism in Epithelial Ovarian Cancer Cells. Proc. Natl. 
Acad. Sci. U. S. A. 2015, 112 (29), E3800–E3805. 
(82)  Millett, A. J.; Habtemariam, A.; Romero-Canelón, I.; Clarkson, G. J.; Sadler, P. J. 
Contrasting Anticancer Activity of Half-Sandwich Iridium(III) Complexes 
Bearing Functionally Diverse 2-Phenylpyridine Ligands. Organometallics 2015, 
34 (11), 2683–2694. 
(83)  Peacock, A. F. A.; Habtemariam, A.; Fernández, R.; Walland, V.; Fabbiani, F. P. 
A.; Parsons, S.; Aird, R. E.; Jodrell, D. I.; Sadler, P. J. Tuning the Reactivity of 
Osmium(II) and Ruthenium(II) Arene Complexes under Physiological 
Conditions. J. Am. Chem. Soc. 2006, 128 (5), 1739–1748. 
(84)  Morris, R. E.; Aird, R. E.; Del Socorro Murdoch, P.; Chen, H.; Cummings, J.; 
Hughes, N. D.; Parsons, S.; Parkin, A.; Boyd, G.; Jodrell, D. I.; et al. Inhibition of 
Cancer Cell Growth by Ruthenium(II) Arene Complexes. J. Med. Chem. 2001, 44 
(22), 3616–3621. 
Chapter 1 Introduction 
72 
 
(85)  Ang, W. H.; Casini, A.; Sava, G.; Dyson, P. J. Organometallic Ruthenium-Based 
Antitumor Compounds with Novel Modes of Action. J. Organomet. Chem. 2011, 
696 (5), 989–998. 
(86)  Barragán, F.; López-Senín, P.; Salassa, L.; Betanzos-Lara, S.; Habtemariam, A.; 
Moreno, V.; Sadler, P. J.; Marchán, V. Photocontrolled DNA Binding of a 
Receptor-Targeted Organometallic Ruthenium(II) Complex. J. Am. Chem. Soc. 
2011, 133 (35), 14098–14108. 
(87)  Lovejoy, K. S.; Lippard, S. J. Non-Traditional Platinum Compounds for 
Improved Accumulation, Oral Bioavailability, and Tumor Targeting. Dalton 
Trans. 2009, 10651–10659. 
(88)  Wang, J.; Liu, G.; Leung, K.; Loffroy, R.; Lu, P.-X.; J. Wáng, Y. Opportunities 
and Challenges of Fluorescent Carbon Dots in Translational Optical Imaging. 
Curr. Pharm. Desi. 2015, pp 5401–5416. 
(89)  Shi, H.; Romero-Canelón, I.; Hreusova, M.; Novakova, O.; Venkatesh, V.; 
Habtemariam, A.; Clarkson, G. J.; Song, J. I.; Brabec, V.; Sadler, P. J. 
Photoactivatable Cell-Selective Dinuclear Trans-Diazidoplatinum(IV) Anticancer 
Prodrugs. Inorg. Chem. 2018, 57 (22), 14409–14420. 
(90)  Farrer, N. J.; Salassa, L.; Sadler, P. J. Photoactivated Chemotherapy (PACT): The 
Potential of Excited-State d-Block Metals in Medicine. Dalton Trans. 2009, No. 
48, 10690–10701. 
(91)  Shi, H.; Clarkson, G. J.; Sadler, P. J. Dual Action Photosensitive Platinum(II) 
Anticancer Prodrugs with Photoreleasable Azide Ligands. Inorganica Chim. Acta 
2019, 489 (December 2018), 230–235. 
(92)  Davies, M. J. The Oxidative Environment and Protein Damage. Biochim. 
Biophys. Acta - Proteins Proteomics 2005, 1703 (2), 93–109. 
(93)  Zhang, P.; Chiu, C. K. C.; Huang, H.; Lam, Y. P. Y.; Habtemariam, A.; 
Malcomson, T.; Paterson, M. J.; Clarkson, G. J.; O’Connor, P. B.; Chao, H.; et al. 
Organoiridium Photosensitizers Induce Specific Oxidative Attack on Proteins 
Chapter 1 Introduction 
73 
 
within Cancer Cells. Angew. Chemie Int. Ed. 2017, 14898–14902. 
(94)  Gracanin, M.; Hawkins, C. L.; Pattison, D. I.; Davies, M. J. Singlet-Oxygen-
Mediated Amino Acid and Protein Oxidation: Formation of Tryptophan 
Peroxides and Decomposition Products. Free Radic. Biol. Med. 2009, 47 (1), 92–
102. 
(95)  Josefsen, L. B.; Boyle, R. W. Photodynamic Therapy and the Development of 
Metal-Based Photosensitisers. Met. Based. Drugs 2008, 2008, 1–23. 
(96)  Nam, J. S.; Kang, M. G.; Kang, J.; Park, S. Y.; Lee, S. J. C.; Kim, H. T.; Seo, J. 
K.; Kwon, O. H.; Lim, M. H.; Rhee, H. W.; et al. Endoplasmic Reticulum-
Localized Iridium(III) Complexes as Efficient Photodynamic Therapy Agents via 
Protein Modifications. J. Am. Chem. Soc. 2016, 138 (34), 10968–10977. 
(97)  Wasinger, V. C.; Cordwell, S. J.; Poljak, A.; Yan, J. X.; Gooley, A. A.; Wilkins, 
M. R.; Duncan, M. W.; Harris, R.; Williams, K. L.; Humphery‐Smith, I. Progress 
with Gene‐product Mapping of the Mollicutes: Mycoplasma Genitalium. 
Electrophoresis 1995, 16 (1), 1090–1094. 
(98)  Walther, T. C.; Mann, M. Mass Spectrometry-Based Proteomics in Cell Biology. 
J. Cell Biol. 2010, 190 (4), 491–500. 
(99)  McDonald, W. H.; Yates, J. R. Shotgun Proteomics and Biomarker Discovery. 
Dis. Markers 2002, 18 (2), 99–105. 
(100)  Gillette, M. A.; Carr, S. A. Quantitative Analysis of Peptides and Proteins in 
Biomedicine by Targeted Mass Spectrometry. Nat. Methods 2013, 10 (1), 28–34. 
(101)  Anderson, L. C.; Dehart, C. J.; Kaiser, N. K.; Fellers, R. T.; Smith, D. F.; Greer, 
J. B.; Leduc, R. D.; Blakney, G. T.; Thomas, P. M.; Kelleher, N. L.; et al. 
Identification and Characterization of Human Proteoforms by Top-Down LC-21 
Tesla FT-ICR Mass Spectrometry. J. Proteome Res. 2017, 16 (2), 1087–1096. 
(102)  Elzek, M. A.; Rodland, K. D. Proteomics of Ovarian Cancer: Functional Insights 
and Clinical Applications. Cancer Metastasis Rev. 2015, 34 (1), 83–96. 
Chapter 1 Introduction 
74 
 
(103)  Wootton, C. A.; Lam, Y. P. Y.; Willetts, M.; van Agthoven, M. A.; Barrow, M. 
P.; Sadler, P. J.; O′Connor, P. B. Automatic Assignment of Metal-Containing 
Peptides in Proteomic LC-MS and MS/MS Data Sets. Analyst 2017, 142 (11), 
2029–2037. 
(104)  Fornelli, L.; Toby, T. K.; Schachner, L. F.; Doubleday, P. F.; Srzenti??, K.; 
DeHart, C. J.; Kelleher, N. L. Top-down Proteomics: Where We Are, Where We 
Are Going? J. Proteomics 2016, 10–11. 
(105)  Chen, B.; Brown, K. A.; Lin, Z.; Ge, Y. Top-Down Proteomics: Ready for Prime 
Time? Anal. Chem. 2018, 90 (1), 110–127. 
(106)  Ahn, J.; Cao, M. J.; Yu, Y. Q.; Engen, J. R. Accessing the Reproducibility and 
Specificity of Pepsin and Other Aspartic Proteases. Biochim. Biophys. Acta - 
Proteins Proteomics 2013, 1834 (6), 1222–1229. 
(107)  Suttapitugsakul, S.; Xiao, H.; Smeekens, J.; Wu, R. Evaluation and Optimization 
of Reduction and Alkylation Methods to Maximize Peptide Identification with 
MS-Based Proteomics. Mol. Biosyst. 2017, 13 (12), 2574–2582. 
(108)  Fauchere, J. L.; Pliska, V. Hydrophobic Parameters Pi of Amino Acid Side 
Chains from the Partitioning of N-Acetyl-Amino Acid Amides. Eur. J. Med. 
Chem. 1983, 18 (4), 369–375. 
(109)  Ahn, Y. H.; Kim, J. Y.; Yoo, J. S. Quantitative Mass Spectrometric Analysis of 
Glycoproteins Combined with Enrichment Methods. Mass Spectrosc. Rev. 2015, 
34, 148–165. 
(110)  Boersema, P. J.; Mohammed, S.; Heck, A. J. R. Hydrophilic Interaction Liquid 
Chromatography (HILIC) in Proteomics. Anal. Bioanal. Chem. 2008, 391 (1), 
151–159. 
(111)  Wiese, S.; Reidegeld, K. A.; Meyer, H. E.; Warscheid, B. Protein Labeling by 
ITRAQ: A New Tool for Quantitative Mass Spectrometry in Proteome Research. 
Proteomics 2007, 7 (3), 340–350. 
(112)  Wong, J. W. H.; G., C. An Overview of Label-Free Quantification Methods in 
Chapter 1 Introduction 
75 
 
Proteomics by Mass Spectrometry; 2009, Humana Press, New Jersey, USA. 
(113)  Naylor, B. C.; Porter, M. T.; Wilson, E.; Herring, A.; Lofthouse, S.; Hannemann, 
A.; Piccolo, S. R.; Rockwood, A. L.; Price, J. C. DeuteRater: A Tool for 
Quantifying Peptide Isotope Precision and Kinetic Proteomics. Bioinformatics 
2017, 33 (10), 1514–1520. 
(114)  Smith, R.; Taylor, R. M.; Prince, J. T. Current Controlled Vocabularies Are 
Insufficient to Uniquely Map Molecular Entities to Mass Spectrometry Signal. 
BMC Bioinformatics 2015, 16 (7), S2. 
(115)  Unwin, R. D. Quantification of Proteins by ITRAQ. In LC-MS/MS in Proteomics 
- Methods and Applications; Cutillas, P. R., Timms, J. F., Eds.; Humana Press, 
2010; pp 205–215. 
(116)  Chen, X.; Wei, S.; Ji, Y.; Guo, X.; Yang, F. Quantitative Proteomics Using 
SILAC: Principles, Applications, and Developments. Proteomics 2015, 15 (18), 
3175–3192. 
(117)  Mann, M. Functional and Quantitative Proteomics Using SILAC. Nat. Rev. Mol. 
Cell Biol. 2006, 7 (12), 952–958. 
(118)  Mann, M.; Jensen, O. N. Proteomic Analysis of Post-Translational Modifications. 
Nat. Biotechnol. 2003, 21 (March), 255–261. 
(119)  del Monte, F.; Agnetti, G. Protein Post-Translational Modifications and 
Misfolding: New Concepts in Heart Failure. Proteomics - Clin. Appl. 2014, 8 (7–
8), 534–542. 
(120)  Seo, J.-W.; Lee, K.-J. Post-Translational Modifications and Their Biological 
Functions: Proteomic Analysis and Systematic Approaches. J. Biochem. Mol. 
Biol. 2011, 37 (1), 35–44. 
(121)  Szatrowski, T. P.; Nathan, C. F. Production of Large Amounts of Hydrogen 
Peroxide by Human Tumor Cells. Cancer Res. 1991, 51 (3), 794–798. 
(122)  Oattison, D. I.; Rahmanto, A. S.; Davis, M. J. Photo-Oxidation of Proteins. 
Chapter 1 Introduction 
76 
 
Photochem. Photobiol. Sci. 2012, 11, 38. 
 





Metallodrug-Peptide Interactions Studied by Ultra-High Resolution Mass 
Spectrometry 
Together with the increased use of platinum-based anticancer agents over the 
past decades, there is also a significant increase in platinum resistant cancer cases.  
Transition metal-based complexes possess a range of geometries and activities against 
many different forms of cancer.  Potent piano-stool compounds, such as those based on 
ruthenium, iridium, and osmium, have been shown to be extremely effective and 
selective against cancerous cells, including resistant strains.1 
Bottom-up MS analysis is often employed by researchers due to the relatively 
low instrument requirement compared to top-down approach.  However, sensitive 
modification such as metallodrug binding can present challenges to the experiments.  
Herein, microwave digestion, an alternative digestion method was investigated to 
compare to standard tryptic digestion, looking into possibilities of achieving an effective 
digestion in 15 min rather than the standard 16 h tryptic digestion.  Different 
fragmentation and hyphenated techniques were also used to investigate the effectiveness 
of studying system with fragile modifications.  The osmium complex (Os1-Cl) was 
synthesised by Dr. Carlos Sanchez-Cano.  Sample preparation and all data were 
produced, analysed, and interpreted by the author of this thesis. 
A manuscript entitled “Metallodrug-Peptide Interactions Studied by Ultra-High 
Resolution Mass Spectrometry” by Cookson K. C. Chiu, Yuko P. Y. Lam, Christopher 
A. Wootton, Mark P. Barrow, Peter J. Sadler, and Peter B. O’Connor, has been prepared 
for submission to the Journal of the American Society for Mass Spectrometry (JASMS) 
based directly on the contents and findings of this chapter. 
  





Here we investigate the effectiveness of alternative digestion methods for bottom 
up analysis, and develop a methodology for localising metallodrug-binding sites.  
Bovine serum albumin (BSA) has long been used for bottom-up digestion and LC-MS 
analysis optimisation as it produces a wide variety of representative tryptic peptides 
upon digestion, therefore it was used as a model protein to obtain a mixture of peptides 
for bottom-up metallo-interaction analysis.  The methodology developed herein 
identified metallated species in a drug-peptide mixture effectively, and same 
methodology can potentially be applied to more complex biomolecule systems, such as 
drug-cell MS analysis, to evaluate their behaviour towards commonly encountered 
biomolecules.  
Introduction 
 Metal-based chemotherapies are at the forefront of anticancer therapy, with 
predominantly platinum based compounds, such as cisplatin, carboplatin, and oxaliplatin 
being used in chemotherapy treatments for various types of cancer.3  However, the 
number of platinum-resistant cancer cases has continuously increased with the increased 
use of platinum-based anti-cancer agents.4  Therefore, potently cytotoxic and anti-
proliferative compounds have been developed using a range of other transition metals, 
including ruthenium,5–8 iridium,9–12 osmium,2,13–15, rhodium,16, gold,17,18 as well as new 
platinum-based designs.19–22  These new transition metal-based drugs have been shown 
to have varying mechanisms of action (MoA) against cancerous cell components, while 
some are able to disrupt vital processes in cells in order to kill cancer cells, such as 
interaction between the metallodrug and mitochondria.23,24  It is therefore of much 
interest to investigate the ability of these new metallodrugs to react with different 
biomolecules, to further study different possible MoA against cancerous cells.  
Metallodrugs are often designed as pro-drugs (non-active compounds), and ideally only 
activated when the drug is inside/near the cancerous cells, to increase effectiveness and 
selectivity towards cancerous cells, minimising the side effects from reacting with 
healthy cells inside the body.  During the journey towards the target, the composition of 
metallodrugs is often found to change, from drug activation (desired), or exposure to a 




change in environment; pH, temperature, salt concentration, etc., (often undesired).  
Therefore, it is important to characterise the behaviour as well as composition of the 
metallodrug, to provide more information on how the metallodrug interacts with the 
biomolecules. 
Many analytical techniques have been utilised to study metal-biomolecule 
interactions, often 1H NMR,25 or x-ray crystallography.26  These techniques possess 
powerful ability to provide structural information and sometimes able to identify and 
locate the modifications on biomolecules.  However, a mixture of products often 
introduces issues to these analytical techniques due to the inherent lack of separation 
ability.  Therefore, to address these issues, other analytical techniques are being 
explored which possess the ability of handling mixtures of adducts effectively.  Mass 
spectrometry (MS) is increasingly being employed to study biological systems, due to 
its high sensitivity and ability to cope with complex samples.  With the aid of tandem 
mass spectrometry (MS/MS), fragmentation of the ionised target species provides an in-
depth chemical and structural information of the complex biological system.  An 
extensive array of fragmentation techniques has been developed, including collisionally 
activated dissociation (CAD),27 electron capture dissociation (ECD),28 infrared multi-
photon dissociation (IRMPD),29 etc.  Different fragmentation techniques have their own 
advantages, allowing a more comprehensive analysis. 
Fourier transform-ion cyclotron resonance mass spectrometry (FT-ICR MS) uses 
electric and magnetic fields to trap ions of interest within a Penning trap during MS/MS 
experiments and detection.30,31  Latest commercial setups allow resolving powers of 
500,000 – 10,000,000 or above,32 which is not achievable by other mass spectrometers.  
With the capability of isolating ions of interest using a quadrupole, applying collisional 
activation, and electron/photon-based dissociation techniques upon ions of interests, FT-
ICR MS provides the largest array of fragmentation techniques and highest mass 
accuracy of any mass spectrometer, with mass errors into sub parts-per-million (ppm) 
and even parts-per-billion (ppb) ranges. 
The interaction between an osmium-(II) complex and a DNA 12-mer was 
studied by Wootton et al.  The chlorido ligand was found to be dissociated and produced 




a doubly charged species (Os1, Scheme 2.1).  The DNA-12mer was observed to be 
osmiated (osmium bound) and the binding locations were found to be guanine3 and 
cytosine10 with the aid of electron detachment dissociation MS/MS.
2 
Here we investigated the effectiveness of microwave digestion compared to 
standard tryptic digestion of BSA.  A bottom-up metallo-interaction methodology was 
also developed to study the interaction between model BSA tryptic digest and an 
osmium-(II) arene anticancer complex, Os1-Cl (Scheme 2.1).  Ultra-high resolution 
mass spectrometry together with various MS/MS techniques to investigate the binding 
location of the metallodrug on the biomolecule.  Reversed phase (RP) nano-liquid 
chromatography (nLC) was also coupled to FT-ICR MS to separate the complex 
generated from the tryptic digestion of BSA, minimising the ion suppression/space 
charge effects from having too many ions in the ICR cell during excitation and 
detection, allowing better observation and study on the osmiated species.  
 
Scheme 2.1: The Os(II) arene complex, Os1-Cl studied in this work and the species 
(Os1) detected via nano-electrospray ionisation mass spectrometry (nESI-MS). 






Bovine serum albumin (BSA, ≥ 98%, fatty acid free), formic acid, ammonium 
bicarbonate (AmmBic), dithiothreitol (DTT), iodoacetamide (IAA), and trypsin were all 
purchased from Sigma Aldrich (Dorset, England). LCMS grade acetonitrile (MeCN) 
was purchased from VWR (Lutterworth, UK). Ultra-pure water (18.2 MΩcm-1) was 
obtained from a Milli-Q UV III water purification system (Milli-Q, Hertfordshire, UK) 
Preparation of osmium complex 
[(η6-bip)Os(en)Cl]PF6 (Os1-Cl·PF6) was synthesised and characterised as 
described previously by Dr. Carlos Sanchez-Cano.33 
Preparation of BSA tryptic digest 
Standard Digestion 
BSA was reduced using 50 mM of DTT, alkylated with 100 mM of IAA, and 
tryptic digested with 1 µg/µL of trypsin in 100 mM of AmmBic at 37 oC for 16 h.  
Digested samples were then desalted using C18 SPE cartridges (Thermo Fisher 
Scientific, Waltham, UK) as follows; washed twice with 1% formic acid-acidified water 
and eluted using 80% MeCN/aqueous solution.  Desalted samples were then filtered 
through 3 kDa molecular weight cut-off filters (Millipore, Hertfordshire, UK) to remove 
any digested proteins above 3 kDa.  The resulting BSA digest samples had a 
concentration of 1 mg/mL, with an assumption of a 100% digestion efficiency from 
initial protein concentration.  
Microwave Digestion 
 BSA was reduced using 50 mM of DTT, and separated into two batches, one 
batch alkylated with 100 mM of IAA, and the other one without.  Then 12 µL of 1 
µg/µL of trypsin was added into the sample.  The sample mixture was microwave-
digested using a CEM Discover SP-D 80 Automated Microwave Digestion System 
(Buckingham, UK).  Digestion temperature was optimised to 100 oC, ramp time of 1 
min, hold time of 15 min, and power of 20 W to achieve optimum digestion.  The 




resulting BSA digest sample had a concentration of 1 mg/mL total peptide/protein 
content. 
Preparation of Os1-BSA digest reaction 
 Osmium complex, Os1-Cl (250 µM) was reacted with the BSA digest, to a 1:1 
molar ratio using 1 mg/mL protein digest and an average peptide mass of 1500 Da.  The 
reaction mixture was incubated under 37 oC for one day.  Samples for direct infusion 
MS were diluted 100-fold with 50:50 (v/v) H2O:MeCN and 0.1% formic acid.  Samples 
for nLC-FT-ICR MS analysis were diluted 25-fold with water. 
Nano-LC Separation 
 All LC separations were achieved using an EASY-nano-LC II system (Proxeon, 
Hemel Hempstead, UK) with a 3 cm, C18 RP trapping column (150 µm, 3 µm particle 
size, pore size of 300 Å), and a 25 cm, C18 RP analytical column (75 µm, 3 µm particle 
size, pore size of 300 Å).  Separation of tryptic digest samples was achieved using an 
acidified water/MeCN (solvent + 0.1% formic acid) gradient from 5% B (MeCN) to 
30% B over 30 min before a 30 min wash of 80% B.  12 µL (7 pmol) of sample was 
injected for each nLC-MS or nLC-MS/MS run. 
Mass Spectrometry 
All samples were analysed using nano-electrospray ionisation (nESI) for 
increased sensitivity and lower the sample consumption compared to standard 
electrospray ionisation (ESI).  All experiments were carried out on a SolariX FT-ICR 
mass spectrometer, fitted with a 12 tesla actively shielded superconducting magnet 
(Bruker Daltonik GmbH, Bremen, Germany).  All samples were sprayed in positive ion 
mode.  For direct infusion MS experiments, ions were accumulated for 0.5 s in the 
hexapole-based collision cell before transferred to the infinity cell for detection.34 
For CAD MS/MS experiments, ions of interest were isolated using the front-end 
quadrupole using an isolation window of 10 m/z.  Selected ions were then accelerated 
into argon collision gas at 12 V (for unmodified peptides) and 5 V for (osmiated 
species).  Ions were continuously accumulated for 4 s before transmission and detection. 




For ECD MS/MS experiments, ions of interest were isolated using the front-end 
quadrupole using an isolation window of 10 m/z, then accumulated in the hexapole for 4 
s.  Isolated ions of interest were then transferred and trapped in the infinity cell.  
Trapped ions were then irradiated for 0.15 s with 1.2 eV electrons produced from a 1.5 
A hollow cathode dispenser via an extraction lens held at 18 V. 
All nLC-MS spectra were peak picked with the Sophisticated Numerical 
Annotation Procedure – Liquid Chromatography (SNAP-LC) algorithm developed by 
Wootton et al.35  Osmiated-species were peak picked using the following parameters: 
quality factor of 0.95, a signal-to-noise ratio (S/N) threshold of 2, and a maximum 
charge state of 5+, a constant building block (base elementary composition) of C = 
4.9384, N = 1.3577, O = 1.4773, S = 0.0417, H = 7.7583. 
Auto MS/MS with a prefer list of osmiated species picked out by the SNAP-LC 
algorithm was performed to fragment the selected osmiated species.  Intensity threshold 
of 1x106 was used and all singly-charged ions are excluded from the fragmentation list.  
The isolated osmium species were further accumulated for 3 s in the hexapole before 
being transferred into the infinity cell for ECD MS/MS. 
All spectra were internally calibrated using a quadratic calibration function,36 
manually interpreted and assigned via DataAnalysis v4.2 (Bruker Daltonik GmbH, 
Bremen, Germany). 
Results and Discussion 
 Serum albumin is the most abundant protein in blood plasma, and it is 
responsible for drug transportation in bodies, therefore BSA was chosen as a model 
protein for the method development of metallodrug binding site studies.  BSA digestion 
was achieved using two different methods, standard digestion and microwave digestion.  
Microwave digestion was achieved in 15 min while standard digestion often requires 16 
hr or more to achieve an effective level of digestion.  BSA was reduced with 50 mM of 
DTT and separated into two batches of sample, one then treated with IAA to achieve 
alkylation of cysteine and the other one without.  Both batches then underwent the same 
microwave digestion process and yielded different results in observed peptides.  




Peptides observed in the non-alkylated sample (Figure 2.1a) were larger in size and 
more highly charged compared to the ones observed in the alkylated sample (Figure 
2.1b).  One of advantages of using electrospray ionisation (ESI) is the ability to generate 
multiply charged molecular ions from the analytes without fragmenting them.  In FT-
ICR MS, the detected signal is proportional to the charge of the species too, therefore, it 
is more sensitive to multiply-charged ions compared to singly-charged ions.  Figure 1b 
shows a wide range of singly-charged ions, believed to be due to the extra vibrational 
energy transferred into BSA by the microwave, and overcome the bond strength 
between residues, therefore, some very small peptides (3-residue short peptides are not 
often observed) were produced.  While in Figure 2.1a, doubly-charged or even triply-
charged peptides are observed, which is believed that the protein structure is still 
“protected” by the reforming disulfide bonds, by not using an alkylating reagent to block 
off the free thiols from DTT reduction.  Therefore, the only location that can carry a 
charge is the N-terminus of the short peptide, while in the non-alkylated sample, there 
are more sites on the peptide can carry charges, e.g. histidine (H), lysine (K), arginine 
(R), and the N-terminus. 





Figure 2.1 Microwave digestion of BSA.  a) reduced with DTT b) reduced with 
DTT and alkylated with IAA.  Observed peptides (P) are annotated with their 
amino acid sequence numbers. 




 BSA was tryptic-digested overnight to create a mixture of peptides and reacted 
with the Os1-Cl in a 1:1 ratio for a day at 37 oC.  The sample was diluted and analysed 
by FT-ICR MS via direct infusion (Figure 2.2).  The resulting mass spectrum was 
internally calibrated by using unmodified BSA peptides (Table S2.1).  SNAP peak 
picking algorithm was used to look for species containing an osmium isotope pattern 
(Figure 2.2 inset). Four osmiated species were detected using SNAP (labelled in purple).  
It is important to identify the peptide, but also to locate exactly which residue the 
osmium complex is binding to, and the type of interaction, such as covalent interaction 
or non-covalent interaction.  Different tandem mass spectrometry (MS/MS) techniques 
were used to investigate the binding. 
 
Figure 2.2 Full mass spectrum of the [Os1-Cl]-BSA digest reaction mixture.  
Purple stars and purple assignments represent osmiated species.  Inset on the right 
shows the comparison between the observed species (top) and the simulation 
(bottom). 
 Collisionally activated dissociation (CAD) was chosen to perform the MS/MS 
experiment on the osmiated species ([P156-160]
2+).  The dissociation process is performed 




inside the hexapole collision cell, located after the quadrupole.  The species of interest 
(867.42385 m/z) was isolated inside the quadrupole and accelerated into a cloud of inert 
argon gas molecules in the hexapole collision cell.  CAD is a slow heating process 
which tends to cleave the amide bond on the protein/peptide backbone.  However, if 
there are any weaker interactions, such as non-covalent interactions, π-π stacking, 
hydrogen bonding, etc., these interactions will often be broken before the 
protein/peptide backbone.  5 V of collision energy was applied to osmiated species 
(Figure 2.3, Table S2.2), and unfortunately, the osmium complex dissociated readily, 
and was observed as a free metallodrug ion (Os1).  However, important information was 
also obtained from the CAD MS/MS spectrum, the peptide (residue 156-160, KFWGK) 
was observed as a dimer and the interaction between the osmium complex and the 
peptide dimer was weak. 
 
Figure 2.3 CAD MS/MS of the osmiated species (867.42385 m/z).  Inset shows the 
comparison between the observed species (top) and the simulation (bottom). 
Other fragmentation techniques were required to investigate the binding while 
the osmium complex is retained.  Electron capture dissociation (ECD) is a radical driven 




fragmentation process,28 meaning unlike CAD fragmenting the species using a slow 
heating approach, ECD cleaves bonds preferentially, such as the N-Cα bond on the 
protein/peptide backbone, therefore, weak interactions/labile modifications, are 
normally preserved with ECD MS/MS.  Figure 2.4 shows that the osmium complex 
(Os1) is successfully retained on the peptide.  Note that the two positive charges are 
contributed by the osmium complex by losing the chlorido ligand from Os1-Cl and 
binding to the neutral peptide, which is often observed in metallated species,2,10 
especially if the metal complex itself is a charge carrier (Table S2.3). 
 
Figure 2.4 ECD MS/MS of the osmiated species (867.42385 m/z).  Osmium 
containing species are labelled in purple.  Inset shows the comparison between the 
observed species (top), [(WGK+KFWGK)]+Os1]2+, and the simulation (bottom). 
 By combining information gathered from the low energy (5 V) CAD MS/MS 
and ECD MS/MS spectra, the conclusion can be made that the binding interaction of 
Os1 to the dimer peptide was weak, therefore, even applying a low collision energy to 
the osmiated species caused the dissociation of the metallodrug.  From the 
fragmentation pattern observed in Figure 2.4, the binding interactions in the osmiated 




species were suggested to be a coordinate covalent bond, donated from nitrogen on the 
side chain of a lysine (K) residue and a weak π-π interaction between the phenyl ring of 
Os1 and the indole side chain of the tryptophan (W) residue.  A proposed structure of 
the osmiated species is shown below in Figure 2.5. 
 
Figure 2.5 Full protein sequence of BSA (top), the species of interest is highlighted 
in purple.  A proposed binding interaction between Os1 and the peptide dimer is 
shown (bottom right), fragments with purple stars represent the presence of 
osmium. 
 By direct infusion of the (Os1-Cl)-BSA reaction products, a few osmiated 
species were observed. However, they appeared to be in low intensity, which restricted 
effective isolation and fragmentation.  Low intensity can be caused by either inherently 
low ion abundance in the sample or more often by space charge effects or saturating the 




ICR cell with undesired ions.38  Therefore, online-separation was performed by coupling 
a nano LC (nLC) to the mass spectrometer, so that the peptide mixture can be separated 
prior to MS analysis.  Peptides were separated using a reversed phase (RP) C18 column 
according to the hydrophobicity of the peptide.39  The more hydrophobic the peptide is, 
the more it is retained on the column and eluted at later retention time.  nLC-MS was 
performed first in order to obtain m/z information of the separated peptide mixture 
throughout the retention times (Figure 2.6a).  The nLC-MS data were peak-picked using 
Sophisticated Numerical Annotation Procedure - Liquid Chromatography (SNAP-LC) 
algorithm developed by Wootton et al.35, to pick out automatically any osmiated species 
in each spectrum along the retention times (Figure 2.6b).  nLC-ECD MS/MS was then 
performed using a prefer list of osmiated peaks generated by the algorithm in the 
previous step (Figure 2.6c).  Extraction ion chromatograms (EIC) of osmiated peaks 
from the prefer list can be obtained from the nLC-MS/MS data, and the binding of Os1 
on each detected osmiated peptide investigated (Figure 2.6d). 
  





Figure 2.6 nLC-MS/MS experimental workflow to obtain metal-binding 
information.  a) Total ion chromatogram (TIC) of the nLC-MS run is shown, and 
obtained m/z information of the peptide mixture, b) SNAP-LC peak picking 
algorithm was applied to pick out osmiated species (shown in purple in the 
chromatogram) and generate a prefer list of osmiated species, c) nLC-ECD MS/MS 
using the prefer list, EIC of the fragmented osmiated species are shown in green in 
the chromatogram, d) example of visualising the ECD MS/MS of one of the 
osmiated peaks (728.25912 m/z, shown in red in the chromatogram). 
Figure 2.7 shows the ECD MS/MS spectrum of an osmiated species at 
728.25912 m/z (Table S2.4).  It is worth noting that, the unmodified peptide 
(pENCDQFEK) is observed. This is believed to be due to a dissociation of the osmium 
drug during transmission with some of the precursor ions or an electron is captured at 
the metal centre, causing instability of the complex and dissociated the ligand/peptide.  
Despite the dissociation of the osmium drug, some useful osmiated fragments were still 
observed, allowing the characterisation of the binding site of the osmium drug.  A series 
of osmiated z fragments were observed, from z2 to z5, narrowed down the binding region 
to the two residues (glutamic acid (E) and lysine (K) near the C-terminus).  728.25912 




m/z was observed as a doubly-charged species, and the two positive charges were 
contributed by the osmium metal centre.  The nitrogen from the lysine side chain 
donates two electrons to form a coordinate covalent bond with the metal centre, as 
shown in the proposed structure in Figure 2.7. 
 
Figure 2.7 ECD MS/MS of the osmiated species, 728.25912 m/z, resulting from the 
reaction of Os1 with pENCDQFEK (residue 413-420).  Osmium containing species 
are labelled in purple. Inset on the left shows the dissociation of the osmium 
complex, Os1, and inset on the right shows an overlapping isotope pattern by the 
unmodified peptide [pENCDQFEK]1+ (shown in red) and [z5+Os1-2H]1+ (shown in 
blue). 





Figure 2.8 ECD MS/MS of the osmiated species, 718.58996 m/z.  Osmium 
containing species are labelled in purple. Inset on the left shows an overlap 
distribution of the osmium complex, Os1 is shown in red and Os1-H is shown in 
blue. Inset on the right shows a unique side chain loss of the arginine residue from 
the charge-reduced species. 
 The peak with 718.58996 m/z is another osmiated species 
(ECCHGDLLECADDR+Os1) picked out by the SNAP-LC algorithm and the ECD 




MS/MS spectrum is shown below in Figure 2.8 (Table S2.5).  From the inset of the left, 
it shows an overlap isotope distribution of two osmium complexes, Os1 (C14H18N2Os, 
shown with red simulation) and Os1-H (C14H17N2Os, shown with blue simulation).  The 
unmodified peptide (ECCHGDLLECADDR) (residue 267-280) was observed.  
However, it is important to investigate whether the peptide binds to Os1 or Os1-H.  The 
osmium containing fragments have narrowed the binding site to the arginine residue (R) 
and the C-terminus.  There is one important species in the ECD MS/MS spectrum that 
allows the determination of the exact binding site, whether the osmium complex is 
binding to the arginine side chain or the C-terminus.  The unique loss of arginine side 
chain (CH5N3, -59.048 Da) was observed from the charge-reduced species (CRS).
40  It is 
worth noting that the species still possesses a distinct osmium isotope pattern, 
suggesting that the loss of the arginine side chain is not influencing the observation of 
osmium binding.  Therefore, the peptide is binding to the osmium complex via the C-
terminal carboxylate group (COO-), leaving the osmium complex at a charge of 1+, and 
the remaining two positive charges are contributed by 2 protons on the peptide. 
 Figure 2.9 shows another osmiated peptide at 663.79464 m/z, and two osmium 
complexes with different composition, Os1 and Os1-H were observed in the spectrum 
again.  The fragmentation pattern localises the binding site to glutamic acid (E) and 
valine (V) in the peptide sequence (Table S2.6).  However, valine is not a viable binding 
location because of the purely hydrocarbon side chain, therefore, the peptide is binding 
to the osmium complex via the carboxylate side chain of glutamic acid.  The interaction 
leaves the osmium complex at a 1+ charge and together with a proton from the peptide, 
allowed the observation of the osmiated peptide precursor as a doubly charged species. 





Figure 2.9 ECD MS/MS of the osmiated species, 663.79464 m/z.  Osmium 
containing species are labelled in purple. Inset shows an overlap distribution of the 
osmium complex, Os1 is shown in red and Os1-H is shown in blue. 
 From the peak list generated by the SNAP-LC algorithm, a series of nLC-ECD 
MS/MS experiments were performed and are summarised Figure 2.10.  Even though a 
separation process was performed using a RP C18 column prior to MS analysis, ion 
suppression and co-elution were still potential obstacles to obtain effective isolation and 
fragmentation.  And unfortunately, this is exactly what was observed with the nLC-




MS/MS experiments.  To overcome this problem, a truly data-independent acquisition 
method, such as two dimensional mass spectrometry,41 would be required, so that all 
observed precursor can be fragmented and characterised. 
 
Figure 2.10 Osmiated BSA peptides identified from the SNAP-LC analysis of the 
nLC-MS data.  The identified binding locations are highlighted in purple. 
Conclusions 
 Microwave digestion was found to have digested BSA extensively into short 
peptides, yielding dominantly singly-charged species compared to standard tryptic 
digestion, which mainly multiply-charged species were observed.  Parameters of 
microwave digestion can be further optimised, e.g. lowering down the power and shorter 
hold time. 
Os1-Cl was reacted with a tryptic digested BSA as a model system to develop a 
methodology for metallodrug-binding site MS analysis.  Using ultra-high resolution 
mass spectrometry, the metallodrug Os1-Cl was shown to react with the tryptic digested 
BSA protein and produced a series of osmiated species.  With direct infusion, a few 




osmiated peptides were observed in low intensities possibly due to ion suppression and 
space charge effects from the high abundance unmodified peptides. 
 With CAD MS/MS, the osmium complex dissociated readily even using low 
collision energy (5 V), leaving with the unmodified peptide, suggesting the binding 
interaction between the osmium complex and the target peptide is weaker than the 
protein backbone.  ECD MS/MS was shown to preserve the osmium complex on the 
target peptides upon electron-based fragmentation, and more binding information was 
revealed.  Os1-Cl was found to interact with the side chain of lysine of peptide KFWGK 
(156-160) as well as a weak π-π interaction with the aromatic region of tryptophan.  
 nLC-MS and nLC-MS/MS were also attempted to separate the complex mixture 
of tryptic digested peptides (unmodified and osmiated), so that more osmiated species 
can be observed and studied.  SNAP-LC algorithm was used to pick out any species 
containing an osmium modification,35 and generated a prefer list for targeted nLC-ECD 
MS/MS experiments, to study the exact binding location of the osmium complex in the 
target peptides.  More osmiated peptides with higher ion intensities were indeed 
observed and allowed more effective isolation and fragmentation compared to direct 
infusion, binding sites were revealed to be the side chains of glutamic acids and lysines, 
as well as the N- and C- termini.  
 This work demonstrates the flexibility of FT-ICR mass spectrometry and its 
capability to employ different fragmentation techniques to characterise metallodrug 
binding to biomolecules of interest.  FT-ICR MS can also be coupled to hyphenated 
techniques, such as liquid chromatography (LC) or gas chromatography (GC) for 
analyte separation prior to MS analysis.  FT-ICR MS provides the highest resolving 
power and mass accuracy performance of any MS platform available, offer extremely 
high confident spectral assignment, with mass errors often measured to sub-ppm or even 
ppb.  Therefore, FT-ICR MS is particularly adept for the characterisation of 
metallodrug-biomolecule interactions. 
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Table S2.1 Assignments for Figure 2.2: Full MS of [Os1-Cl]-BSA.  Osmiated 
species are highlighted in purple. 







Mass Error (ppm) 
[P249-256] 2+ C42H69N9O14 461.747638 461.747652 0.03 
[P37-44] 2+ C43H65N11O15 487.732538 487.732863 0.67 
[P337-340] 1+ C20H37N6O8S 521.238800 521.238954 0.30 
[P157-160] 1+ C28H37N6O5 537.282000 537.281730 -0.50 
[P437-451] 3+ C72H129N20O23 547.317417 547.316932 -0.89 
[P499-507] 2+ C43H77N15O17S2 569.752638 569.752840 0.35 
[P257-266] 2+ C52H94N14O15 577.350588 577.350358 -0.40 
[P66-75] 2+ C53H88N12O17 582.318988 582.318997 0.02 
[P25-34] 2+ C49H82N18O17 597.304738 597.304625 -0.19 
[P223-232] 2+ C50H84N16O16S 598.298038 598.298125 0.15 
[P35-44] 2+ C58H86N14O17 625.314238 625.314125 -0.18 
[P236-241] 1+ C31H49N10O8 689.372900 689.372881 -0.03 
[P223-228] 1+ C28H52N9O10S 706.355200 706.355128 -0.10 
[P106-122] 3+ C83H131N24O35S3 706.611817 706.612325 0.72 
[P400-412] 2+ C70H121N19O20 773.951238 773.951128 -0.14 
[P257-263] 1+ C35H65N8O12 789.471600 789.471689 0.11 
[P437-451] 2+ C72H128N20O23 820.472488 820.472406 -0.10 
[P156-160] 2+ C82H114N18O12Os 867.423852 867.423896 0.05 
[P249-256] 1+ C42H68N9O14 922.488000 922.488128 0.14 
[P161-167] 1+ C44H67N10O12 927.493400 927.493654 0.27 
[P341-346] 2+ C78H115N20O24Os 953.900301 953.900952 0.68 
[P598-607] 1+ C44H80N11O15 1002.583000 1002.582965 -0.03 
[P549-557] 1+ C46H84N11O14 1014.619400 1014.618565 -0.82 
[P310-318] 1+ C44H74N13O16S 1072.509200 1072.508912 -0.27 
 
Average -0.01 ppm 
Absolute Average 0.37 ppm 
Standard Deviation 0.41 ppm 
 




Table S2.2 Assignments for Figure 2.3: CAD MS/MS of the osmiated species at 
867.42385 m/z.  Osmiated species are highlighted in purple. 







Mass Error (ppm) 
[Os1] 1+ C14H18N2Os 406.107956 406.10795 -0.02 
[P156-160] 2+ C82H114N18O12Os 867.423852 867.42377 -0.10 
[P156-160] 2+ C68H97N16O12 1329.746639 1329.74684 0.15 
 
Average 0.01 ppm 
Absolute Average 0.02 ppm 
Standard Deviation 0.09 ppm 
 
Table S2.3 Assignments for Figure 2.4: ECD MS/MS of the osmiated species at 












[Os1] 1+ C14H17N2Os 405.100131 405.10012 -0.03 
[FWGK] 1+ C28H37N6O5 537.281995 537.28188 -0.22 
[(GK)+Os1] 1+ C22H18N5O3Os 592.101967 592.10207 0.17 
[(KFWGK)2+Os1] 2+ C82H114N18O12Os 867.423852 867.42406 0.24 
[(GK+KFWGK)+Os1] 1+ C56H83N13O9Os 1273.605078 1273.60603 0.74 
[(WGK+KFWGK)+Os1] 1+ C67H85N15O10Os 1451.621978 1451.62111 -0.60 
[(KFWG+KFWGK)+Os1] 1+ C76H95N15O11Os 1585.695326 1585.69412 -0.76 
 













Table S2.4 Assignments for Figure 2.7: ECD MS/MS of the osmiated species at 












Os1 1+ C14H17N2Os1 405.100131 405.10013 0.00 
z2+Os1-H 1+ C25H37N4O5Os1 665.237429 665.23686 -0.86 
M 2+ C57H80N14O17Os1S1 728.257656 728.25759 -0.09 
z3+Os1-H 1+ C34H46N5O6Os1 812.305927 812.30578 -0.18 
z4+Os1-2H 1+ C39H53N7O8Os1 939.356737 939.35667 -0.07 
z5+Os1-2H-CO2 1+ C42H58N8O9Os1 1010.393890 1010.39390 0.01 
pENCDQFEK 1+ C43H63N12O17S1 1051.414936 1051.41476 -0.17 
z5+Os1-2H 1+ C43H58N8O11Os1 1054.383739 1054.38340 -0.32 
M-CONH2•-
C4H11N-H 
1+ C52H66N12O16Os1S1 1338.405171 1338.40618 0.75 
M-CONH2•-H 1+ C56H77N13O16Os1S1 1411.494381 1411.49488 0.35 
M-H 1+• C57H79N14O17Os1S1 1455.508034 1455.50860 0.39 
 
Average -0.02 ppm 
Absolute Average 0.29 ppm 
Standard Deviation 0.42 ppm 
 
  




Table S2.5 Assignments for Figure 2.8: ECD MS/MS of the osmiated species at 












z1 1+ C6H13N3O2 159.100228 159.10023 0.01 
z2 1+ C10H18N4O5 274.127172 274.12717 -0.01 
z1+Os1 1+ C20H27N5O2Os1 561.177478 561.17716 -0.57 
c4 1+ C21H34N9O8S2 604.196629 604.19663 0.00 
c5 1+ C23H37N10O9S2 661.218093 661.21759 -0.76 
z2+Os1 1+ C24H35N6O5Os1 679.227915 679.22725 -0.98 
[M+2H] 3+ C80H123N24O28Os1S3 718.590039 718.58996 -0.11 
c6 1+ C27H42N11O12S2 776.245037 776.24456 -0.61 
z3+Os1 1+ C28H37N7O8Os1 791.231421 791.23162 0.25 
z11+Os1 2+ C65H97N18O21S1Os1 844.820213 844.82040 0.22 
ECCHGDLLECADDR 2+ C66H106N22O28S3 875.334903 875.33445 -0.52 
c7 1+ C33H53N12O13S2 889.329101 889.32869 -0.46 
c8 1+ C39H64N13O14S2 1002.413165 1002.41276 -0.40 
CRS-CH5N3 2+ C79H119N21O28Os1S3 1048.865073 1048.86508 0.01 
c9 1+ C44H71N14O17S2 1131.455759 1131.45678 0.90 
c10 1+ C49H79N16O19S3 1291.486408 1291.48595 -0.35 
ECCHGDLLECADDR-
H2O 
1+ C66H103N22O27S3 1731.651966 1731.65112 -0.49 
ECCHGDLLECADDR 1+ C66H105N22O28S3 1749.662530 1749.66201 -0.30 
 
Average -0.23 ppm 










Table S2.6 Assignments for Figure 2.9: ECD MS/MS of the osmiated species at 
663.79464 m/z.  Osmiated species are highlighted in purple. 









Os1 1+ C14H17N2Os1 405.100131 405.09994 -0.47 
M+H 2+ C56H85N11O14Os1 663.794317 663.79464 0.49 
z4+Os1 1+ C34H54N6O8Os1 866.361435 866.36071 -0.84 
AEFVEVTK 1+ C42H68N9O14 922.488024 922.48859 0.61 
z5+Os1-2H 1+ C39H61N7O9Os1 963.414258 963.41465 0.41 
c6+Os1 1+ C46H66N9O10Os1 1096.454534 1096.45506 0.48 
z6+Os1 1+ C48H71N8O10Os1 1111.490620 1111.49097 0.31 
c7+Os1 1+ C50H73N10O12Os1 1197.502276 1197.50269 0.35 
M+H 1+• C56H85N11O14Os1 1326.581356 1326.58186 0.38 
 
Average 0.19 ppm 
Absolute Average 0.48 ppm 
Standard Deviation 0.50 ppm 
 




Reduction of Disulfide Bonds in Proteins for Enhanced MS and MS/MS 
Capabilities 
 Disulfide bonds have important biological functions but also present a distinct 
challenge in tandem mass spectrometry analysis of proteins.  Chemical reduction and 
alkylation are often used to overcome this hurdle in bottom-up or top-down approaches, 
however, they often induce undesired modifications or present limited effectiveness by 
the sample conditions, such as pH environment which is non-optimum for reducing 
disulfide bonds. 
 This chapter of the thesis is centred around the study of alternative reduction 
techniques, without the need of introducing extra chemicals into the sample for 
reduction.  These alternative methods have shown to effectively reduce the disulfide 
bonds, yielding better fragmentation efficiencies, and allow better protein identification 
and characterisation with tandem mass spectrometry, allowing future studies of 
metallodrug modified proteins without chemical digestion. 
 Although the results presented within this chapter are predominantly based on 
FT-ICR MS and all results were analysed and written by the thesis Author, this was a 
collaborative project with researchers, namely; Christopher Wootton assisted with some 
of the data acquisition and helped with analysing the complex data.  Antec Scientific 
kindly provided the ROXY electrochemical system for this electrochemical reduction 
study, which was later published as an application note for Antec, titled “Monitoring the 
Electrochemical Reduction of Disulfide Bonds in Proteins for Enhanced MS and 
MS/MS Capabilities” and can be found on the Antec Scientific webpage: 
“https://antecscientific.com/support/documents-and-downloads/application-notes” by 
Christopher A. Wootton and Cookson Chiu, Agnieszka Kraj, Thomas Lambert, Simon 
Lambert, and Peter B. O’Connor. 
A manuscript entitled “Reduction of Disulfide Bonds in Proteins for Enhanced 
MS and MS/MS Capabilities” by Cookson K. C. Chiu and Christopher A. Wootton, 
Mark P. Barrow, and Peter B. O’Connor, has been prepared for submission to the 
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Journal of the American Society for Mass Spectrometry (JASMS) based directly on the 
contents and findings of this chapter. 
  




 Disulfide bonds are an important class of protein post-translational modifications 
and involved in many vital biological functions, e.g. protein folding and tertiary 
structure.  However, the presence of disulfide bonds in proteins often present as a 
challenge in MS/MS-based experiments.  Fragmentation efficiency in tandem mass 
spectrometry (MS/MS) is often hindered by the presence of “disulfide bond protected” 
regions, by creating cyclic structures along the protein backbone.  Chemical reduction 
and alkylation are often used to reduce these disulfide linkages and “open up” the 
protein structure, allowing more protonation, thus, achieving higher charge states.  
However, by inducing chemical-based reducing reagents into the sample can easily 
disrupt many chemically labile modifications or worse, induce modifications onto the 
proteins artificially, increasing the difficulty of data analysis greatly.  Alternative 
reduction methods, such as electrochemical reduction and radical-induced reduction, 
have been investigated to cleave these cystine linkages without traditional techniques, 
preventing unnecessary chemical disruptions of the sample. Herein, the performance and 
capability of electrochemical reduction and radical-induced reduction were investigated 
by using medium-sized proteins, including lysozyme, ribonuclease A, and insulin.  The 
reduction processes of both methods were monitored using ultra-high resolution mass 
spectrometry, with the aid of various fragmentation techniques.  The results show that 
both methods can effectively reduce the disulfide bonds and enhance the fragmentation 
efficiency, allowing better protein identification and characterisation, and present 
possible methods for studying proteins modified with chemically labile species, such as 
chemotherapeutic metallodrugs. 
Introduction 
Proteomics is a popular research topic worldwide and many branches of research 
are very active, including protein identification,1 protein quantification,2,3 post-
translation modification (PTM) characterisation,4,5 and even protein structure 
elucidation.6  Proteomics is important because it provides insight into the mechanisms 
and inner working of cells, which is critical to understand how diseases affect the host 
and to design appropriate targeted treatments.  Bottom-up proteomics studies have 
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shown much success in the study of entire host proteomes over the years.7  However, 
there are inherent disadvantages of bottom-up proteomics, including loss of PTMs,8 
inaccurate protein identification etc.  Therefore, top-down (intact protein) proteomics 
studies have steadily increased in popularity in recent years for studying biological 
molecules/systems of interest.  The top-down approach preserves the most information 
of the initial biological system, including intact protein sequences and chemical 
modifications (e.g. PTMs) as less disruptive chemicals are needed, which could 
alter/dissociate labile modifications and interactions in-between or within the proteins. 
Drug target analysis is particularly important in drug design to enhance a drug’s 
selectivity and specificity.  However, one particularly challenging hurdle for top-down 
analysis using MS and MS/MS is the presence of disulfide bonds within proteins of 
interest.  Cystine disulfide bonds are covalent linkages within protein structures and 
occur frequently in both intra-protein and inter-protein linkages.  The formation of 
disulfide bonds in proteins is an important PTM related to protein folding and conferring 
stability on protein tertiary structures.9,10  However, these disulfide linkages create 
cyclic regions within the protein sequence which hinder fragmentation and the 
production of sequence informative fragments, limiting the fragmentation efficiency 
upon MS/MS.  Breaking disulfide linkages is often achieved by using chemical-based 
reducing reagents, such as dithiothreitol (DTT), reducing the sulphur-sulphur linkage to 
2 free thiols (SH).  Reformation of disulfide bonds is often quickly observed after 
reduction (< 1 h), therefore, alkylating reagents such as iodoacetamide (IAA) are often 
added to the reduced sample, preventing the reformation of disulfide bonds by reacting 
with the free thiols.  These chemicals are often used in bottom-up or top-down analysis, 
however, these reactions often use very harsh reagents and conditions, e.g. using excess 
of reducing and alkylation reagents to maximise their effectiveness and turnover, which 
can easily damage certain protein/modification functional groups, and can easily modify 
analytes artificially providing misleading information during analysis and requiring 
further sample preparation/clean up steps downstream.  Alternative reduction techniques 
have therefore been studied to overcome the use of chemical-based reduction. 
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Electrochemistry (EC) has been shown to reduce disulfide bonds successfully, 
enhancing the fragmentation performance and increasing the protein sequence cleavage 
coverage upon MS/MS.11,12  By reducing the disulfide bonds electrochemically, no 
chemical-based reducing reagents are needed during sample preparation, meaning the 
protein structure/modifications are less likely to be affected, and no extra clean up steps 
are required prior to MS analysis.  The electrochemical cell can also be hyphenated with 
MS for online disulfide bond reduction, allowing more effective reduction without extra 
sample preparation, preventing the loss of sample or contamination when performing the 
reduction process separately. 
Plasma-induced or ultraviolet induced radicals have also been shown to be able 
to reduce disulfide linkages successfully.  Xia et al. have shown plasma-induced 
radicals, often hydroxyl radicals, initiated from a low-temperature helium plasma were 
able to break disulfide bonds via dissociative addition.10,13  Later, Xia et al. discovered 
that ultraviolet photo-induced radicals can also break disulfide linkages by irradiating 
the nano electrospray ionisation (nESI) plume with ultraviolet photons (185 and 254 
nm).  Small oxygen-containing radical species can be produced from oxygen in air and 
react in situ with the disulfide bonds within the nESI plume.  Oxygen in air absorbs 
energy from ultraviolet photons and generate reactive atomic oxygen (O(3P)) and 
metastable excited oxygen (O(1D)), which further react with the water molecules in the 
solvent system and produce hydroxyl radicals (•OH).  The hydroxyl radicals then react 
with the saturated alcohol (methanol, CH3OH) in the solvent system and generate 
carbon-centred hydroxyalkyl radicals (•CH2OH, Scheme 3.1).
14  The hydroxyalkyl 
radicals have been shown to break the disulfide bonds and allow better cleavage 
coverage for tandem mass spectrometry experiments. 




Scheme 3.1 (a) oxygen in air irradiated by UV photons and becomes reactive 
atomic oxygen, (b) metastable excited oxygen reacts with water and create 
hydroxyl radicals, (c) Hydroxyl radicals react with methanol and generate 
hydroxyalkyl radicals and water.14 
 Top-down analysis often involves larger proteins, therefore, extremely accurate 
measurement of the protein’s intact mass-to-charge ratio (m/z) and MS/MS fragments 
are critical for top-down proteomics analysis, to resolve and identify fragments, PTMs, 
and thus, proteins and proteoforms.  Fourier transform-ion cyclotron resonance mass 
spectrometry (FT-ICR MS) is an analytical technique especially well-known for its 
ultra-high resolution, routinely 500,000 - 1,000,000 resolving power,15 and the highest 
mass accuracy, usually obtaining sub parts-per-million (ppm) to parts-per-billion (ppb) 
ranges of mass errors.16  FT-ICR MS also offers the widest array of fragmentation 
techniques, such as collisionally activated dissociation (CAD),17 electron capture 
dissociation (ECD),18 electron induced dissociation (EID),19 electron detachment 
dissociation (EDD),20 infrared multiphoton dissociation (IRMPD),21 ultraviolet 
photodissociation (UVPD),22 etc.  These important features offered by FT-ICR MS 
allow extremely accurate measurement of the protein’s intact m/z and provide sequence-
informative fragments using various fragmentation techniques. 
 Herein two different instrumentation-based methods are investigated; 
electrochemical reduction and radical-induced reduction of disulfide bonds within 
protein structures, enabling more effective MS and MS/MS experiments.23  Both 
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techniques enabled a large increase in subsequent MS/MS fragmentation and sequence 
cleavage coverage.  In addition, analysis of isotopic patterns shows that the EC 
reduction process occurs in a sequential manner depending on the electrode potential 




Human lysozyme (hLZ), human insulin, bovine ribonuclease A (RNAase A), 
formic acid, dithiothreitol (DTT), and iodoacetamide (IAA) were all purchased from 
Sigma Aldrich (Dorset, England).  LCMS grade acetonitrile (MeCN) was purchased 
from VWR (Lutterworth, UK). LCMS grade methanol (CH3OH) was purchased from 
Thermo Fisher Scientific (Waltham, UK).  Ultra-pure water (18.2 MΩcm-1) was 
obtained from a Milli-Q UV III water purification system (Milli-Q, Hertfordshire, UK). 
Electrochemical Reduction 
 Electrochemical reduction of disulfide bonds was achieved using a ROXY EC 
system (Antec, The Netherlands), consisting of a potentiostat, equipped with a µ-
PrepCell 2.0 fitted with a proprietary Ti-Blue electrode (methylene blue coated titanium 
electrode), and a syringe pump.  Samples (non-reduced intact proteins) were passed 
through an electrochemical cell, at a constant flow rate ~ 1-2 µL/minute, using a syringe 
pump (Figure 1).  Disulfide bonds present in the sample were reduced when the sample 
was passed through the electrochemical cell.  The potentiostat provided a consistent 
negative voltage for disulfide bond reduction.  The µ-PrepCell 2.0 is a thin-layer 
electrochemical cell consisting of a Ti-Blue working electrode (WE), a conductive 
polymeric auxiliary electrode (conductive PEEK) (AUX), and a palladium/hydrogen 
(Pd/H2) reference electrode (REF).  A 75 µm spacer was used between the AUX 
electrode and base EC cell to provide a flow path, allowing smaller dead volumes than 
previous 150 µm spacer designs.  The flow rate and spacer height dictated dwell time 
within the cell, thus affecting reaction time and products.  These were optimised to be 
balanced with good ESI spray conditions to 75 µm spacer and 1-2 µL/minute flow rate. 




Figure 3.1 Schematic representation of the electrochemical disulfide bond 
reduction set up.  A ROXY electrochemical cell is installed after the syringe pump 
and prior to the mass spectrometer.  The samples were reduced in the ROXY 
electrochemical cell (orange arrows indicate sample flow direction).  REF is the 
reference electrode, AUX is the auxiliary electrode, and WE is the working 
electrode.   
Radical-Induced Reduction 
A 2.54 cm lamp length, 0.64 cm diameter, double bore tubing low pressure 
mercury (LP Hg) lamp with a synthetic quartz lamp case (model number: 81-1057-51; 
BHK, Inc., California, USA), operating at 20 mA, was used to initiate the radical 
reactions by generating hydroxyalkyl radicals.  The lamp specifications from the 
manufacturer states the minimum intensity with the primary wavelength (254 nm) at 20 
cm distance was measured 73 µW/cm2 and 42 µW/cm2 for 185 nm measured in an 
argon atmosphere.  The mercury lamp was placed ~ 2 cm away from the centre of the 
nESI plume (Figure 2).  The arc lamp was driven by a power supply (start voltage of 
1050 V and operational voltage of 320 V) (BHK, Inc., California, USA) which allowed 
stable use for many hours with no noticeable change. 




Figure 3.2 Schematic representation of the radical-induced disulfide bond 
reduction set up.  The UV lamp was placed 2 cm next to the nESI plume, allowing 
the UV photons to react with the methanol in the sample and create hydroxyalkyl 
radicals. 
Mass Spectrometry 
 Samples for electrochemical reduction were analysed with electrospray 
ionisation (ESI) to achieve a constant flow rate of ~ 1-2 µL/minute.  Samples with 
radical-induced reduction were analysed with nESI using borosilicate glass capillary, 
pulled with a P-97 Flaming/Brown micropipette puller (Sutter Instrument, California, 
USA).  All experiments were carried out on a SolariX FT-ICR mass spectrometer, fitted 
with a 12 tesla actively shielded magnet (Bruker Daltonik GmbH, Bremen, Germany).  
All samples were sprayed in positive ion mode.  For MS experiments, ions were 
accumulated for 0.1-0.5 s in the hexapole-based collision cell before transferred to the 
infinity cell for excitation and detection.24 
 For CAD MS/MS experiments, ions of interest were isolated using the front-end 
quadrupole using an isolation window of 10-30 m/z.  Selected ions were then accelerated 
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into argon collision gas at 18-25 V.  Ions were continuously accumulated for 3 s before 
transmission and detection. 
 For ECD MS/MS experiments, ions of interest were isolated using the front-end 
quadrupole using a window of 4-10 m/z, then accumulated in the hexapole for 3-4 s.  
Isolated ions of interest were then transferred and trapped in the infinity cell.  Trapped 
ions were then irradiated for 15-25 ms with 1.2 eV electrons produced from a 1.5 A 
hollow cathode dispenser via an extraction lens held at 18 V. 
 All spectra were internally calibrated using a quadratic calibration function25 and 
peak picked using Sophisticated Numerical Annotation Procedure (SNAP) algorithm 
v2.0 using the following parameters: quality factor of 0.80, a signal-to-noise (S/N) 
threshold of 2, and a maximum charge state of 20+, a constant building block (base 
elementary composition) of C = 4.9384, N = 1.3577, O = 1.4773, S = 0.0417, H = 
7.7583.  All spectra were then manually interpreted and assigned via DataAnalysis v4.2 
(Bruker Daltonik GmbH, Bremen, Germany). 
Results and Discussion 
Electrochemical Reduction 
 Heavily disulfide-bonded proteins (such as lysozyme (4 disulfides), RNAase A 
(4 disulfides), and antibodies (16 disulfides) etc.) were ionised and analysed using ESI-
MS, but are often observed at lower charger states (higher m/z) and narrower charge 
state distributions compared to non-disulfide-bonded analogous species as the protein 
structures are held together with cystine linkages, preventing further regions being 
protonated.  As a result of these effects, observation of high charge states for lower limit 
of detection and for more extensive fragmentation in MS/MS experiments is often 
limited.  Thus, the use of a denaturing/acidified solvent system has become a common 
technique to maximise the level of protonation on biomolecules by unfolding the protein 
structure.  However, due to the presence of these cystine linkages, even in a 
denaturing/acidified solvent system, many proteins, such as human lysozyme (hLZ) and 
ribonuclease A (RNAase A) were observed in relatively low charge states, from 8+ to 
12+ (Figure 3.3a and 3.4a respectively).  However, with electrochemical reduction, 
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whole new arrays of charge state distributions were observed for both hLZ and RNAase 
A samples when disulfide bonds were reduced at -2.0 V with the ROXY-EC system.  A 
charge state distribution of 8+ to 20+ (8 new charge states) was observed for hLZ 
(Figure 3.3b) and 8+ to 18+ (6 new charge states) for RNAase A (Figure 3.4b). 
 
Figure 3.3 ESI-MS spectra of hLZ under denaturing conditions (50:50 H2O:MeCN 
+ 1% formic acid).  a) no reduction by ROXY-EC system, b) reduced by ROXY-
EC system at -2.0 V. 
 
Figure 3.4 ESI-MS spectra of RNAase A under denaturing conditions (50:50 
H2O:MeCN + 0.1% formic acid).  a) no reduction by ROXY-EC system, b) reduced 
by ROXY-EC system at -2.0 V. 
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 For species such as insulin26 and antibodies27, the reduction of disulfide bonds 
results in the separation of peptide chains, forming distinctly different product species, 
and be observed in the resulting mass spectrum.  However, for species having 
intramolecular disulfide bonds such as hLZ and RNAase A, reduction of each disulfide 
bond only results in an addition of two nominal mass units (2H, 2.015650 Da).  Due to 
the extended isotopic pattern of larger biomolecule species, separating the new reduced 
species (+2H) isotopic pattern from that of the non-reduced species is particularly 
challenging, even for ultra-high resolution instrumentation such as FT-ICR MS (Figure 
3.5). 
 
Figure 3.5 Isotopic simulations of the reduction products of hLZ (charge state 9+).  
a) non-reduced hLZ, b) hLZ with 1 disulfide bond reduced, c) hLZ with 2 disulfide 
bonds reduced, d) hLZ with 3 disulfide bonds reduced, e) hLZ with 4 disulfide 
bonds reduced (fully reduced). 
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Instead, a statistical approach was adopted in which each individual isotope and 
its peak area was measured from each charge state observed for each reduction potential 
(14 different potentials, from -2.6 V to 0 V, with increments of 0.2 V) produced from 
the ROXY-EC system, constituting ~ 2500 isotopes measured for each protein (hLZ and 
RNAase A)  At certain reduction potentials, some disulfide bonds were reduced, while 
others remained, the isotopes could then be used to calculate how many disulfide bonds 
had been reduced by comparing the isotope peak areas with that of the non-reduced 
isotopic pattern.  Isotopic peak measurements were weight-averaged and scaled 
according to their differences between the non-reduced protein form (e.g. Figure 3.5a 
for hLZ) and the fully reduced protein form (Figure 3.5e for hLZ). This scaling provided 
a percentage of reduction measurement, which could easily be converted to the number 
of disulfide bonds via division by the number of disulfide bonds in the protein of interest 
(e.g. the 4 disulfide bonds in hLZ equate to 25% reduction per disulfide bond).  The 




        [Eq. 1] 
where x̅i is the weighted average of the i+ charge state at the reducing potential, m/z is 
the mass-to-charge ratio of individual isotope in the i+ charge state distribution, and A is 




× 100%    [Eq. 2] 
where scaled x̅i is scaled weighted average of the i+ charge state at the reducing 
potential, x̅i(non-reduced) is the weighted average of the i+ charge state from simulation, and 
x̅i(fully reduced) is the weighted average of the i+ charge state from simulation. 










  [Eq. 3] 
where ƩAi is the sum of peak areas of all isotopes from i+ charge state, and ƩAall is the 
sum of peak areas of all isotopes from all charge states. 
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 The results (shown below in Figures 3.6 and 3.7) show that the electrochemical 
reduction process is sequential, and that disulfide bonds can be selectively reduced by 
applying the correct potential.  The results also show that as disulfide bonds are reduced, 
they are able to unfold even more under the denaturing conditions used (50:50 
H2O:MeCN + 1% formic acid) and attain higher charge states during the ESI process. 
 
Figure 3.6 Number of disulfide bonds reduced as a function of EC potential using 
the ROXY EC system to reduce hLZ.  Each charge state is shown separately to 
show transitions of proteins to higher charge states upon reduction. 




Figure 3.7 Number of disulfide bonds reduced as a function of EC potential using 
the ROXY EC system to reduce RNAase A.  Each charge state is shown separately 
to show transitions of proteins to higher charge states upon reduction. 
 Figures 3.6 and 3.7 show that the more reduced protein species occupy most of 
the higher charge states, while the less reduced species still reside within the lower 
charge states more naturally seen from the control spectra (Figures 3.3a and 3.4a).  This 
approach also demonstrated the inaccuracy with using one charge state to monitor the 
reduction process, as reduced (and thus more unfolded) species readily adopt more 
highly charged states, monitoring a single, lower charge state from the control spectrum 
would lead to an underestimate of the overall reduction taking place. 
 Full reduction of all 4 disulfide bonds in each protein can be observed in both 
hLZ and RNAase A.  The hLZ protein species was calculated to be fully reduced at a 
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potential of -2.2 V (at certain charge states), while RNAase A at -2.0V.  The average 
number of disulfide bonds reduced at a given potential, using the findings shown in 
Figures 3.6 and 3.7, are shown in Figure 3.8, emphasising the differences for the two 
proteins studied. 
 
Figure 3.8 Average number of disulfide bonds reduced at each potential using the 
ROXY-EC system for hLZ (top) and RNAase A (bottom). 
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 Human insulin was also used to investigate the reduction performance of the 
ROXY-EC system (Figure 3.9).  Unlike hLZ and RNAase A, when insulin is fully 
reduced, the two polypeptide chains (Chain A and Chain B) will be dissociated, which 
can be used to monitor the reduction event.  Using ESI-MS, 4+ to 6+ charge states of 
intact insulin were observed ([M+nH]n+)  Separated chains (Chain A (CA) and Chain 
B(CB)) were then observed with increasing reduction time.  The longer the reaction 
time, the higher the percentage of conversion (from intact insulin to the separated CA 
and CB) (Figure 10).  The percentage of conversion can be calculated using the equation 
below. 
𝑃𝑒𝑟𝑐𝑒𝑛𝑡𝑎𝑔𝑒 𝑜𝑓 𝐶𝑜𝑛𝑣𝑒𝑟𝑠𝑖𝑜𝑛 =
∑(𝐴(𝐶𝐴+𝐶𝐵))
∑(𝐴(𝑖𝑛𝑡𝑎𝑐𝑡))
× 100%   [Eq. 4] 
where Ʃ(A(CA+CB)) is the sum of peak areas of CA and CB, Ʃ(A(intact)) is the sum of peak 
areas of intact insulin. 
 
Figure 3.9 ESI-MS of insulin upon electrochemical reduction (EC voltage = -2.0 V) 
over a time period of 15.2 min.  a) t = 0 and no reduction, b) t = 8.2 min and 
conversion of 6.4%, c) t = 10.0 min and conversion of 10.3%, d) t = 11.6 min and 
conversion of 26.7%, e) t = 13.0 min and conversion of 40.3, and f) t = 15.2 min and 
conversion of 56.8%. 




Figure 3.10 Plot of percentage conversion (from intact to CA and CB) as a function 
of time. 
 Higher charge states have been shown to provide more extensive fragmentation 
during MS/MS experiments, and thus improve sequence/cleavage coverage, and overall 
protein characterisation.23  These benefits were also highlighted for the species observed 
above.  The hLZ species detected were subjected to CAD MS/MS and ECD MS/MS 
fragmentation in both their non-reduced and reduced forms.  Figures 3.11 and 3.12 
(Table S3.1) show the CAD MS/MS spectrum and the fragmentation map for the non-
reduced hLZ species.  From the fragmentation map in Figure 3.12, fragments near the 
termini are observed, as expected with CAD MS/MS, and it is clearly shown that the 
“disulfide bond protected” regions were not fragmented, yielding a cleavage coverage of 
10%.  However, by applying an EC voltage of -2.2 V, the disulfide linkages were 
reduced and allowed more protonation on the protein backbone, yielded an observation 
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of higher charge states (as shown in Figure 3.3b).  By applying CAD MS/MS to the 
reduced hLC species, a slight increase of cleavage coverage was observed from 10% to 
17% and more importantly, fragments were observed in the “disulfide bond protected” 
regions, allowing more sequence informative coverage (Figures 3.13 and 3.14, Table 
S3.2). 
 
Figure 3.11 CAD MS/MS spectrum of the non-reduced (no EC reduction) hLZ 
species. 
 
Figure 3.12 Fragmentation map for the CAD MS/MS spectrum of the non-reduced 
(no EC reduction) hLZ species, disulfide bonds are shown in red. 




Figure 3.13 CAD MS/MS spectrum of the reduced hLZ species (EC voltage = -2.2 
V). 
 
Figure 3.14 Fragmentation map for the CAD MS/MS spectrum of the reduced hLZ 
species (EC voltage = -2.2 V). 
 ECD MS/MS was also applied to investigate the difference in cleavage coverage 
between the non-reduced and reduced hLZ species.  Figures 3.15 and 3.16 (Table S3.3) 
show the ECD MS/MS spectrum and the fragmentation map of the non-reduced hLZ 
species.  Like CAD MS/MS of the same species, there were minimal fragments 
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observed in the “disulfide bond protected” regions, yielding a total cleavage coverage of 
3%, even though electrons were successfully captured by the non-reduced species, 
shown by the observation of a series of charge reduced species (CRS).  By applying an 
EC voltage of -2.2 V, the hLZ species was fully reduced and upon ECD MS/MS, a vast 
increase of 22% in cleavage coverage was observed (from 3% to 25%, ~7-fold 
increase), allowed much more extensive fragmentation and characterisation of the 
protein species, including the “disulfide bond protected” regions (Figures 3.17 and 3.18, 
Table S3.4). 
 
Figure 3.15 ECD MS/MS spectrum of the non-reduced (no EC reduction) hLZ 
species. 
 
Figure 3.16 Fragmentation map for the ECD MS/MS spectrum of the non-reduced 
(no EC reduction) hLZ species, disulfide bonds are shown in red. 




Figure 3.17 ECD MS/MS spectrum of the reduced hLZ species (EC voltage = -2.2 
V). 
 
Figure 3.18 Fragmentation map for the ECD MS/MS spectrum of the reduced hLZ 
species (EC voltage = -2.2 V). 
By comparing the cleavage coverage obtained by CAD and ECD MS/MS 
experiments on the non-reduced (EC voltage = 0V) and the fully reduced (EC voltage = 
-2.2 V) hLZ, a significant increase of 23% was observed (from 12% to 35%) (Figures 
3.19 and 3.20).  The increase in cleavage coverage on the protein backbone, even within 
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in “disulfide bond protected” regions, suggests the protein structure was opened up 
successfully upon EC reduction, allowing more protonation, and more extensive 
fragmentation. 
 
Figure 3.19 Combined fragmentation map of CAD and ECD MS/MS for the non-
reduced hLZ (no EC reduction). b and y fragments are shown in green; c and z 
fragments are shown in blue. Disulfide bonds are shown in red. 
 
Figure 3.20 Combined fragmentation map of CAD and ECD MS/MS for the fully 
reduced hLZ (EC voltage = -2.2 V). b and y fragments are shown in green; c and z 
fragments are shown in blue. 
  




 Xia et al. previously reported the use of a mercury lamp to cleave disulfide 
bonds in model peptides, e.g. C*IELLQARC* (* indicates cysteine linkages), and 
achieved more fragments upon fragmentation.14  By using a 50:50 H2O:CH3OH solvent 
system, and by irradiating with a mercury lamp, the UV photons can initiate a radical 
based reaction (Scheme 3.1), producing hydroxymethyl radicals (•CH2OH), which can 
react with free thiols preventing disulfide bond reformation from the disulfide cleaved 
species.  Herein, human insulin was used to investigate the performance of radical-
induced reduction by the mercury lamp on larger biomolecules. 
 The radical-induced reduction experiments were conducted using nano 
electrospray ionisation (nESI) and the experimental set up is shown in Figure 3.2.  Non-
reduced human insulin (intact) was observed from 3+ to 6+ charge states and it is worth 
noting that the insulin dimer was also observed as [2M+7H]7+ at t = 0 min when the 
mercury lamp was not switched on (Figure 3.21a).  With mercury lamp irradiation for 
5.3 min, only insulin monomer from 4+ to 6+ charge states and very low intensity of CA 
and CB were observed, suggesting the disulfide linkages were starting to be reduced and 
allowed more protons to attach to the insulin backbone.  At t = 7.0 min, CA and CB were 
observed with slightly higher abundance, and even more CA and CB were observed at t = 
27.0 min, showing the two inter-chain disulfide bonds were reduced effectively.  
However, unlike the electrochemical reduction approach, the intact insulin species were 
still dominant in the spectrum. 




Figure 3.21 nESI-MS of human insulin.  a) mercury lamp off and t = 0 min, b) 
mercury lamp on and t = 5.3 min, c) mercury lamp on and t = 7.0 min, and d) 
mercury lamp on and t = 27.0 min. 
 Figure 3.22 shows the nESI-MS spectrum of the insulin species when the 
mercury lamp been switched on for 27 min.  Aside from the observation of CA and CB, a 
series of “CH2OH” adducts were observed on different charge state species.  With the 
aid of ultra-high resolution MS, e.g. FT-ICR MS, all these species were isotopically 
resolved, allowing accurate assignments.  It is worth noting that, in some of the reduced 
species, S• instead of SH was observed, which could provide insight into the mechanism 
of the radical-induced reduction. 




Figure 3.22 nESI-MS of human insulin (mercury lamp on for 27.0 min), a series of 
CH2OH adducts were observed for different peaks (both intact and separated 
insulin). 
 MS/MS experiments were conducted to study the effect of fragmentation on 
non-reduced insulin. Figures 3.23 and 3.24 (Table S3.5) show the ECD MS/MS 
spectrum and the fragmentation map of intact insulin [M+5H]5+ respectively.  Disulfide 
bonds were previously shown to be preferentially cleaved with ECD MS/MS,28 which is 
also observed in the fragmentation map in Figure 24.  Aside from the fragments outside 
the “disulfide bond protected” regions, some fragments were also observed inside the 
regions, which the total cleavage coverage calculated to be 51%.  Figure 3.25 (Table 
S3.6) shows the fragmentation map of the CAD MS/MS of the same species, and apart 
from the fragments near the termini, no fragments from inside the “protected” region 
were observed, as expected.  The cleavage coverage was calculated to be 39%. 




Figure 3.23 ECD MS/MS spectrum of intact insulin species [M+5H]5+.  Fragments 
from CA are shown in blue, fragments from CB are shown in red, fragments from 
CB with an intact CA are shown in purple, and fragments from CA with an intact 
CB are shown in green. 
 
Figure 3.24 Fragmentation map of the ECD MS/MS spectrum of intact insulin 
species [M+5H]5+.  Fragments including the other intact chain are labelled in 
green.  Disulfide bonds are shown in red. 




Figure 3.25 Fragmentation map of the CAD MS/MS spectrum of intact insulin 
species [M+5H]5+.  Disulfide bonds are shown in red. 
 Insulin was chemically reduced with DTT and alkylated with IAA to achieve the 
two separated chains (CA and CB).  The chain B obtained was used to compare the 
fragmentation with the chain B produced from radical-induced reduction.  Figure 3.26 
(Table S3.7) shows the ECD MS/MS spectrum and the fragmentation map of the 
separated chain B produced from radical-induced reduction using the mercury lamp and 
yielded a cleavage coverage of 79%.  Figures 3.27 and 3.28 (Tables S3.8 and S3.9) 
show the fragmentation maps of the ECD MS/MS and CAD MS/MS of the same species 
obtained from chemical reduction and alkylation.  Interestingly, with ECD MS/MS no 
fragments were observed in the region between Cys7 to Cys19, even though the 
observation of CB indicated CB was no longer attached to CA.  This may suggest the two 
cysteine residues on CB (originally being inter-chain disulfide bonded with CA) have 
now formed a disulfide bond and protected the region, yielding a cleavage coverage of 
45%.  However, the fragmentation map of CAD MS/MS shows an almost complete 
cleavage coverage of 97%, which suggests there is no disulfide bond between the Cys7 
and Cys19.  This phenomenon, may be due to the non-optimum pH condition for the 
chemical reduction step with DTT.  During the insulin sample preparation, a small 
volume of formic acid was needed to lower to pH of the solvent in order to dissolve all 
the solid.  However, the reducing power of DTT is limited to pH values above 7 (basic), 
since only the negatively charged thiolate (S-) is reactive and hence led to an incomplete 
reduction before the alkylation step with IAA. 




Figure 3.26 ECD MS/MS of the CB produced from radical-induced reduction using 
the mercury lamp. 
 
Figure 3.27 Fragmentation map of ECD MS/MS of the CB produced from chemical 
reduction. 
 
Figure 3.28 Fragmentation map of CAD MS/MS of the CB produced from chemical 
reduction. 




 Disulfide bonds within protein architectures, though critical for biological 
function, present distinct challenges for effective MS and MS/MS characterisation of 
target proteins.  Electrochemical reduction and radical-induced reduction of disulfide 
bonds provide an effective, chemical-free method for reduction which requires no 
further sample preparation and can provide complete disulfide bond reduction in many 
protein targets. 
 The electrochemical reduction process was monitored using human lysozyme, 
bovine ribonuclease A, and human insulin.  The ROXY-EC reduction was shown to 
occur in a sequential process and could be used to reduce selectively certain disulfide 
bonds in stages.  The reduced protein species were shown to be more effectively ionised 
during ESI-MS and attained much higher charge states than non-reduced species.  
However, the electrochemical voltage required to fully reduce a disulfide bonded protein 
is protein-dependent, which can be measured using a statistical method, especially with 
large intra-disulfide bonded proteins, where the change in mass is often minimal.  
Insulin also used as an example of protein with inter-chain disulfide bonds.  By reducing 
the cysteine linkages, two separated polypeptide chains can be observed in a mass 
spectrum.  The presence and abundance of the separated polypeptide chains could be 
used as an indication of percentage conversion (from intact insulin to the separated 
polypeptide chains).  The ion abundance of the polypeptide chains was found to be the 
dominant peaks in the ESI-MS spectrum, overtaking the intact insulin species.  In 
addition to monitoring the reduction process, the enhancement of MS/MS capabilities 
was also studied. The reduced species were shown to undergo fragmentation much more 
readily in subsequent MS/MS experiments.  With ECD MS/MS, the reduced species 
was shown to have an over 7-fold increase in cleavage coverage compared to the non-
reduced species, for certain proteins. 
 Radical-induced reduction was achieved using a mercury arc lamp, irradiating 
UV photons to initiate the radical-based reactions.  The performance of the reduction 
process was shown using human insulin as a model protein.  The two separated 
polypeptide chains were observed to increase in intensity with the irradiation time, 
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suggesting the reduction process occurred in the solution phase, and allowed more 
polypeptide chains to be observed with longer irradiation time.  However, unlike EC 
reduction mentioned above, the intact protein species remained the dominant species in 
the MS spectrum.  Without reducing the target protein (intact protein), the fragments 
observed were limited with CAD MS/MS and ECD MS/MS shown to yield better 
fragmentation with its inherent disulfide bond preferentiality.  Chemical reduction using 
DTT was found to perform poorly with samples requiring low pH conditions, because 
DTT is only active when the sulphur is a negatively charged thiolate (S-), which requires 
a basic or at least neutral pH condition to achieve.  Incomplete chemical reduction was 
observed by analysing the CAD MS/MS and ECD MS/MS of the chain B of insulin.  
While using radical-induced reduction, which does not require a chemical reducing 
agent, like DTT, successfully reduced intact insulin to the two separated polypeptide 
chains, by showing a promising 79% cleavage coverage with ECD MS/MS of the chain 
B of insulin. 
 Electrochemical reduction and radical-induced reduction have been shown to be 
an effective tool for top-down analysis and can greatly assist in protein identification 
and characterisation, which is a key research area in proteomics studies, especially those 
containing chemically sensitive modifications, such as metallodrugs. 
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Table S3.1 Assignments for Figures 3.11 and 3.12: CAD MS/MS of the non-












b19 3+ C95H165N30O26S2 735.397877 735.39787 -0.01 
b6-H2O 1+ C34H53N10O7S1 745.381392 745.38176 0.49 
MH-H2O 12+ C633H1002N200O185S10 1223.769068 1223.76911 0.03 
MH-H2O 11+ C633H1001N200O185S10 1334.929231 1334.92932 0.07 
MH-NH3 11+ C633H1000N199O186S10 1335.018687 1335.01808 -0.45 
b123 10+ C602H954N192O176S9 1397.690345 1397.69026 -0.06 
y125 10+ C602H953N191O179S10 1404.184936 1404.18553 0.42 
y128-H2O 10+ C622H979N197O183S10 1445.605092 1445.60559 0.34 
b128-H2O 10+ C626H986N198O182S10 1450.911385 1450.91165 0.18 
y124-H2O 9+ C599H945N190O177S9 1546.646926 1546.64608 -0.55 
y124 9+ C599H947N190O178S9 1548.648100 1548.64868 0.37 
y125 9+ C602H952N191O179S10 1560.093565 1560.09325 -0.20 
b124-NH3 9+ C611H959N192O178S9 1569.103661 1569.10395 0.18 
y126-H2O 9+ C608H962N195O179S10 1575.436959 1575.43681 -0.09 
y126 9+ C608H964N195O180S10 1577.438133 1577.43838 0.16 
b126 9+ C621H979N196O181S9 1596.231832 1596.23143 -0.25 
b127-H2O 9+ C623H980N197O181S9 1600.566377 1600.56693 0.35 
b128-H2O 9+ C626H985N198O182S10 1612.011842 1612.01158 -0.16 
y129 9+ C627H989N198O185S10 1619.124736 1619.12435 -0.24 
b14 1+ C76H132N25O19S1 1730.984657 1730.98401 -0.37 
y124-H2O 8+ C599H944N190O177S9 1739.851883 1739.85178 -0.06 
b124 8+ C611H961N193O178S9 1767.244028 1767.24424 0.12 
b125-H2O 8+ C616H968N194O178S9 1777.376259 1777.37626 0.00 
b125 8+ C616H970N194O179S9 1779.627580 1779.62788 0.17 
y16-NH3 1+ C75H123N28O24S2 1863.870100 1863.87162 0.82 
b124 7+ C611H960N193O178S9 2019.563564 2019.56373 0.08 
 
Average 0.05 ppm 
Absolute Average 0.24 ppm 
Standard Deviation 0.31 ppm 
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b5 1+ C31H50N9O7 660.382772 660.38294 0.25 
b26 4+ C130H222N40O35S2 741.906020 741.90614 0.16 
b6 1+ C34H55N10O8S1 763.391957 763.39178 -0.23 
b27 4+ C134H228N42O37S2 770.416752 770.41697 0.28 
y41 6+ C198H327N71O55S3 779.235046 779.23454 -0.65 
b13 2+ C70H121N21O18S1 787.945411 787.94533 -0.10 
b28 4+ C145H238N44O38S2 816.936580 816.93634 -0.29 
y28 4+ C142H227N51O38S2 829.670441 829.66993 -0.62 
y44 6+ C212H349N75O61S3 836.260701 836.26126 0.67 
MH-H2O 17+ C633H1007N200O185S10 864.133247 864.13358 0.39 
MH 17+ C633H1009N200O186S10 865.192692 865.19268 -0.01 
b7-H2O 1+ C39H60N11O10S1 874.423986 874.42321 -0.89 
b7 1+ C39H62N11O11S1 892.434551 892.43437 -0.20 
b55 7+ C273H429N82O82S4 899.439495 899.43864 -0.95 
MH 16+ C633H1008N200O186S10 919.204280 919.20448 0.22 
y31 4+ C157H253N57O43S2 922.219558 922.21987 0.34 
y101 12+ C483H761N155O147S7 942.373476 942.37364 0.17 
MH 15+ C633H1007N200O186S10 980.417414 980.41679 -0.64 
y101 11+ C483H760N155O147S7 1027.952221 1027.95265 0.42 
MH 14+ C633H1006N200O186S10 1050.375281 1050.37536 0.08 
y18 2+ C85H146N35O27S2 1076.527895 1076.52683 -0.99 
y10 1+ C47H78N15O14S1 1108.556792 1108.55583 -0.87 
MH 13+ C633H1005N200O186S10 1131.091897 1131.09121 -0.61 
b10-H2O 1+ C54H88N17O13S1 1214.646275 1214.64706 0.65 
MH 12+ C633H1004N200O186S10 1225.269948 1225.27064 0.56 
MH 11+ C633H1003N200O186S10 1336.566555 1336.56689 0.25 
b12-H2O 1+ C64H106N19O16S1 1428.778018 1428.77694 -0.75 
MH-H2O 10+ C633H1000N200O185S10 1468.321426 1468.32170 0.19 
MH 10+ C633H1002N200O186S10 1470.122483 1470.12270 0.15 
y13 1+ C61H101N22O20S1 1493.727775 1493.72629 -0.99 
y14-NH3 1+ C66H106N23O22S1 1604.759804 1604.75908 -0.45 
y14 1+ C66H109N24O22S1 1621.786353 1621.78488 -0.91 
MH-H2O 9+ C633H999N200O185S10 1631.356332 1631.35770 0.84 
MH 9+ C633H1001N200O186S10 1633.357506 1633.35746 -0.03 
y43 3+ C208H341N74O58S3 1633.171812 1633.17136 -0.28 
y29-H2O 2+ C146H228N52O40S2 1706.841796 1706.84140 -0.23 
y29 2+ C146H230N52O41S2 1715.847078 1715.84738 0.18 
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MH 8+ C633H1000N200O186S10 1837.401284 1837.40166 0.20 
b35-NH3 2+ C184H292N52O47S4 2055.046470 2055.04633 -0.07 
 
Average -0.12 ppm 
Absolute Average 0.43 ppm 
Standard Deviation 0.52 ppm 
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Table S3.3 Assignments for Figures 3.15 and 3.16: ECD MS/MS of the non-reduced 
hLZ species. 









c3 1+ C20H34N5O3 392.265616 392.26557 -0.12 
c4 1+ C25H41N6O6 521.308210 521.30850 0.56 
[c+1]78 8+ C386H600N117O114S6 1111.287873 1111.28695 -0.83 
c78 7+ C386H598N117O114S6 1269.755414 1269.75569 0.22 
MH 11+ C633H1003N200O186S10 1336.566555 1336.56586 -0.52 
z124 9+ C599H945N189O178S9 1546.868242 1546.86921 0.63 
 
Average -0.01 ppm 
Absolute Average 0.48 ppm 
Standard Deviation 0.59 ppm 
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Table S3.4 Assignments for Figures 3.17 and 3.18: ECD MS/MS of the EC-reduced 
hLZ species. 







c3 1+ C20H34N5O3 392.265616 392.26565 0.09 
c17 4+ C89H161N29O22S2 513.044762 513.04451 -0.49 
c4 1+ C25H41N6O6 521.308210 521.30835 0.27 
c14 3+ C76H137N26O19S1 583.341919 583.34164 -0.48 
c20 4+ C104H178N32O28S2 596.822696 596.82232 -0.63 
c10 2+ C54H94N18O14S1 625.345333 625.34535 0.03 
c21 4+ C110H190N36O29S2 635.847974 635.84808 0.17 
c16 3+ C84H151N28O21S1 640.043762 640.04384 0.12 
c22 4+ C112H193N37O30S2 650.103340 650.10357 0.35 
c11 2+ C58H101N19O16S1 675.869172 675.86941 0.35 
c5 1+ C31H53N10O7 677.409321 677.40901 -0.46 
c23 4+ C118H204N38O31S2 678.374356 678.37413 -0.33 
c17 3+ C89H160N29O22S2 683.723924 683.72390 -0.04 
c25 4+ C127H220N40O34S2 728.403379 728.40344 0.08 
c12 2+ C64H112N20O17S1 732.411204 732.41152 0.43 
c26 4+ C130H225N41O35S2 746.162657 746.16236 -0.40 
c6 1+ C34H58N11O8S1 780.418506 780.41818 -0.42 
c20 3+ C104H177N32O28S2 795.427836 795.42772 -0.15 
c13 2+ C70H124N22O18S1 796.458686 796.45876 0.09 
c28 4+ C145H241N45O38S2 821.193218 821.19310 -0.14 
c35 5+ C184H301N54O47S4 829.433573 829.43348 -0.11 
c43 6+ C219H356N66O60S4 833.094746 833.09491 0.20 
c36 5+ C187H306N55O49S4 846.839979 846.83962 -0.42 
c29 4+ C150H250N46O39S3 853.953339 853.95331 -0.03 
c14 2+ C76H136N26O19S1 874.509241 874.50926 0.02 
c45 6+ C232H371N69O64S4 879.279122 879.27931 0.21 
c23 3+ C118H203N38O31S2 904.163382 904.16316 -0.25 
c7 1+ C39H65N12O11S1 909.461100 909.46152 0.46 
c32 4+ C162H271N49O42S4 925.735930 925.73623 0.32 
[c+1]24 3+ C121H209N39O33S2 933.509999 933.50932 -0.73 
c41 5+ C212H343N64O57S4 965.095281 965.09562 0.35 
c25 3+ C127H219N40O34S2 970.868747 970.86807 -0.70 
MH 15+ C633H1007N200O186S10 980.417414 980.41798 0.58 
c26 3+ C130H224N41O35S2 994.547785 994.54743 -0.36 
c43 5+ C219H355N66O60S4 999.512240 999.51237 0.13 
c17 2+ C89H159N29O22S2 1025.082247 1025.08234 0.09 
c35 4+ C184H300N54O47S4 1036.540147 1036.54078 0.61 
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c54 6+ C271H428N82O81S4 1042.512379 1042.51257 0.18 
MH 14+ C633H1006N200O186S10 1050.375281 1050.37522 -0.06 
[z+2]36 4+ C180H296N65O48S3 1058.046485 1058.04646 -0.02 
c9 1+ C48H81N14O13S1 1093.582278 1093.58211 -0.15 
c19 2+ C95H167N31O26S2 1111.106451 1111.10668 0.21 
MH 13+ C633H1005N200O186S10 1131.095897 1131.09548 -0.37 
c20 2+ C104H176N32O28S2 1192.638116 1192.63829 0.15 
MH 12+ C633H1004N200O186S10 1225.269948 1225.26964 -0.25 
[c+2]78 7+ C386H600N117O114S6 1270.043361 1270.04391 0.43 
[c-1]124 11+ C611H966N194O178S9 1286.999340 1286.99923 -0.09 
MH 11+ C633H1003N200O186S10 1336.566555 1336.56669 0.10 
MH 10+ C633H1002N200O186S10 1470.122483 1470.12297 0.33 
z124 9+ C599H945N189O178S9 1546.868242 1546.86836 0.08 
MH 9+ C633H1001N200O186S10 1633.357506 1633.35720 -0.19 
[z+3]126 8+ C608H964N194O180S10 1772.867580 1772.86700 -0.33 
MH 8+ C633H1000N200O186S10 1837.401284 1837.40228 0.54 
MH 7+ C633H999N200O186S10 2099.743285 2099.74403 0.35 
MH 6+ C633H998N200O186S10 2449.532620 2449.53445 0.75 
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Table S3.5 Assignments for Figures 3.23 and 3.24: ECD MS/MS of the intact 
insulin species [M+5H]5+. 








c3(CB) 1+ C18H28N5O4 378.213581 378.21351 -0.19 
c4(CA) 1+ C18H34N5O6 416.250361 416.25026 -0.24 
z4(CB) 1+ C19H34N4O7 430.242202 430.24205 -0.35 
c4(CB) 1+ C23H36N7O6 506.272159 506.27201 -0.29 
c5(CA) 1+ C23H42N7O8 544.308939 544.30882 -0.22 
z5(CB) 1+ C28H43N5O9 593.305531 593.30544 -0.15 
c5(CB) 1+ C29H43N10O7 643.331071 643.33104 -0.05 
z6(CB) 1+ C37H52N6O10 740.373945 740.37401 0.09 
c6(CB) 1+ C35H54N11O8 756.415135 756.41532 0.24 
z15-H(CB) 2+ C84H120N18O22S1 882.426717 882.42636 -0.40 
z7(CB) 1+ C46H61N7O11 887.442359 887.44260 0.27 
c8(CB) 1+ C40H62N13O10S1 916.445784 916.44578 0.00 
z16-H(CB) 2+ C90H131N19O23S1 938.968750 938.96879 0.04 
z8(CB) 1+ C48H64N8O12 944.463823 944.46368 -0.15 
z17-H(CB) 2+ C93H136N20O24S1 974.487307 974.48677 -0.55 
c9(CB) 1+ C43H67N14O12S1 1003.477813 1003.47808 0.27 
z9-H(CB) 1+ C54H75N12O13 1099.557109 1099.55607 -0.94 
z9+H(CB) 1+ C54H77N12O13 1101.572759 1101.57289 0.12 
c10(CB) 1+ C49H74N17O13S1 1140.536725 1140.53724 0.45 
z10(CA) 1+ C54H78N12O19S1 1230.522145 1230.52251 0.30 
c11(CB) 1+ C55H85N18O14S1 1253.620789 1253.62187 0.86 
c11+CB 3+ C203H311N53O58S5 1526.386755 1526.38628 -0.31 
c21+CA 3+ C203H312N53O64S6 1569.369883 1569.37058 0.44 
c22+CA 3+ C209H324N57O65S6 1621.403586 1621.40442 0.51 
c23+CA 3+ C211H327N58O66S6 1640.410741 1640.41209 0.82 
z24+CA 3+ C222H334N54O69S6 1684.086482 1684.08725 0.46 
c24+CA 3+ C220H336N59O67S6 1689.433545 1689.43309 -0.27 
z25+CA 3+ C228H345N55O70S6 1721.781170 1721.78259 0.82 
c25+CA 3+ C229H345N60O68S6 1738.456350 1738.45711 0.44 
z16+CB 3+ C234H346N58O69S6 1754.788548 1754.78991 0.78 
z26+CA 3+ C234H352N58O71S6 1767.467474 1767.46820 0.41 
c26+CA 3+ C238H354N61O70S6 1792.810793 1792.80986 -0.52 
z27+CA 3+ C239H360N60O73S6 1810.153666 1810.15287 -0.44 
z18+CB 3+ C244H361N61O74S6 1840.488938 1840.49057 0.89 
z28+CA 3+ C243H366N62O75S6 1848.167976 1848.16751 -0.25 
c28+CA 3+ C247H368N63O73S6 1858.844274 1858.84415 -0.07 
z29+CA 3+ C248H375N63O76S6 1881.190780 1881.19254 0.94 
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c14+CA 2+ C167H257N46O54S5 1965.368542 1965.36759 -0.48 
c15+CA 2+ C173H268N47O55S5 2021.910574 2021.90948 -0.54 
z18+CA 2+ C197H294N46O62S5 2227.992964 2227.99250 -0.21 
z19+CA 2+ C202H303N47O63S5 2277.527171 2277.52659 -0.26 
c11+CB 2+ C203H310N53O58S5 2289.076494 2289.07793 0.63 
z20+CA 2+ C208H314N48O64S5 2334.069203 2334.06976 0.24 
c21+CA 2+ C203H311N53O64S6 2353.551186 2353.55291 0.73 
z21+CA 2+ C214H321N51O65S5 2402.598659 2402.59685 -0.75 
c22+CA 2+ C209H323N57O65S6 2431.601741 2431.60240 0.27 
c23+CA 2+ C211H326N58O66S6 2460.112473 2460.11346 0.40 
z24+CA 2+ C222H333N54O69S6 2525.626085 2525.62843 0.93 
c24+CA 2+ C220H335N59O67S6 2533.646680 2533.64533 -0.53 
z25+CA 2+ C228H344N55O70S6 2582.168117 2582.16989 0.69 
c25+CA 2+ C229H344N60O68S6 2607.180887 2607.17911 -0.68 
z26+CA 2+ C234H351N58O71S6 2650.697573 2650.70018 0.98 
c26+CA 2+ C238H353N61O70S6 2688.712551 2688.71455 0.74 
 
Average 0.11 ppm 
Absolute Average 0.45 ppm 
Standard Deviation 0.51 ppm 
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b2(CA) 1+ C8H15N2O2 171.112804 171.11280 -0.02 
b2(CB) 1+ C14H19N2O2 247.144104 247.14413 0.11 
y2(CB) 1+ C10H22N3O4 248.160483 248.16049 0.03 
b3(CA) 1+ C13H24N3O3 270.181218 270.18121 -0.03 
y3-H2O(CB) 1+ C15H27N4O4 327.202682 327.20263 -0.16 
y3(CB) 1+ C15H29N4O5 345.213247 345.21343 0.53 
b3(CB) 1+ C18H25N4O4 361.187032 361.18728 0.69 
b4(CA) 1+ C18H31N4O6 399.223812 399.22370 -0.28 
y4(CB) 1+ C19H36N5O7 446.260926 446.26111 0.41 
b4(CB) 1+ C23H33N6O6 489.245610 489.24538 -0.47 
b5(CA) 1+ C23H39N6O8 527.282390 527.28196 -0.82 
y9-H2O(CB) 2+ C54H77N13O12 549.790185 549.79058 0.72 
y9(CB) 2+ C54H79N13O13 558.795467 558.79543 -0.07 
y5-H2O(CB) 1+ C28H43N6O8 591.313690 591.31326 -0.73 
b5-CO(CB) 1+ C28H40N9O6 598.309607 598.30962 0.02 
y5(CB) 1+ C28H45N6O9 609.324255 609.32458 0.53 
y10-H2O(CB) 2+ C59H84N14O15 614.311482 614.31130 -0.30 
y10(CB) 2+ C59H86N14O16 623.316764 623.31726 0.80 
y11-H2O(CB) 2+ C61H87N15O16 642.822214 642.82226 0.07 
y11(CB) 2+ C61H89N15O17 651.827496 651.82777 0.42 
b6(CB) 1+ C35H51N10O8 739.388586 739.38898 0.53 
y6(CB) 1+ C37H54N7O10 756.392669 756.39208 -0.78 
y7(CB) 1+ C46H63N8O11 903.461083 903.46177 0.76 
y8(CB) 1+ C48H66N9O12 960.482547 960.48339 0.88 
M-H2O-NH3 5+ C257H383N64O76S6 1154.927958 1154.92738 -0.50 
M-NH3 5+ C257H386N65O76S6 1158.934486 1158.93514 0.56 
 
Average 0.11 ppm 
Absolute Average 0.43 ppm 
Standard Deviation 0.52 ppm 
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Table S3.7 Assignments for Figure 3.26: ECD MS/MS of the CB produced from 
radical-induced reduction. 









c3 1+ C18H28N5O4 378.213581 378.21359 0.02 
z4 1+ C19H34N4O7 430.242202 430.24208 -0.28 
a4+H 1+ C22H34N6O5 462.258520 462.25848 -0.09 
c4 1+ C23H36N7O6 506.272159 506.27205 -0.22 
z5 1+ C28H43N5O9 593.305531 593.30555 0.03 
c5 1+ C29H43N10O7 643.331071 643.33110 0.05 
a6+H 1+ C34H52N10O7 712.401496 712.40200 0.71 
z6 1+ C37H52N6O10 740.373945 740.37495 1.36 
c6 1+ C35H54N11O8 756.415135 756.41429 -1.12 
z14+H 2+ C75H113N17O20S1 801.902878 801.90199 -1.11 
a8+H 1+ C39H60N12O9S1 872.432145 872.43264 0.57 
z15-H 2+ C84H120N18O22S1 882.426717 882.42742 0.80 
z7 1+ C46H61N7O11 887.442359 887.44275 0.44 
c8 1+ C40H62N13O10S1 916.445784 916.44630 0.56 
z16 2+ C90H132N19O23S1 939.472662 939.47290 0.25 
z8 1+ C48H64N8O12 944.463823 944.46525 1.51 
c17-H 2+ C89H137N24O23S1 970.999909 971.00070 0.81 
z17 2+ C93H137N20O24S1 974.991219 974.99128 0.06 
a18+H 2+ C93H145N24O23S1 999.031209 999.03129 0.08 
z29-2H 3+ C149H224N38O41S2 1088.534541 1088.53320 -1.23 
a29 3+ C153H228N39O38S2 1094.551084 1094.54987 -1.11 
a10+H 1+ C48H72N16O12S1 1096.523086 1096.52253 -0.51 
z9+H 1+ C54H77N12O13 1101.572759 1101.57219 -0.52 
c21-2H 2+ C104H160N28O29S2 1164.566825 1164.56630 -0.45 
z21 2+ C115H171N26O30S1 1214.118211 1214.11788 -0.27 
a22+H 2+ C109H172N31O29S2 1221.618386 1221.61763 -0.62 
c22-2H 2+ C110H172N32O30S2 1242.617381 1242.61600 -1.11 
c24-H 2+ C121H185N34O32S2 1345.166232 1345.16583 -0.30 
a25+H 2+ C129H193N34O32S2 1397.197532 1397.19594 -1.14 
c25-2H 2+ C130H193N35O33S2 1418.196527 1418.19583 -0.49 
z26-H 2+ C135H201N33O36S2 1462.217125 1462.21591 -0.83 
c26-H 2+ C139H203N36O35S2 1500.232104 1500.23240 0.20 
z27-H 2+ C140H209N35O38S2 1526.246414 1526.24592 -0.32 
z28 2+ C144H216N37O40S2 1583.771791 1583.77034 -0.92 
 
Average -0.15 ppm 
Absolute Average 0.59 ppm 
Standard Deviation 0.72 ppm 
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Table S3.8 Assignments for Figure 3.27: ECD MS/MS of the CB produced from 
chemical reduction. 








c3 1+ C18H28N5O4 378.213581 378.21356 -0.06 
z.4 1+ C19H35N4O7 431.250027 431.25003 0.01 
c4 1+ C23H36N7O6 506.272159 506.27170 -0.91 
c.20 4+ C99H156N27O26S2 550.778358 550.77851 0.28 
z5 1+ C28H43N5O9 593.305531 593.30497 -0.95 
c5 1+ C29H43N10O7 643.331071 643.33113 0.09 
z6 1+ C37H52N6O10 740.373945 740.37425 0.41 
c6 1+ C35H54N11O8 756.415135 756.41510 -0.05 
z7 1+ C46H61N7O11 887.442359 887.44251 0.17 
z8 1+ C48H64N8O12 944.463823 944.46325 -0.61 
z.28 3+ C144H218N37O40S2 1056.519561 1056.51965 0.08 
z.9 1+ C54H77N12O13 1101.572759 1101.57297 0.19 
c29 3+ C154H231N40O39S2 1109.558238 1109.55869 0.41 
c.21 2+ C104H161N28O29S2 1165.070738 1165.07054 -0.17 
z.10 1+ C59H84N13O16 1230.615353 1230.61542 0.05 
c22 2+ C110H174N32O30S2 1243.625206 1243.62487 -0.27 
c23 2+ C112H177N33O31S2 1272.135938 1272.13533 -0.48 
c.24 2+ C121H185N34O32S2 1345.166232 1345.16550 -0.54 
c.25 2+ C130H194N35O33S2 1418.700439 1418.70004 -0.28 
c.26 2+ C139H203N36O35S2 1500.232104 1500.23269 0.39 
 
Average -0.11 ppm 
Absolute Average 0.32 ppm 
Standard Deviation 0.41 ppm 
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Table S3.9 Assignments for Figure 3.28: CAD MS/MS of the CB produced from 
chemical reduction. 








b2-CO 1+ C13H19N2O1 219.149189 219.14921 0.10 
b2 1+ C14H19N2O2 247.144104 247.14408 -0.10 
y2 1+ C10H22N3O4 248.160483 248.16046 -0.09 
y3-H2O 1+ C15H27N4O4 327.202682 327.20270 0.06 
y3-NH3 1+ C15H26N3O5 328.186698 328.18659 -0.33 
y3 1+ C15H29N4O5 345.213247 345.21328 0.10 
b3 1+ C18H25N4O4 361.187032 361.18701 -0.06 
y4-H2O 1+ C19H34N5O6 428.250361 428.25040 0.09 
y4 1+ C19H36N5O7 446.260926 446.26086 -0.15 
b4-NH3 1+ C23H30N5O6 472.219061 472.21881 -0.53 
b4 1+ C23H33N6O6 489.245610 489.24546 -0.31 
b10-CO 2+ C48H72N16O12S1 548.261268 548.26120 -0.12 
y9-H2O 2+ C54H77N13O12 549.790185 549.79046 0.50 
b10-H2O 2+ C49H70N16O12S1 553.253444 553.25346 0.03 
y9 2+ C54H79N13O13 558.795467 558.79533 -0.25 
b10 2+ C49H72N16O13S1 562.258726 562.25872 -0.01 
b5-CO2 1+ C28H40N9O5 582.314692 582.31443 -0.45 
y5-H2O 1+ C28H43N6O8 591.313690 591.31348 -0.36 
b5-CO 1+ C28H40N9O6 598.309607 598.30958 -0.05 
b11-CO 2+ C54H83N17O13S1 604.803300 604.80334 0.07 
b5-H2O 1+ C29H38N9O6 608.293957 608.29412 0.27 
y5 1+ C28H45N6O9 609.324255 609.32421 -0.07 
b11-NH3 2+ C55H80N16O14S1 610.287484 610.28759 0.17 
y10-H2O 2+ C59H84N14O15 614.311482 614.31126 -0.36 
b11 2+ C55H83N17O14S1 618.800758 618.80073 -0.05 
y10 2+ C59H86N14O16 623.316764 623.31630 -0.74 
b5 1+ C29H40N9O7 626.304522 626.30455 0.04 
y11-H2O 2+ C61H87N15O16 642.822214 642.82189 -0.50 
y11 2+ C61H89N15O17 651.827496 651.82757 0.11 
b12-CO 2+ C59H92N18O14S1 654.337507 654.33763 0.19 
b12-H2O 2+ C60H90N18O14S1 659.329682 659.33029 0.92 
b12-NH3 2+ C60H89N17O15S1 659.821691 659.82183 0.21 
b12 2+ C60H92N18O15S1 668.334965 668.33527 0.46 
y12 2+ C64H94N16O18S1 703.332089 703.33223 0.20 
b6-CO 1+ C34H51N10O7 711.393671 711.39321 -0.65 
b13-CO 2+ C64H99N19O17S1 718.858805 718.85833 -0.66 
b13-NH3 2+ C65H96N18O18S1 724.342988 724.34243 -0.77 
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b13 2+ C65H99N19O18S1 732.856262 732.85655 0.39 
y26 4+ C135H206N34O36S2 735.868838 735.86871 -0.17 
b6 1+ C35H51N10O8 739.388586 739.38877 0.25 
y13-H2O 2+ C69H101N17O18S1 743.861013 743.86166 0.87 
y13 2+ C69H103N17O19S1 752.866295 752.86616 -0.18 
y6 1+ C37H54N7O10 756.392669 756.39277 0.13 
b14-NH3 2+ C68H101N19O19S1 759.861545 759.86133 -0.28 
y27-H2O 4+ C140H212N36O37S2 763.380841 763.38021 -0.83 
b14 2+ C68H104N20O19S1 768.374819 768.37472 -0.13 
y28 4+ C144H220N38O40S2 796.394214 796.39409 -0.16 
y21 3+ C115H174N27O30S1 815.087474 815.08781 0.41 
y29 4+ C149H229N39O41S2 821.161318 821.16124 -0.09 
b15 2+ C74H115N21O20S1 824.916851 824.91722 0.45 
b23 3+ C112H175N32O31S2 842.750868 842.75092 0.06 
y23 3+ C120H182N29O33S1 863.105305 863.10596 0.76 
y15-H2O 2+ C84H121N19O21S1 881.934710 881.93473 0.02 
b8 1+ C40H59N12O10S1 899.419235 899.41952 0.32 
b16 2+ C83H124N22O22S1 906.448515 906.44796 -0.61 
y8 1+ C48H66N9O12 960.482547 960.48315 0.63 
b17 2+ C89H135N23O23S1 962.990548 962.99139 0.87 
b9-H2O 1+ C43H62N13O11S1 968.440699 968.44034 -0.37 
b28-NH3 3+ C148H213N36O38S2 1055.508885 1055.50943 0.52 
y19-H2O 2+ C103H153N23O27S1 1088.050802 1088.05099 0.17 
y19 2+ C103H155N23O28S1 1097.056085 1097.05628 0.18 
y20 2+ C109H166N24O29S1 1153.598117 1153.59720 -0.79 
b21 2+ C104H159N27O29S2 1157.061376 1157.06055 -0.71 
b22 2+ C110H171N31O30S2 1235.111931 1235.11234 0.33 
b23 2+ C112H174N32O31S2 1263.622663 1263.62164 -0.81 
y24-NH3 2+ C123H183N29O34S2 1337.145637 1337.14504 -0.45 
y24 2+ C123H186N30O34S2 1345.658912 1345.65975 0.62 
b25 2+ C130H192N34O33S2 1410.691077 1410.69205 0.69 
 
Average  -0.01 ppm 
Absolute Average 0.34 ppm 
Standard Deviation 0.44 ppm 
 





Organoiridium Photosensitisers Induce Specific Oxidative Attack on Proteins 
within Cancer Cells 
The photocatalytic octahedral iridium-(III)-based anticancer complexes, 
[Ir(C,N)2(S,S)] (Series 1) and [Ir(C,N)2(O,O)]
+ (Series 2), where C,N = phenylquinoline, 
and O,O = a diketonate, S,S = a dithione chelating ligands, show the ability of 
generating singlet oxygen (1O2) upon irradiation with visible blue light (463 nm), and 
oxidise the model peptide, [Lys3]-Bombesin (L3BBS).  Proteomics studies of human 
lung cancer cells (A549) revealed that photoactivation of the iridium complex caused 
selective oxidative damage to specific histidine residues in the key cellular proteins heat 
shock protein 70 kDa, which is involved in protein folding and protection of cells from 
stress, and aldose reductase, which plays a key role in hyperglycemia-induced oxidative 
stress.  The oxidative stress induced by iridium photosensitisers during photoactivation 
increased the levels of enzymes involved in the glycolytic pathway. 
 Iridium-(III)-based photosensitisers were synthesised and their IC50 values were 
studied by Dr. Pingyu Zhang.  The drug treated A549 lung cancer cell cultures were 
prepared by Dr. Pingyu Zhang and Dr. Huaiyi Huang.  Cell lysis and nLC studies were 
carried out with the assistance of Dr. Yuko P. Y. Lam.  Sample preparation and all data 
were produced, analysed and written by the thesis Author.  A significant part of this 
chapter was published in Angewandte Chemie International Edition, as a paper entitled 
“Organoiridium Photosensitizers Induce Specific Oxidative Attack on Proteins within 
Cancer Cells” https://onlinelibrary.wiley.com/doi/full/10.1002/anie.201709082 
  





 Metal-based chemotherapies have been widely used for many years around the 
world.  Platinum-based compounds, such as cisplatin, oxaliplatin, and carboplatin 
(Scheme 1) are the most commonly used metal-based anticancer agents to treat different 
types of cancers.  However platinum resistance is now a common problem.1  Every 
metallodrug has its own mechanism of action (MoA). Cisplatin’s mechanism is centred 
around reacting with the DNA of the cancerous cells, disrupting its structure, resulting 
in failure of transcription, i.e. anti-proliferation.  However, studies have shown 90-98% 
of cisplatin becomes protein-bound after just one day of injection, meaning most of the 
drug cannot reach the desired target (DNA of the cancerous cells),2,3 vastly influencing 
the effectiveness of the treatment, and inducing undesired side effects to the patients.  
Therefore, there is an essential need to develop different metal-based anticancer drugs, 
with different mechanisms of action to attack cancer cells.  Different metallodrugs, such 
as iridium,4,5 rhodium,6 platinum,7 osmium,8,9 gold,10 ruthenium11, have been designed 
to possess different properties.  Interest in the use of luminescent transition metal 
complexes for various application has increased enormously over the past several 
decades, particularly as photosensitisers for photodynamic therapy (PDT).12–14  PDT has 
been widely used in the last 40 years, PDT involves absorption of light by a 
photosensitiser promoting formation of a triple state that can polarise the spins of the 
ground-state 3O2 to generate highly toxic singlet oxygen (
1O2).  However, selectivity is 
also an important criterion for being an effective anticancer drug, as these drugs are 
often cytotoxic, if selectivity is low, healthy cells could be affected or even killed too.  
To enhance selectivity of a metallodrug, pro-drugs (inactive drugs) are often designed to 
possess low cytotoxicity and only become highly cytotoxic when activated, usually by 
the change in chemical environment, such as pH or salt concentration, or even activated 
with light, also known as photoactivatable chemotherapy (PACT).15 





Scheme 4.1 Platinum-based anticancer drugs. 
Different analytical techniques have been utilised to study the interaction 
between metallodrugs and biomolecules, such as 1H-NMR or x-ray crystallography.16,17  
These techniques are often used to provide structural information and sometimes able to 
identify and locate the modifications on biomolecules.  However, due to the inherent 
lack of separation ability, the capabilities of these analytical techniques are often 
limited.  Other techniques which possess the ability of handling mixtures of 
products/adducts are required to study these metallodrug-biomolecules systems more 
comprehensively.  Mass spectrometry (MS) is increasing being used to study biological 
systems, due to its high sensitivity and ability to cope with complex samples.  
Electrospray ionisation (ESI),18 and nano electrospray ionisation (nESI),19 are the most 
commonly used soft ionisation techniques to generate multiply-charged species, which 
allow to study large biomolecules in the lower mass-to-charge ratio (m/z) region.  MS 
can also be coupled to hyphenated techniques, such as liquid chromatography (LC) or 
gas chromatography (GC), which allows separation prior to MS analysis and simplify 
the complexity of the sample.  MS also has the ability of separating species of interest, 
often using a quadrupole, tandem mass spectrometry (MS/MS) experiments which can 
be performed to fragment the separated ions, obtaining structural/sequence informative 
fragments.  An extensive array of fragmentation techniques has been developed, 
including collisionally activated dissociation (CAD),20 electron capture dissociation 
(ECD),21 infrared multi-photon dissociation (IRMPD),22 ultraviolet photodissociation 
(UVPD)23 etc. 
Fourier transform-ion cyclotron resonance mass spectrometry (FT-ICR MS) uses 
both electric and magnetic fields to trap species of interest for detection.  FT-ICR MS is 




well-known for its ultra-high resolving power and mass accuracy, which is not 
comparable by other mass spectrometers.  With the capability of isolating ions of 
interest using a quadrupole, applying collisional activation, and electron/photon-based 
dissociation techniques upon ions of interests, FT-ICR MS provides the largest array of 
fragmentation techniques and highest mass accuracy of any mass spectrometer, with 
mass errors into sub parts-per-million (ppm) and even parts-per-billion (ppb) ranges. 
 Herein, the interaction and MoA of [Lys3]-Bombesin (L3BBS) and iridium-(III)-
based complexes (PZ1-PZ6) was studied using ultra-high resolution FT-ICR MS 
together with various MS/MS techniques to characterise the oxidation sites on the 
peptide.  Reversed phase (RP) nano-LC (nLC) was coupled to the FT-ICR MS to study 
the effect of the most potent iridium complex (PZ6) on lung cancer cell line A549 and 
perform quantitative MS using label-free quantification. 
Experimental 
Materials 
 [Lys3]-Bombesin (L3BBS), chicken lysozyme, formic acid, ammonium 
bicarbonate (AmmBic), dithiothreitol (DTT), iodoacetamide (IAA), and trypsin were all 
purchased from Sigma Aldrich (Dorset, England). Human lung carcinoma (A549) cell 
line was purchased from the European Collection of Authenticated Cell Cultures 
(ECACC) (Salisbury, UK).  LCMS grade acetonitrile (MeCN) was purchased from 
VWR (Lutterworth, UK).  LCMS grade methanol (CH3OH), hypersep C18 RP 
cartridges were purchased from Thermo Fisher Scientific (Waltham, UK).  Ultra-pure 
water (18.2 MΩcm-1) was obtained from a Milli-Q UV III water purification system 
(Milli-Q, Hertfordshire, UK).  The dinuclear iridium complex [(C,N)4Ir2Cl2] was 
prepared by Dr. Pingyu Zhang according to literature methods reported below.24 
Synthesis of the iridium-(III)-based complexes (PZ1-PZ3) 
 A mixture containing the dithione (0.015 mmol), Ag2O (0.15 mmol) and the 
corresponding iridium dimer (0.07 mmol) in CH2Cl2 (50 mL) was heated in a sealed 
tube overnight at 348 K.  After cooling to ambient temperature, the mixture was filtered 
through celite and washed with CH2Cl2.  The filtrate was concentrated under reduced 




pressure and purified on a silica column by Biotage flash chromatography with 
CH2Cl2:CH3OH (v/v 80:20) as eluant. 
Synthesis of the iridium-(III)-based complexes (PZ4-PZ6) 
 A mixture containing the diketonate (0.015 mmol) and the corresponding iridium 
dimer (0.07 mmol) in CH2Cl2 (50 mL) was heated in a sealed tube for 2 hours at 348 K.  
After cooling to ambient temperature, the mixture was filtered through celite and 
washed with CH2Cl2.  The filtrate was concentrated under reduced pressure and purified 
on a silica column by Biotage flash chromatography with CH2Cl2:CH3OH (v/v 95:5) as 
eluant. 
FT-ICR MS study of PZx-L3BBS reactions 
 Aqueous solutions of L3BBS (1 mM) and iridium-(III)-based complexes (PZ1-
PZ6, 250 µM, in 50:50 H2O:MeCN) were mixed in 1:2 and 1:5 (peptide:drug) molar 
ratios.  The sample incubation and irradiation conditions mirrored the IC50 testing 
conditions for each compound.  Briefly samples were incubated for 1 h or 2 h (for PZ1-
PZ3, and PZ4-PZ6 respectively) at 348 K.  Followed by 5 min of irradiation with 463 
nm visible blue light, and further incubation of 47 h or 46 h for PZ1-PZ3, and PZ4-PZ6, 
respectively.  All sample preparation, incubations, and mass spectrometry analysis were 
conducted in darkness or with very low levels of red light to avoid activation of the 
complexes.  Samples were then diluted with ultra-pure water to 5 µM total concentration 
for FT-ICR MS analysis (Figure 4.1).  All samples were analysed using nESI for 
increased sensitivity and lower the sample consumption compared to conventional ESI.  
All MS experiments were carried out using a SolariX FT-ICR mass spectrometer, fitted 
with a 12 tesla actively shielded magnet (Bruker Daltonik GmbH, Bremen, Germany).  
All samples were sprayed in positive ion mode. For MS experiments, ions were 
accumulated for 0.5 s in the hexapole-based collision cell before transferred to the 
infinity cell for excitation and detection. 
 For ECD MS/MS experiments, ions of interest were isolated using the front-end 
quadrupole using a wide isolation window (30-50 m/z), then accumulated in the 
hexapole for 4 s. The isolated ion packets of interest were then transferred into the 




infinity cell.  In cell isolation, Multi-Correlated Harmonic Excitation Fields (Multi-
CHEF),25 was also used to further isolate the ions of interest, with notch width of 0.5 
m/z, and isolation power of 50%, to achieve a cleaner isolation.  The isolated ions were 
then irradiated with 1.2 eV electrons, with pulse length of 0.15 s, generated from a 1.5 A 
hollow cathode dispenser via an extraction lens held at 18 V. 
 All spectra were internally calibrated using a quadratic calibration function, 
manually interpreted, and assigned via DataAnalysis v4.2 (Bruker Daltonik GmbH, 
Bremen, Germany). 
 
Figure 4.1 FT-ICR MS study of PZx-L3BBS reaction. 
 
  




nLC-FT-ICR MS/MS of the PZ6-A549 lung cancer cell line 
Proteomics for Target Site Identification 
 Approximately 1x109 A549 lung cancer cells were treated with PZ6 (10 µM) in 
the dark or with 10 min of blue LED irradiation (463 nm).  All cells were harvested and 
lysed by sonicating with glass beads at 277 K in a Tris-buffer solution (50 mM Tris-HCl 
with 1% glycerol, pH 7.5).  The samples were sonicated for 30 s and cooled for 5 min, 
the sonication process being repeated 10 times.  All samples were centrifuged for 30 
min at 5,000 g at 277 K to remove the pellets.  The supernatant from each sample was 
then quantified against a standard calibration curve of bovine serum albumin (BSA) 
using Bradford Reagent (Sigma Aldrich Company Ltd; Dorset, England).  The 
concentrations of proteins in these samples were then calculated. 
 The above samples were diluted using 100 mM AmmBic solution (Sigma 
Aldrich Company Ltd; Dorset, England); the disulfide bonds were reduced with 50 mM 
DTT (Sigma Aldrich Company Ltd; Dorset, England) and the free cysteine thiols were 
alkylated with 100 mM IAA (Sigma Aldrich Company Ltd; Dorset, England).  The 
alkylated lysate was then digested with trypsin (Sigma Aldrich Company Ltd; Dorset, 
England) by incubating the mixture for 16 h at 310 K.  The digested peptides were 
desalted using C18 RP cartridges (Thermo Fisher Scientific, Waltham, UK), washed 
twice with Milli-Q water and then eluted with 80% MeCN/aqueous solution. Desalted 
samples were dried down with Speed Vac concentrator (Thermo Fisher Scientific, 
Waltham, UK) and re-dissolved in Milli-Q water into concentration of 1 mg/mL. 
 nLC separations were achieved using an EASY nano-LC II system (Proxeon, 
Hemel Hempstead, UK) with a in-home-made 18 cm, C18 RP nano capillary column 
(75 µm, 5 µm particle size, pore size of 300 Å) and a 3 cm C18 RP pre-column (150 
µm, 5 µm particle size, pore size of 300 Å).  Separation of tryptic digested cell was 
achieved using an acidified H2O/MeCN gradient from 5% MeCN to 30% MeCN over 
120 min, acidified with formic acid, followed by a second gradient of 15 min from 30% 
MeCN to 80% MeCN.  Finally, with a 35-min wash of 80% MeCN at a constant 600 
nL/min flow rate. 




 nLC-MS/MS experiments were carried out by coupling EASY-nLC to SolariX 
FT-ICR MS, via a custom nano-spray source utilising glass nanospray tips, 360 µm tip 
O.D., 50 µm tip I.D., and 8 µm orifice I.D. (New Objective, MA, USA).  Singly-charged 
or unknown charged species were excluded automatically from the MS/MS list, only the 
most intense multiply-charged ions from each scan were isolated in the quadrupole and 
accumulated for 1.2 s in the hexapole collision cell for CAD MS/MS experiments.  1.6 
µg of each sample was injected for each nLC-MS/MS run.  All nLC-MS/MS 
experiments were performed with 5 technical replicates for consistency and 
reproducibility purposes, and more importantly, to increase the reliability of the data 
sets. 
 
Figure 4.2 nLC-FT-ICR MS/MS of the PZ6-A549 lung cancer cell line. 
 Mass lists were generated using the FTMS peak picking algorithm in 
DataAnalysis v4.2 (Bruker Daltonik GmbH, Bremen, Germany) from nLC-MS/MS data 
sets.  Then the mass lists were searched against the Mascot database search engine and 
all identified proteins were filtered with 1% false discovery rate (FDR).  Each oxidised 
peptide picked out by the search engine was manually analysed from the raw nLC-
MS/MS data, and any false positive results were critically eliminated.  The reduced 




datasets (after elimination), were then grouped together, and oxidised peptides that were 
detected three times or more out of the five replicates of data were further selected for 
quantification. 
 Singlet oxygen-induced oxidation of proteins is complicated as discussed in 
several reviews being the result of direct attack on amino acids and secondary attack by 
initially formed peroxides.26,27  On the basis of previous reports, the following 
modifications were included in the search: 
Variable modifications: methionine to sulfoxide (+O), methionine to sulfone (+2O), 
histidine to 2-oxo-histidine (+O), tryptophan to kynurenine (+O2-CO), tryptophan to 3-
hydroxykynurenine (+O2-CO+O), tryptophan to N-formylkynurenine (+2O), cysteine to 
sulfenic acid (+O), cysteine to sulfinic acid (+2O), cysteine to sulfonic acid (+3O), 
phenylalanine to dihydroxyphenylalanine (+2O), tyrosine to dihydroxyphenylalanine 
(+O). 
 In addition, a fixed carbamidomethyl modification of cysteine (from alkylation) 
and variable deamidation modifications of asparagine, glutamine, and phosphorylation 
of serine, threonine, and tyrosine were included. 
 Quantification of peptides was achieved by spiking with a lysozyme tryptic 
digest in 1:6 lysozyme peptide:cell digest volume ratio (lysozyme peptide 0.01 µg/µL, 
cell digest 0.2 µg/µL) into each sample during the nLC-MS/MS runs and by determining 
the ratio between the cell peptide of interest and the specific lysozyme peptide 
(FESNFNTQATNR, 714.8365 m/z).  The differences between the ratios from different 
reaction conditions (control, drug treated with no irradiation, or drug treated with 
irradiation) were compared.  T-tests and p values were determined as measures of the 
level of significance between different samples. 
Pathway Analysis 
 Peptides that were detected 3 times or more out of the 5 replicates of data sets 
were selected for quantification of pathway analysis.  The protein entry lists were 
imported and cross-matched with the Database for Annotation, Visualisation and 
Integrated Discovery (DAVID) Bioinformation Database,28 then a list of related 




pathways was generated and exported by the Kyoto Encyclopedia of Genes and 
Genomes (KEGG) database.29–31  Glycolysis, which was found to have  the most 
number of protein counts and lowest Fisher Exact p-values, were chosen for 
quantification using the methodology described above.  The weighted area ratios were 
calculated using the equation shown below for proteins with multiple identified 
peptides.  This provided a more comprehensive measure of the change in abundance 
under different conditions. 
𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝐹𝑜𝑙𝑑 𝑜𝑓 𝐶ℎ𝑎𝑛𝑔𝑒 = ∑(𝐹 ×
𝐴
∑ 𝐴
)     [Eq. 1] 
where F is the fold of change of a peptide, A is the average area ratio among the 5 
replicates of data sets. 
Results and Discussion 
 Two series of iridium-(III)-based photosensitisers were designed to generate 
highly toxic singlet oxygen (1O2) upon irradiation with visible blue light (463 nm).  
Series one (PZ1-PZ3) ([Ir(C,N)2(S,S)]
+) was designed to retain the dithione ligands 
(shown in blue in Figure 3) upon irradiation, while series two (PZ4-PZ6) 
([Ir(C,N)2(O,O)]) was designed to dissociate the diketonate ligands (shown in green in 
Figure 3) upon irradiation. 





Figure 4.3 Structure of Ir(III)-based photosensitsers, PZ1-PZ6.  Dithione ligands 
(blue) on PZ1-PZ3 are retained upon irradiation, diketonate ligands (green) on 
PZ4-PZ6 are dissociated upon irradiation (dissociation line in red). 
 To study the effectiveness of a drug, it is important to investigate a drug’s MoA.  
These iridium-based photosensitisers were designed to release 1O2 upon irradiation, 
which can oxidise the species in the surrounding environment.  Proteins are a major 
target for oxidants as a result of their high abundance in biological systems.  Oxidation 
can occur at both the protein backbone and on the amino acid side chains.  Some side 
chain oxidation products, including methionine sulfoxide, can be employed as sensitive, 
specific markers of oxidative damage.  Most protein damage is non-repairable, and leads 
to a loss of specificity of protein structure and function.32  Some oxidation products are 
diagnostic for investigating whether the oxidation event is induced by one kind of 




reactive oxygen species (ROS) or another.  For example, different oxidation products of 
tryptophan can be used to diagnose whether the oxidation event is induced by hydroxyl 
radicals (•OH) or 1O2 (Figure 4.4).  Figure 4.4 below shows the possible oxidation 
products of amino acids and the corresponding mass shifts (Δm).  MS with sufficient 
resolving power and mass accuracy, such as FT-ICR MS is able to identify the species 
using these mass shifts and provide a better understanding of the MoA of a drug. 
 
 
Figure 4.4 Oxidation products of amino acids.  1O2 induced oxidation products of 
tryptophan are highlighted in blue and hydroxyl radical induced oxidation 
products of tryptophan are highlighted in red. 
 Bombesin is a known tumour marker peptide for small cell lung carcinoma, 
neuroblastoma, and gastric cancer,33 and therefore was chosen to be a model peptide to 
study the MoA of the iridium-based photosensitisers.  Figures 5 and 6 show the full 
mass spectrum of 2:1 (drug:peptide) reaction ratio of PZ1:L3BBS and 2:1 reaction ratio 
of PZ3-L3BBS analysed using nESI-FT-ICR MS.  Both spectra showed similar results, 
a whole array of oxidised L3BBS was observed in the mass spectrum.  Apart from the 




oxidised products, interestingly, the drugs were found to bind to L3BBS directly, as well 
as the oxidised forms of L3BBS, [PZ1-(S,S)+L3BBS+H]2+,     
[PZ1-(S,S)+L3BBS+O+H]2+, and [PZ1-(S,S)+L3BBS+2O+H]2+.  However, it was 
surprising to observe the loss of dithione ligands in these products, as series one (PZ1-
PZ3) was designed to retain the dithione ligands upon irradiation.  This may indicate the 
Ir-S bonds are not as unreactive as previously expected.  A series of oxidised products 
were also observed and with the aid of ultra-high resolution mass spectrometry and the 
ability to obtain high mass accuracies.  The oxidised products were assigned according 
to the mass shifts from the unmodified doubly charged L3BBS species (796.411734 
m/z).  There are a few oxidised products worthy of a more detailed investigation into the 
loss of (-CO+O2, Δm = 3.984814 Da).  Such modification was seen in 
1O2-induced 
tryptophan oxidation in previous studies (formation of kynurenine, or possibly 3-
hydroxykynurenine),13 which can provide indirect evidence of the generation of 1O2 
during the irradiation process. 
 
Figure 4.5 Full MS of PZ1-L3BBS (2:1) by nESI. Inset (a) shows the formation of 
oxidised products.  Inset (b) shows the formation of iridium-bound products.  
Identities of oxidised products and iridium-bound products are listed below the 
figure. 





Figure 4.6 Full MS of PZ3-L3BBS (2:1) by nESI. Inset (a) shows the simulation of 
PZ3 with the loss of dithione ligand.  Inset (b) shows the formation of iridium-
bound product.  Inset (c) shows the formation of oxidised products.  Inset (d) shows 
the intact PZ3 complex.  Identities of oxidised products and iridium-bound 
products are listed below the figure. 
 Like PZ1 and PZ3, when PZ4 and PZ6 reacted with L3BBS (Figures 4.7 and 
4.8), a series of oxidation products were generated as well as the iridium-bound 
peptides.  The diketonate was dissociated as expected with how this series of drug was 
designed.  More importantly, the formation of kynurenine (mass shift of 3.984814 Da) 
was also observed, indicating the generation of 1O2 in the reaction, which is often 
observed in other PDT.14 





Figure 4.7 Full MS of PZ4-L3BBS (2:1) by nESI. Inset (a) shows the formation of 
oxidised products.  Inset (b) shows the formation of iridium-bound products.  
Identities of oxidised products and iridium-bound products are listed below the 
figure. 
 





Figure 4.8 Full MS of PZ6-L3BBS (2:1) by nESI. Inset (a) shows the formation of 
oxidised products.  Inset (b) shows the formation of iridium-bound products.  
Identities of oxidised products and iridium-bound products are listed below the 
figure. 
 Unlike PZ1, PZ3, PZ4, and PZ6, for PZ2 and PZ5 (Figures 4.9 and 4.10), which 
contained the same (C,N) ligand (shown in Figure 4.3), only oxidised products were 
formed and no iridium-bound product was observed, indicating variable products could 
be formed even when using complexes within the same synthetic series. 





Figure 4.9 Full MS of PZ2-L3BBS (2:1) by nESI. Inset (a) shows the simulation of 
PZ2 with the loss of dithione ligand.  Inset (b) shows simulation of intact PZ2.  
Inset (c) shows the formation of oxidised products.  Identities of oxidised products 
and iridium-bound products are listed below the figure. 





Figure 4.10 Full MS of PZ5-L3BBS (2:1) by nESI. Inset shows the formation of 
oxidised products.  Identities of oxidised products and iridium-bound products are 
listed below the figure. 
 To further investigate the specific oxidation sites in the oxidised L3BBS 
products, a 5:1 reaction ratio of PZ6-L3BBS was prepared, to increase the amount of 
1O2 per L3BBS molecule in the reaction system, thus increasing the number of oxidised 
products.  A full MS (Figure 4.11) was analysed to make sure there were no significant 
differences in products between the 2:1 and 5:1 reaction system.  Up to 5 different 
oxidation products were observed.  Apart from the oxidation products, PZ6 was also 
found with the loss of the diketonate ligand, and addition of one acetonitrile or two 
acetonitrile molecules were observed in the mass spectrum (Figure 4.11).  To study the 
specific oxidation site on the oxidation products, tandem mass spectrometry (MS/MS) 
was required, to fragment the isolated oxidised species and identify binding sites. 





Figure 4.11 Full MS of PZ6-L3BBS (5:1) by nESI. Inset (a) shows the simulation of 
PZ6 with the loss of the diketonate ligand and an addition of an acetonitrile 
molecule.  Inset (b) shows an array of doubly charged oxidised L3BBS products. 
 Specific oxidation sites were investigated by ECD MS/MS.  Initially 
[L3BBS+O+2H]2+, 804.409192 m/z was isolated in the quadrupole with an isolation 
window of 5 m/z, however, with the tight isolation window, the ion intensity decreased 
dramatically.  Therefore, a wider isolation window of 10-20 m/z was used to isolate the 
ions of interest.  Unfortunately, this led to another problem of failing to obtain a “clean” 
isolation of the ion of interest as the other oxidised products were close to each other 
within the target mass ranges.  Therefore, an in-cell isolation technique, multi-CHEF 
was employed.  The ion of interest (804.409192 m/z) was first isolated in the quadrupole 
with a wide isolation window of 30 m/z.  Then the ions were transferred and 
accumulated in the hexapole-based collision cell, and later transferred into the infinity 
cell, where the second isolation event could be carried out.  Ions of interest were 
carefully isolated again inside the infinity cell with a notch width of 0.5 m/z and with 
isolation power of 50%, which allowed to obtain a “clean” isolation of the ion of 
interest, and ECD was applied to fragment the precursor ion (Figure 4.12, Table S4.1). 





Figure 4.12 ECD MS/MS of [L3BBS+O+2H]2+.  Inset shows the simulation of the 
[z11+O]+ fragment ion.  Red labels indicate the presence of oxidation.  The 
oxidation site methionine is highlighted in red.  The fragmentation map is shown 
below the MS/MS spectrum. 
 The mass difference between the unmodified L3BBS (796.411734 m/z) and the 
precursor (804.409192 m/z) is 15.994915 Da, which corresponds to an oxygen atom.  
However, there are multiple possible oxidation sites in the peptide sequence 
(pEQKLGNQWAVGHLM-NH2), which are tryptophan, histidine, and methionine.  
With careful internal calibration and analysis of the MS/MS spectrum, peaks were 
assigned with 100% cleavage coverage.  The fragments observed in the ECD MS/MS 
spectrum are summarised in the fragmentation map below the spectrum.  Fragments 
labelled with a red square indicate the presence of oxidation.  The oxidation site was 
located at the C-terminal methionine, indicating the methionine was oxidised once to 
methionine sulfoxide. 




 Subsequent oxidation products were then isolated in a similar fashion 
(combination of quadrupole isolation and in-cell isolation), and ECD was applied again 
to investigate the oxidation site (shown in Figure 13, Table S2). 
 
Figure 4.13 ECD MS/MS of [L3BBS+4O-CO+2H]2+.  Inset shows the simulation of 
the [z11+4O-CO]+ fragment ion.  Yellow labels indicate the presence of oxidation.  
The oxidation sites tryptophan and histidine are highlighted in yellow.  The 
fragmentation map is shown below the MS/MS spectrum. 
 A cleavage coverage of 62% was observed in the ECD MS/MS of the isolated 
oxidation product of [L3BBS+4O-CO+2H]2+ (814.404106 m/z).  The oxidation sites 
were located into the region containing residues QWAVGH.  Although fragments 
obtained in the ECD MS/MS spectrum were not sufficient to narrow down the oxidation 
sites to individual residues, by analysing individual residue within the region, only 
tryptophan (W) and histidine (H) can be oxidised.  However, histidine can only be 
oxidised once into 2-oxo-histidine, suggesting the remaining modification (+O2-CO+O) 




was on the tryptophan, thus, the formation of 3-hydroxykynurenine (3OH-kyn) (Figure 
4.4).  2-Oxo-histidine is commonly observed when histidine is exposed to a singlet 
oxygen-rich environment and 3OH-kyn is a product induced by 1O2 oxidation of 
tryptophan,12,13,26,34 together provide a strong evidence of the generation of 1O2 when the 
iridium-based photosensitisers are irradiated and activated with visible blue light (463 
nm). 
 Two series of Ir(III)-based photosensitisers were designed to generate highly 
toxic 1O2 upon irradiation with wavelength of 463 nm. 
1O2 generated in cells would 
greatly increase the extent of oxidation events and induce a vast amount of oxidative 
stress, potentially leading to apoptosis. These complexes were reacted with a model 
peptide, L3BBS, to investigate the MoA of these drugs towards biomolecules. A series 
of oxidation events and oxidised products were observed, which was suggested to be 
induced by 1O2 by the formation of kynurenine/3-hydroxykynurenine from tryptophan 
and the observation of 2-oxo-histidine. Surprisingly, the iridium-complexes were found 
to react with L3BBS directly and form iridium-bonded L3BBS products, which could 
provide a bimodal strategy to kill cancer cells, lowering the probably of developing 
resistance against these photosensitisers. 
PZ3 and PZ6 were shown to be more potent out of the six photosensitisers.  
Therefore, they were chosen to study in cells.  PDT in cell experiments was first tested 
by incubating monolayer cancer cells with the photosensitisers (PZ3 and PZ6) at various 
concentrations for 2 h.  In the dark, PZ6 showed no cytotoxicity to both A549 lung 
cancer and MRC-5 normal fibroblasts (IC50 > 100 µM), while PZ3 showed moderate 
toxicity to A549 cells (IC50 = 21.2 µM, Table S4.3).  The potency of both PZ3 and PZ6 
towards cancer cells increased markedly upon irradiation.  Under the same experimental 
conditions, 5-aminolevulinic acid (5-ALA) and cisplatin displayed much lower 
phototoxicity (IC50 > 100 µM).  The phototoxicities of PZ3 and PZ6 towards 3D 
multicellular tumour spheroids (MCTSs) were further investigated.  Untreated MCTSs 
were unaffected by 1-photon (1P) (463 nm) and 2-photon (2P) (750 nm) irradiation.  1P 
refers to a linear absorption process where one photon excites an atom ion or molecule 
from a lower energy level to a higher energy state (excited state) and 2P is the 




absorption of two photons of identical or different frequencies.  PZ6 showed no toxicity 
towards A549 MCTSs in the dark, and no toxicity towards MRC-5 MCTSs in either the 
dark or upon irradiation.  However, the IC50 values for PZ6 towards A549 spheroids 
upon 1P and 2P irradiation were very low (high potency), 1.0 µM and 0.23 µM, 
respectively (Table S4.3).  Interestingly, 2P photocytotoxicity was higher than 1P 
photocytotoxicity for this compound.  Although PZ3 also showed a decent phototoxicity 
to A549 spheroids, it also exhibited some phototoxicity towards the MRC-5 spheroids, 
i.e. insufficient selectivity.  Therefore, PZ6 was chosen to use in the following 
proteomic study. 
A549 lung cancer cell (ca. 1 x 109) were treated with PZ6 (10 µM, 2 h) either in 
the dark or with λ = 463 nm light irradiation.  Proteins from these cells were harvested 
and digested as described in the experimental section.  The digested proteins were 
analysed using a nLC-FT-ICR MS/MS setup equipped with a C18 reversed phase (RP) 
column. Each of the three samples (control, drug treated without irradiation, and drug 
treated with irradiation) were repeated five times for reproducibility and reliability 
purposes.  The nLC-MS/MS data sets were searched against the human proteome 
database using the Mascot search engine, including oxidative modifications of the side 
chains of cysteine (C), histidine (H), tyrosine (Y), phenylalanine (F), methionine (M), 
and tryptophan (W), as well as asparagine (N) and glutamine (Q) deamidation and serine 
(S), threonine (T), and tyrosine (Y) phosphorylation.  With 1% false discovery rate 
(FDR) against the database, all peptide identified by Mascot were manually checked for 
false positives.  Only proteins which detected three times or more (in triplicates) out of 
the five technical replicates under all three conditions were quantified.  212 proteins and 
~ 1500 peptides met these requirements and were identified (Figure 4.14). 





Figure 4.14 Venn diagram of proteins identified by Mascot under three different 
reaction conditions (control, drug treated without irradiation, and drug treated 
with irradiation). 
Quantification was achieved using a label-free approach, by spiking a known 
concentration and volume of tryptic digested lysozyme as an internal control.  A 
lysozyme peptide (FESNFNTQATNR, 714.8365 m/z) was used as a reference peptide to 
compare across different data sets.  Two-tailed t-tests ensured the consistency of the 
reference peptide throughout all data sets, and all p values were calculated to be larger 
than 0.05 (i.e. quantities of the reference lysozyme peptide were statistically similar, and 
consistent throughout all data sets (Table S4.4). 
Five unique oxidised peptides were detected three times or more out of the five 
replicates of nLC-MS/MS runs under all three reaction conditions.  These peptides are 
observed from different proteins and quantified using a label-free approach.  There are 
two commonly used label-free quantification methods in LC-MS, (a) Ion Abundance 
and (b) Ion Abundance Ratio (Figure 4.15).  “Ion Abundance” quantification is achieved 
by comparing directly the peak areas of the extract ion chromatogram (EIC) of the ions 




of interest (Figure 4.15a).  However, this method is often limited by the consistency and 
reproducibility of the LC-MS runs, such as the ionisation efficiency of analytes due to 
the difference in emitter performance.  “Ion Abundance Ratio” quantification refers to 
the comparison between the ratios obtained from the ion of interest and the internal 
control under different conditions (Figure 4.15b). 
 
Figure 4.15 Label-free quantification. (a) Ion Abundance. (b) Ion Abundance 
Ratio. (c) Example of quantifying the oxidised aldose reductase peptide 
(YKPAVNQIECHPYLTQEK + O), 745.3786 m/z.  IS represents internal standard. 
𝐹𝑜𝑙𝑑 𝑜𝑓 𝐶ℎ𝑎𝑛𝑔𝑒 =  
𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝑜𝑓 𝑡ℎ𝑒 𝑎𝑟𝑒𝑎 𝑟𝑎𝑡𝑖𝑜𝑠 (𝑖𝑟𝑟𝑎𝑑𝑖𝑎𝑡𝑒𝑑)
𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝑜𝑓 𝑡ℎ𝑒 𝑎𝑟𝑒𝑎 𝑟𝑎𝑡𝑖𝑜𝑠 (𝑑𝑎𝑟𝑘)
   [Eq. 2] 




 The five oxidised peptides were quantified using the “Ion Abundance Ratio” 
label-free quantification method with the lysozyme reference peptide 
(FESNFNTQATNR, 714.8365 m/z).  T-tests were then conducted and only peptides 
with p values < 0.05 were considered to have significant change between the two 
different reaction conditions (drug treated without irradiation and drug treated with 
irradiation).  Three out of five of the oxidised peptides found to have p values < 0.05, 
i.e. significantly different (Table S4.5).  Two of the three unique peptides were 
upregulated.  The level of oxidised peptide from heat shock protein 70 kDa (Hsp 70), 
Ala329-Arg442, AQIHDIVLVGGSTR (741.4156 m/z), increased by 5.66-fold (Table 
S4.5) for drug-treated cells upon irradiation compared to drug-treated cells in the dark.  
Specific oxidation of His332 to 2-oxo-His332 was identified by nLC-CAD MS/MS with 
cleavage coverage of 62% (Figure 4.16b, Table S4.6).  The second oxidised peptide, 
Tyr178-Lys195, from aldose reductase, YKPAVNQIECHPYLTQEK (745.3780 m/z, 
with alkylated cysteine, Figure 4.17b, Table S4.7) contained 2-oxo-His188 (with 39% 
cleavage coverage using nLC-CAD MS/MS), which increased by 2.93-fold for drug-
treated cells upon irradiation as compared to that in the dark (Table S4.5).  These data 
appear to be the first report of the formation of 2-oxo-histidine after treatment of cancer 
cells with organometallic photosensitisers.35 





Figure 4.16 (a) Structure of Hsp 70 (PDB: 3ATV),36 with the oxidised peptide 
Ala329-Arg342 shown in colour (2-oxo-His332, yellow).  (b) nLC-CAD MS/MS of 
the oxidised peptide from Hsp 70.  Fragments with red labels indicate the presence 
of oxidation.  (Reproduced from Zhang et. al. 2017 with permission)37. 





Figure 4.17 (a) Structure of aldose reductase (PDB: 1US0),38 with the oxidised 
peptide Tyr178-Lys195 shown in colour (2-oxo-His188, yellow).  (b) nLC-CAD 
MS/MS of the oxidised peptide from aldose reductase.  Fragments with red labels 
indicate the presence of oxidation, and an asterisk indicates alkylated cysteine.  
(Reproduced from Zhang et. al. 2017 with permission)37. 




 Pathway analysis was carried out to investigate the overall effect induced by PZ6 
on cell metabolism (method described in the experimental section).  The most 
significant result was the identification of nine unique proteins along the glycolysis 
pathway (Figure 4.18, Table S4.8).  The levels of these proteins, which are all involved 
in the conversion of glucose to pyruvate, increased by factor of ~ 2.1-5.3-fold with 
irradiation of A549 cancer cells treated with PZ6, with the highest increased for 
fructose-biphosphate aldolase.  Cancer cells have been shown to have defective 
mitochondria and increase their rate of glycolysis as a source of adenosine triphosphate 
(ATP) and energy to compensate for this mitochondrial effect.39  Mitochondria, where 
oxygen is reduced to water, is also a major source of ROS in cells.40  During irradiation, 
a vast amount of 1O2 is generated and a loop of ROS-stimulated glucose uptake and 
glucose-stimulated ROS production is triggered.41–43  This process is consistent with the 
up-regulation of proteins in the glycolytic pathway. 





Figure 4.18 Effects of irradiation of PZ6 on the level of proteins associated with 
glycolysis pathway in A549 lung cancer cells.  Nine up-regulated proteins 
highlighted in yellow were identified by nLC-CAD MS/MS, with the magnitude of 
the fold-change indicated in green.  (Reproduced from Zhang et. al. 2017 with 
permission)37. 
Key: PGM: Phosphoglucomutase; EIIGlc: D-glucose Npi-phosphotransferase; HXK: 
Hexokinase; GCK: Glucokinase; ADPGK: ADP dependent glucokinase; G6PT: D-
glucose-6-phosphotransferase; G6P-1-E: D-glucose-6-phosphate 1-epimerase; GPI: 
Glucose-6-phosphate isomerase; BgIA-2: 6-phospho-beta-D-glucosyl-D-glucose 




glycohydrolase; FBP: Fructose-bisphosphatase; PFK: Phosphofructokinase; PFP: D-
fructose-6-Phosphate 1-phosphotransferase; FBA: Fructose-bisphosphate aldolase; TPI: 
Triosephosphate isomerase; GAPDH: Glyceraldehyde-3-phosphate dehydrogenase; 
GAPOR: D-glyceraldehyde-3-phosphate: NADP+ oxidoreductase; BPGM: 
Bisphosphoglycerate mutase; PGK: Phosphoglycerate kinase; PGPM: D-
phosphoglycerate 2,3-phosphomutase; MINPP: Multiple inositol-polyphosphate 
phosphatase; AE: Alpha-enolase; PCK: Phosphoenolpyruvate carboxykinase; PCK 
(ATP): ATP Oxaloacetate carboxy-lyase; PK: pyruvate kinase; PFOR: Pyruvate 
ferredoxin-2-oxidoreductase; OFOR: 2-oxocarboxylate: ferredoxin-2-oxidoreductase; 
ACSL: Acyl-CoA-synthetase; DLAT: Dihydrolipoamide S-acetyltransferase; DLD: 
Dihydrolipoamide dehydrogenase; PD: Pyruvate dehydrogenase; PDC: 2-oxo-acid-
carboxyl-lyase; L-LDH: Lactate dehydrogenase; ALDH: Aldehyde dehydrogenase; 
ADH: Alcohol dehydrogenase; AOR: Alcohol cytochrome c oxidoreductase; MOR: 
Methanol cytochrome c oxidoreductase; AKR: Aldo-keto reductase. 
Conclusions 
 Six iridium-(III)-based photosensitisers were designed to generate singlet oxygen 
upon irradiation with specific wavelength (463 nm, visible blue light) and their 
mechanisms of reaction with the model peptide, [Lys3]-Bombesin, were analysed by FT-
ICR MS.  Four out of the six iridium-based photosensitisers showed the ability to not 
only oxidise, but also chemically bind to the target peptide, which displayed the 
possibility of a dual mechanisms of action against target biomolecules, and lowering the 
chance of developing complete resistance against the photosensitisers.  A series of 
oxidised products of the model peptide were observed and, by using ECD MS/MS, 
oxidation sites were found to be methionine, histidine, and tryptophan.  A specific 
oxidised form of tryptophan, 3-hydroxykynurenine was identified and provided strong 
evidence of the generation of singlet oxygen, and the oxidised form of histidine, 2-oxo-
histidine, was also often observed as a product upon singlet oxygen oxidation.  PZ6 was 
designed to release the diketonate ligand upon irradiation and found to possess the 
highest selectivity among the six photosensitisers, i.e. little to no cytotoxicity in the dark 
and extremely potent when irradiated/activated. 




 In previous reports, the specific nature of the damage to proteins in the cell, 
induced by photodynamic therapy (PDT), has been little studied.  Therefore, effect of 
PZ6 on A549 lung cancer cells was investigated by nLC-FT-ICR CAD MS/MS.  Singlet 
oxygen generated by PZ6 was found to oxidise specific histidine residues in the proteins 
heat shock protein 70 kDa (Hsp 70) and aldose reductase (AR), which have important 
functions in cancer cells.  Hsp 70 is a molecular chaperone for nascent proteins, and 
aberrantly folded, damaged, or mutated proteins.  AR is a monomeric reduced 
nicotinamide adenine dinucleotide phosphate (NADPH)-dependent enzyme, a member 
of the aldo-keto reductase superfamily.  This work appears to be the first report showing 
that specific sites of cellular Hsp 70 and AR can be oxidising during PDT.  The 
combination of oxidative stress induced by photoactivation of PZ6 together with the 
malfunction of mitochondria in cancer cells leads to the increase use of glucose to 
generate energy and is consistent with the observation of increase in the levels of 9 
unique enzymes involved in the glycolytic pathway (by a factor of ~ 2.1-5.3-fold). 
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Table S4.1 Assignments for Figure 4.12: ECD MS/MS of [L3BBS+O+2H]2+.  
Oxidised species are highlighted in red. 
Assignment Charge State Theoretical Mass (m/z) Observed Mass (m/z) Mass Error (ppm) 
[z+1]7 1+ 813.407606 813.40760 -0.01 
z8 1+ 940.458359 940.45845 0.10 
[z+1]8 1+ 941.466184 941.46622 0.04 
[c-1]8 1+ 998.492830 998.49303 0.20 
[c-1]9 1+ 1053.535029 1053.53523 0.19 
c9 1+ 1054.542854 1054.54280 -0.05 
[z+1]9 1+ 1055.509111 1055.50939 0.26 
z10 1+ 1111.522750 1111.52186 -0.80 
[z+1]10 1+ 1112.530575 1112.53016 -0.37 
[c-1]10 1+ 1152.603443 1152.60251 -0.81 
[c-1]11 1+ 1209.624906 1209.62494 0.03 
z11 1+ 1224.606814 1224.60734 0.43 
c12 1+ 1347.691643 1347.69148 -0.12 
[z+1]12 1+ 1353.709602 1353.71058 0.72 
c13 1+ 1460.775707 1460.77509 -0.42 
z13 1+ 1464.765440 1464.76623 0.54 
c14 1+ 1607.811107 1607.81110 0.00 
 
Average 0.00 ppm 
Absolute Average 0.30 ppm 
Standard Deviation 0.42 ppm 
 
  




Table S4.2 Assignments for Figure 4.13: ECD MS/MS of [L3BBS+4O-CO+2H]2+.  
Oxidised species are highlighted in red. 
Assignment Charge State Theoretical Mass (m/z) Observed Mass (m/z) Mass Error (ppm) 
z8 1+ 960.448188 960.44815 -0.04 
[z+1]8 1+ 961.456013 961.45652 0.53 
z9 1+ 1074.491115 1074.49100 -0.11 
[z+1]9 1+ 1075.498940 1075.49935 0.38 
z10 1+ 1131.512579 1131.51286 0.25 
[z+1]10 1+ 1132.520404 1132.52059 0.16 
z11 1+ 1244.596643 1244.59628 -0.29 
z12 1+ 1372.691606 1372.69140 -0.15 
c12 1+ 1383.676387 1383.67658 0.14 
c13 1+ 1496.760451 1496.76071 0.17 
z13 1+ 1516.768908 1516.76887 -0.03 
[z+1]14 1+ 1613.797862 1613.79652 -0.83 
c14 1+ 1627.800936 1627.80198 0.64 
 
Average 0.06 ppm 
Absolute Average 0.29 ppm 
Standard Deviation 0.38 ppm 
 
  




Table S4.3 Cytotoxicity (IC50, µM) of the compounds towards 2D and 3D human 
A549 lung cancer and healthy MRC-5 lung cells. 
 
2D cells or 3D spheroids incubated with the compounds for 2 hours, medium 
replaced in both “dark” and “light” plates with fresh non-drug medium, “light” 
plates irradiated with blue 96-array LEDs (463 nm, 2.88 J/cm2) or 2-photon laser 
beam (750 nm, 10 J/cm2, 100 fs).  All plates incubated for another 46 hours.  N.D. = 
Not Determinable. 
 




Table S4.5 Identification and changes in cellular levels of oxidised peptides 
detected by nLC-MS/MS in 5 triplicate samples, drug-treated without irradiation 
versus drug-treated irradiated.  Peptides labelled in green are up-regulated, in red 
down-regulated, and black indicates peptides with p values > 0.05. 
 
a Fold change = Area ratio (irradiated)/Area ratio (dark) = 0.293/0.0518 = 5.66 x 
b Fold change = Area ratio (irradiated)/Area ratio (dark) = 0.450/0.154 = 2.93 x 
Compound Dark 1P (463 nm) Dark 1P (463 nm) Dark 1P (463 nm) 2P (750 nm) Dark 1P (463 nm) 2P (750 nm)
PZ3 21.2 ± 1.2 0.12 ± 0.04 48.9 ± 5.6 44.5 ± 2.4 30.8 ± 1.4 0.8 ± 0.1 0.20 ± 0.03 54.6 ± 0.9 46.9 ± 3.5 40.7 ± 3.6
PZ6 > 100 0.3 ± 0.1 > 100 > 100 > 100 1.0 ± 0.2 0.23 ± 0.10 > 100 > 100 > 100
5-ALA > 100 > 100 > 100 > 100 > 100  > 100 N.D. > 100 > 100 N.D.
Cisplatin > 50 > 50 > 50 > 50  > 50  > 50 N.D. > 50 > 50 N.D.
2D A549 2D MRC-5 3D A549 Spheroids 3D MRC-5 Spheroids
IC50 (µM)
T Test bewteen p value
Control and Drug treated without Irradiation 0.42
Control and Drug treated with Irradiation 0.16
Drug treated without irradiation and Drug Treated with irradiation 0.26
Protein Entry Protein Peptide Sequence m/z p value Fold of change Modification
A0A0G2JIW1 Heat Shock Protein 70kDa AQIHDIVLVGGSTR 741.4156 0.0029 5.66 x a Oxidation (H)
E9PCX2 Aldose reductase YKPAVNQIECHPYLTQEK 745.3786 0.0013 2.93 x b Oxidation (H)
A6NL76 Actin, muscle protein QEYDEAGPSIVHR 758.8643 0.016 0.34 x Oxidation (H)
Q9BQE3 Tubulin alpha chain RAFVHWYVGEGMEEGEFSEAR 845.3690 0.073 0.64 x Oxidation (H, W, M)
P04350 Tubulin beta chain GHYTEGAELVDAVLDVVR 653.6729 0.46 1.20 x Oxidation (H)




Table S4.6 Assignments for Figure 4.16: nLC-CAD MS/MS of heat shock protein 
70 kDa oxidised peptide, AQIHDIVLVGGSTR.  Fragments with oxidation 
modification are labelled in red. 
Assignment Charge State Theoretical Mass (m/z) Observed Mass (m/z) Mass Error (ppm) 
[y4] 1+ 420.220123 420.22018 0.14 
[b4+O] 1+ 466.240858 466.24092 0.13 
[y5] 1+ 477.241586 477.24147 -0.24 
[y6] 1+ 576.310000 576.31012 0.21 
[y11+O-H2O] 2+ 576.312012 576.31199 -0.04 
[b5+O] 1+ 581.267801 581.26783 0.05 
[y7] 1+ 689.394064 689.39433 0.39 
[b6+O] 1+ 694.351865 694.35161 -0.37 
[y8] 1+ 788.462478 788.46226 -0.28 
[b7+O] 1+ 793.420279 793.41971 -0.72 
[y9] 1+ 901.546542 901.54651 -0.04 
[b8+O] 1+ 906.504343 906.50455 0.23 
[b9+O] 1+ 1005.572757 1005.57262 -0.14 
[y10] 1+ 1016.573485 1016.57398 0.49 
[b10+O] 1+ 1062.594221 1062.59413 -0.09 
 
Average -0.02 ppm 
Absolute Average 0.24 ppm 
Standard Deviation 0.31 ppm 
 
  




Table S4.7 Assignments for Figure 4.17: nLC-CAD MS/MS of aldose reductase 
oxidised peptide, YKPAVNQIECHPYLTQEK.  Fragments with oxidation 
modification are labelled in red. 
Assignment Charge State Theoretical Mass (m/z) Observed Mass (m/z) Mass Error (ppm) 
[y3] 1+ 404.213975 404.21391 -0.16 
[y4] 1+ 505.261653 505.26167 0.03 
[y5] 1+ 618.345717 618.34585 0.22 
[M+3H] 3+ 745.368528 745.36849 -0.05 
[y6] 1+ 781.409046 781.40880 -0.31 
[y7] 1+ 878.461810 878.46207 0.30 
[y15+O] 2+ 923.443625 923.44316 -0.50 
[y16+O-H2O] 2+ 962.964725 962.96462 -0.11 
[y16+O] 2+ 971.970007 971.97022 0.22 
[b11+O] 2+ 1356.636497 1356.63611 -0.29 
 
Average -0.07 ppm 
Absolute Average 0.22 ppm 
Standard Deviation 0.26 ppm 
 
  




Table S4.8 Quantification of proteins in the glycolytic pathway, the level of 22 
peptides from 9 proteins increase significantly as a result of 465 nm blue visible 
light irradiation of A549 human lung cancer cells treated with PZ6. 





ALDH IQQLEALQR 5.01E-03 +3.35 +3.35 
AE LNVTEQEKIDK 7.45E-03 +3.83 +3.83 
FBA GILAADESTGSIAKR 9.20E-04 +5.25 +5.25 
GPI HFVALSTNTTK 9.79E-05 +4.35 +4.35 
GAPDH VVDLMAHMASKE 3.01E-02 +2.42 +2.42 
L-LDH 
IVADKDYSVTANSK 8.19E-03 +1.97 
+2.11 
VIGSGCNLDSAR 1.30E-02 +2.00 
VTLTSEEEAR 4.29E-04 +2.81 
DLADELALVDVIEDKLK 1.80E-02 +2.36 
PGK AHSSMVGVNLPQK 3.59E-03 +2.98 +2.98 
PK 
AGKPVICATQMLESMIK 5.02E-03 +3.79 
+3.47 
FGVEQDVDMVFASFIR 2.01E-02 +3.56 
GSGTAEVELKK 3.83E-02 +2.04 
GVNLPGAAVDLPAVSEKDIQDLK 9.88E-03 +10.59 
ITLDNAYMEK 9.18E-03 +3.96 
LNFSHGTHEYHAETIK 8.36E-04 +3.60 
RFDEILEASDGIMVAR 3.01E-02 +2.02 
TATESFASDPILYRPVAVALDTK 3.31E-02 +2.11 
TPI 
IAVAAQNCYK 1.46E-03 +6.28 
+4.40 
IIYGGSVTGATCK 1.14E-02 +1.79 
SNVSDAVAQSTR 2.20E-04 +4.82 
VVLAYEPVWAIGTGK 2.36E-03 +6.49 
 
a ALDH: Aldehyde dehydrogenase; AE: Alpha-enolase; FBA: Fructose-bisphosphate 
aldolase; GPI: Glucose-6-phosphate isomerase; GAPDH: Glyceraldehyde-3-phosphate 
dehydrogenase; L-LDH: L-lactate dehydrogenase; PGK: Phosphoglycerate kinase; PK: 
Pyruvate kinase; TPI: Triosephosphate isomerase. b Weighted average. 




Metallodrug-Proteomics Pathway Analysis using nLC-FT-ICR MS 
 Quantitative nLC-FT-ICR MS/MS was used to study the proteomic effects of an 
osmium-based anticancer drug against A2780 ovarian cancer cells and an iridium-based 
antimicrobial complex against Staphylococcus aureus.  Promising results are reported in 
this chapter. 
The piano-stool osmium-based anticancer complex, [(η6-bip)Os(azpy-
NMe2)I]PF6, attacks energy production when administered to A2780 human ovarian 
cancer cells.  Pyruvate was selectively accumulated, allowing increased energy 
production for extra amino acid biosynthesis and cell division. 
An iridium-based antimicrobial complex, [(CpXbiph)Ir(TolBig)Cl]Cl, is shown to 
trigger a series of secondary responses from the bacterial cells by inducing a vast 
amount of stress, including oxidative stress.  Extra protein/DNA biosynthesis events 
were triggered by the observation of up-regulated ribosomal proteins.  These responses 
require a large amount of energy which was supported by the up-regulations of energy 
production-related enzymes. 
The osmium-(II)-based anticancer complex was synthesised by Dr. Russell 
Needham and the drug treatment of A2780 ovarian cancer cell culture was carried out 
by Hannah Bridgewater.  The iridium-(III)-based antimicrobial complex was 
synthesised and the drug treatment of S. aureus cell culture was carried out by Dr. Feng 
Chen.  Sample preparation and all data were produced, analysed, and written by the 
thesis Author. 
  




 Drug resistance is a critical problem in medical treatments which results in 
lowered effectiveness of drugs and more importantly, lowers the survival rate in 
patients.1  Metallodrugs are commonly used against different diseases, such as bacterial 
infection2 and different cancers.3,4  These metallodrugs are usually transition metal-
based, e.g. iridium,5,6 osmium,3,7 ruthenium,8,9 gold,10,11 rhodium,12,13 platinum.14,15  
With the advantage of possessing multiple oxidation states, these metallodrugs are often 
designed as pro-drugs, and activated with specific stimulations, such as change in 
chemical environment (temperature, pH, salt concentration), or even with light (often 
used in photoactivatable chemotherapy or photodynamic therapy),6,16,17 to enhance the 
selectivity towards the desired targets, such as bacterial or cancerous cells.  These 
metallodrugs often possess different mechanisms of action (MoA) to overcome drug 
resistance and improve the effectiveness and increase the survival rate in patients.  The 
study of new MoA’s for these metallodrugs is often achieved by monitoring the changes 
in cells, such as the protein content of cells.  The change in protein content can often 
provide insights into which metabolic pathways the metallodrugs affect in cells. 
 Proteomics is the study of the proteome and mass spectrometry (MS) is one the 
most commonly used analytical techniques because of its capability to analyse complex 
mixtures of analytes.  Intact protein analysis (top-down proteomics) requires mass 
spectrometers with very high performance which are often very expensive, and 
therefore, bottom-up analysis is more commonly used.  Bottom-up proteomics refers to 
the study of enzymatically digested proteins.  Bottom-up proteomics creates even more 
species prior to MS analysis compared to intact protein analysis because each protein is 
digested into dozens of smaller peptides and often require more clean-up steps but is still 
the most employed approach to proteomics as the performance requirement of 
instruments is the lowest.  Due to the complexity of proteomics samples, online or 
offline separation steps such as liquid chromatography (LC) are often used to separate 
the sample mixtures prior to MS analysis, in order to “simplify” the complexity of the 
protein/peptide mixtures, making the analysis more feasible.  Reversed phase (RP) 
chromatography is the most common separation method used in LC proteomics studies 
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based on the hydrophobicity of the proteins/peptides.  The more hydrophobic a species 
is, the longer the species is retained in the column and eluted at later time compared to 
hydrophilic species.  The eluted species are then ionised, transmitted, and detected by 
the MS detector.  Tandem mass spectrometry (MS/MS) allows fragmentation of the 
analyte species and can identify them.  Different MS/MS fragmentation techniques, such 
as collisionally activated dissociation (CAD),18 electron capture dissociation (ECD),19 
infrared multiphoton dissociation (IRMPD),20 ultraviolet photodissociation (UVPD)21, 
have been developed to provide informative fragments.  Fourier transform-ion cyclotron 
resonance mass spectrometry (FT-ICR MS) not only provides the highest resolution and 
mass accuracy, but also possesses the largest array of fragmentation techniques. 
 In addition to protein/peptide identification, quantification is one of the main 
focuses of proteomics studies.  Label-free quantification allows quantification of the 
protein/peptide content without the need of introducing chemical tags into the sample.  
Assumptions are made that under well controlled conditions with sufficient data 
redundancy, identical peptides across different LC-MS/MS experiments can be 
compared directly.22  The quantified proteins/peptides can be mapped onto metabolic 
pathways and provide insights into the MoA’s of these new metallodrugs against 
diseases. 
 Herein, the MoA of an osmium-based metallodrug on A2780 ovarian cells and 
the MoA of an iridium-based metallodrug in Staphylococcus aureus (S. aureus) were 
investigated with nLC-FT-ICR MS/MS. 
Experimental 
Materials 
 Chicken lysozyme, formic acid, ammonium bicarbonate (AmmBic), 
dithiothreitol (DTT), iodoacetamide (IAA), glycerol, acetone, and trypsin were all 
purchased from Sigma Aldrich (Dorset, England).  LCMS grade acetonitrile (MeCN) 
was purchased from VWR (Lutterworth, UK).  Hypersep C18 RP cartridges were 
purchased from Thermo Fisher Scientific (Waltham, UK).  Ultra-pure water (18.2 
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MΩcm-1) was obtained from a Milli-Q UV III water purification system (Milli-Q, 
Hertfordshire, UK). 
Synthesis of the osmium-based complex (FY12) 
 [(η6-bip)Os(azpy-NMe2)I]PF6 (FY12) was synthesised and characterised as 
described previously by Dr. Russell Needham.23 
Synthesis of the iridium-based complex (CF281) 
 [(CpXbiph)Ir(TolBig)Cl]Cl (CF281) was synthesised and characterised as 
described previously by Dr. Feng Chen.2 
Preparation of the FY12 - A2780 ovarian cancer cell sample 
Approximately 1 x 109 of A2780 human ovarian cancer cells were treated with 
FY12 (IC50 concentration, 0.14 µM in 5% DMSO and 95% media).  All cells were 
harvested and lysed by sonicating with glass beads at 277 K in a Tris-buffer solution (50 
mM Tris-HCl with 1% glycerol; pH 7.5).  The samples were sonicated for 30 s and 
cooled for 1 min; the sonication process being repeated 45 times for effective cell lysis.  
All samples were then centrifuged for 30 min at 5,000 g at 277 K to remove the pellets.  
The supernatant from each sample was then quantified against a standard calibration 
curve of bovine serum albumin (BSA) using Bradford Reagent (Sigma Aldrich 
Company Ltd; Dorset, England).  The concentrations of proteins in these samples were 
then calculated using the calibration curve.  
The above samples were diluted using 100 mM ammonium bicarbonate solution 
(Sigma Aldrich Company Ltd; Dorset, England); the disulfide bonds were reduced with 
50 mM dithiothreitol (Sigma Aldrich Company Ltd; Dorset, England) and the free 
cysteine thiols were alkylated with 100 mM iodoacetamide (Sigma Aldrich Company 
Ltd; Dorset, England).  The alkylated lysate was then digested with trypsin (Sigma 
Aldrich Company Ltd; Dorset, England) by incubating the mixture for 16 h at 310 K.  
The digested peptides were desalted using C18 SPE cartridges (Thermo Scientific), 
washed twice with Milli-Q water and then eluted with 80% MeCN/aqueous solution.  
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Desalted samples were dried down with a Speed Vac concentrator (Thermo Scientific) 
and re-dissolved in Milli-Q water to a concentration of 1 mg/mL. 
Preparation of the CF281 - S. aureus sample 
S. aureus was cultured overnight with a culture density of 1 x 107, after exposure 
to the iridium complex at the concentration of 0 and 1 minimum inhibitory 
concentration (MIC) values (2 samples) for 1 h at 310 K.  All cells were harvested and 
lysed by using a homogeniser at 277 K in a Tris-buffer solution (50 mM Tris-HCl, 2.5% 
sodium dodecyl sulphate (SDS), and 5% glycerol, pH 7.5).  The samples were 
homogenised for 5 s and cooled down for 30 s at a power setting of 50%; the 
homogenisation process being repeated 20 times for effective cell lysis.  Lysed samples 
were centrifuged at 13,000 rpm for 20 min at 277 K.  Supernatants were transferred into 
fresh falcon tubes and 5 mL of cold acetone were added to each sample and kept at 253 
K for 2 h for protein precipitation.  Fractions of samples were collected and allowed to 
grow on agar plates overnight to ensure all bacterial cells were killed.  Samples were 
centrifuged again at 13,000 rpm for 15 min at 277 K the next morning after ensuring all 
bacterial cells were killed.  Supernatants were removed and fresh cold acetone was 
added to wash the samples, followed by centrifugation at 13,000 rpm for 15 min at 277 
K again.  Pellets were transferred into fresh Eppendorfs and 100 µL of 8 M urea was 
added to re-dissolve the pellets.  The re-dissolved pellet was then quantified against a 
standard calibration curve of bovine serum albumin (BSA) using Bradford reagent 
(Sigma Aldrich Company Ltd., Dorset, England).  The concentrations of proteins in 
these samples were then back calculated according to the absorbance reading from the 
microplate reader.  The above samples were diluted using 100 mM ammonium 
bicarbonate solution (Sigma Aldrich Company Ltd., Dorset, England), the disulfide 
bonds were reduced with 50 mM dithiothreitol (Sigma Aldrich Company Ltd., Dorset, 
England), and the free cysteine thiols were alkylated with 100 mM iodoacetamide 
(Sigma Aldrich Company Ltd., Dorset, England).  The alkylated lysate was digested 
with trypsin (1 µg/µL) (Sigma Aldrich Company Ltd., Dorset, England) by incubating 
the mixture for 16 h at 310 K. The digested peptides were desalted using C18 SPE 
cartridges (Thermo Scientific), washed twice with Milli-Q water and then eluted with 
80:20 MeCN:aqueous solution. Desalted samples were dried down with Speed Vac 
Chapter 5 Metallodrug-Proteomics Pathway Analysis using nLC-FT-ICR MS 
205 
 
concentrator (Thermo Scientific) and re-dissolved in Milli-Q water into concentration of 
1 mg/mL. 
nLC-FT-ICR MS/MS 
nLC separations were achieved using an EASY nano-LC II system (Proxeon, 
Hemel Hempstead, UK) with a home-made 18 cm, C18 reverse phase (RP) nano 
capillary column (75 µm, 3 µm particle size, pore size of 300 Å) and a 3 cm C18 RP 
pre-column (150 µm, 3 µm particle size, pore size of 300 Å).  Separation of tryptic cell 
digest was achieved using a formic acid-acidified water/acetonitrile gradient from 5% 
MeCN to 30% MeCN over 150 min, holding for 5 minutes at 30% MeCN, followed by 
a second gradient of 15 min from 30% MeCN to 80% MeCN.  Finally, with a 30-min 
wash of 80% MeCN at a constant flow rate of 500 nL/min. 
nLC-MS/MS experiments were carried out by coupling EASY nano-LC II 
system (Proxeon, Hemel Hempstead, UK) to a Bruker SolariX Fourier Transform-Ion 
Cyclotron Resonance Mass Spectrometer (FT-ICR MS) fitted with a 12 tesla actively 
shielded magnet (Bruker Daltonics, Bremen, Germany), via a custom nano-spray source 
utilising glass nanospray tips, 360 µm tip O.D., 50 µm tip I.D., and 8 µm orifice I.D. 
(New Objective, MA, USA).  Singly-charged or unknown-charge species were excluded 
automatically from the MS/MS list, only the most intense multiply charged ions from 
each scan were isolated in the quadrupole and accumulated for 1 - 1.2 s in the hexapole 
collision cell for collisionally activated dissociation (CAD) MS/MS experiments. 1.6 
and 2.25 μg (FY12 -A2780 and CF281 - S. aureus, respectively) of each sample was 
injected for each nLC-MS/MS run.  All nLC-MS/MS experiments were done with at 
least 5 technical replicates for consistency, reproducibility, and reliability of the data. 




Figure 5.1 nLC-FT-ICR MS/MS workflow of the FY12 - A2780 cancer cell and 
CF281 - S. aureus bacterial cells.   
Mass lists were generated by the FTMS peak picking algorithm in DataAnalysis 
v4.2 (Bruker Daltonik GmbH, Bremen, Germany) from nLC-MS/MS data sets and 
matched against the Mascot database search engine.  All the identified proteins were 
filtered with 1% false discovery rate (FDR).  Each peptide picked out by the search 
engine was manually analysed from the raw LC-MS/MS data, and any false positive 
results were critically eliminated.  The reduced datasets (after elimination) were then 
grouped together, and peptides that were detected 3 times or more out of the 5 replicates 
of data were further selected for quantification. 
Quantification of peptides was made by spiking with chicken egg white 
lysozyme digest (HEWL) to the cancer cell digest in 1:6 HEWL digest : cell digest 
volume ratio (lysozyme peptides 0.02 μg/μL, cell digest 0.4 μg/μL) into each sample 
during the nLC-MS/MS runs, and by determining the ratio between the cell peptide of 
interest and the specific lysozyme peptide. The differences between the ratios from the 
control sample set and the drug treated sample set were compared.  T-tests and p values 
were determined as measures of the level of significance between the different samples. 




 Peptides that were detected 3 times or more out of the 5 replicates of data sets 
were selected for quantification of pathway analysis.  The protein entry lists were 
imported and cross-matched with the Database for Annotation, Visualisation and 
Integrated Discovery (DAVID) Bioinformation Database,24 then a list of related 
pathways was generated and exported by the Kyoto Encyclopedia of Genes and 
Genomes (KEGG) database.25–27  Peptides were quantified using the methodology 
described above.  The weighted area ratio was calculated using the equation shown 
below for proteins with multiple identified peptides.  This provided a more 
comprehensive measure of the change in abundance under different conditions.  Protein 
Clustering was achieved with String database v11.0. 
𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝐹𝑜𝑙𝑑 𝑜𝑓 𝐶ℎ𝑎𝑛𝑔𝑒 = ∑(𝐹 ×
𝐴
∑ 𝐴
)     [Eq. 1] 
where F is the fold of change of a peptide, A is the average area ratio among the 5 
replicates of data sets. 
Results and Discussion 
FY12-A2780 Ovarian Cancer Cells 
Two batches of A2780 human ovarian cells (ca 1 x 109 each) were cultured, one 
batch treated with FY12 (10 µM) and the other batch without (control).  Proteins from 
these cells were harvested and digested as described in the experimental section.  The 
digested proteins were analysed by coupling a nLC to the FT-ICR MS equipped with a 
C18 reversed phase (RP) column.  Each of the two samples (control and drug treated) 
were repeated five times for reproducibility and reliability purposes.  These data sets 
were searched against the human proteome database using the Mascot search engine 
with the oxidation of amino acid side chains (histidine, tryptophan, and methionine), 
deamidation of asparagine and glutamine, phosphorylation of serine, threonine, and 
tyrosine as variable modification and carbamidomethyl (from alkylation) as a fixed 
modification.  With 1% false discovery rate (FDR), all identified peptides were 
manually checked for false positives.  Only peptides which detected three times or more 
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out of the five replicates under the two different reaction conditions were quantified.  
231 unique proteins and ~ 1500 peptides met these requirements and quantified (Figure 
5.2). 
 
Figure 5.2 Venn diagram of proteins identified by Mascot under two different 
reaction conditions (control and drug treated). 
 The 231 protein identities were imported onto the DAVID bioinformatics 
database (DAVID Bioinformatics Resources 6.8),24 and mapped onto metabolic 
pathways, summarised in Figure 5.3. 
 
Figure 5.3 Mutual proteins mapped onto eleven different metabolic pathways by 
DAVID bioinformatics database. 
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Quantification of peptides was achieved by measuring the peak areas of the 
peptide of interest and the reference peptide from the extract ion chromatograms (EIC), 
calculating the ratio and compared between the two conditions. 
𝐼𝑜𝑛 𝐴𝑏𝑢𝑛𝑑𝑎𝑛𝑐𝑒 𝑅𝑎𝑡𝑖𝑜 =
𝐴𝑝𝑒𝑝𝑡𝑖𝑑𝑒 𝑜𝑓 𝑖𝑛𝑡𝑒𝑟𝑒𝑠𝑡
𝐴𝑟𝑒𝑓𝑒𝑟𝑒𝑛𝑐𝑒 𝑝𝑒𝑝𝑡𝑖𝑑𝑒
     [Eq. 2] 
These mutual proteins were quantified using a label-free approach with 
lysozyme tryptic digest as an internal control.  A specific lysozyme peptide 
(FESNFNTQATNR, 714.8365 m/z) was chosen as the reference peptide and a t-test was 
performed to ensure the detection of this peptide was statistically consistent enough for 
quantification purposes between the two different reaction conditions.  The p value was 
calculated to be > 0.05, showing this lysozyme peptide is statistically consistent enough 
and can be used as a reference peptide for quantification purposes (Table S5.1).  The 
changes in quantity of each protein are summarised in Figure 5.4 and Tables S5.2 and 
S5.3. 
 
Figure 5.4 Summary of the quantified proteins in metabolic pathways.  Quantity 
changes (fold change) are shown in brackets.  Up-regulated proteins are shown in 
green and down-regulated proteins are shown in red. 
 Glycolysis pathway was found to have the lowest p value of 1.5 x 10-10, 
suggesting this pathway was affected most significantly out of the eleven metabolic 
pathways (Figure 5.5).  Glucose-6-phosphate isomerase (GPI) was found down-
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regulated (0.68x) and GPI is responsible for the interconversion of glucose-6-phosphate 
(α-D-Glucose-6P or β-D-Glucose-6P) and fructose-6-phospate (β-D-Fructose-6P).  The 
down-regulation of GPI prevents the back conversion from β-D-fructose-6P to α/β-D-
glucose-6P, supported by the observation of up-regulated fructose-biphosphate aldolase 
(FBA).  FBA was observed to have been up-regulated by 1.37-fold and is responsible 
for the breakdown of fructose 1,6-biphosphate (β-D-fructose-1,6P2) into 
dihydroxyacetone (DHAP) and glyceraldehyde 3-phosphate (G3P).  Triosephosphate 
isomerase (TPI 1) was up-regulated by 2.68-fold, the largest change in quantity out of 
the nine detected proteins in the glycolysis pathway.  TPI 1 catalyses the isomerisation 
of DHAP and G3P, leads to a selective accumulation of G3P in the system. 
 Phosphoglycerate kinase was down-regulated (PGK, 0.83x) while 
bisphosphoglycerate mutase was up-regulated (BPGM, 1.66x).  PGK contributes to the 
interconversion of 2-phosphoglycerate (glycerate-2P) and 3-phosphoglycerate 
(glycerate-3P).  While BPGM is responsible for the conversion of 2,3-
bisphosphoglycerate (glycerate-2,3P2) from 1,3-bisphosphoglycerate (glycerate-1,3P2) 
and the formation of glycerate-2P, which is an irreversible reaction.  glycerate-2P serves 
as a substrate in the ninth step of the glycolysis pathway and plays an important role in 
the eventual production of pyruvate. 
 α-Enolase (AE) contributes to the interconversion between glycerate-2P and 
phosphoenol pyruvate (PEP), which is a reversible reaction.  When A2780 ovarian 
cancer cells were treated with FY12, AE was down-regulated by 0.77-fold, while 
phosphoenolpyruvate carboxykinase (PCK 1,2) was up-regulated by 2.46-fold, the 
second largest change upon drug treatment.  PCK 1,2 irreversibly converts oxaloacetate 
into PEP.  With the down-regulation of AE and up-regulation of PCK 1,2, the amount of 
PEP was vastly accumulated selectively.  Pyruvate kinase (PK) and lactate 
dehydrogenase (L-LDH) were both up-regulated, by 1.34-fold and 1.58-fold, 
respectively.  These two enzymes contribute to the production of pyruvate, which 
supplies energy to cells through the citrate cycle, also known as the Krebs cycle when 
oxygen is present.28  The selective accumulation of pyruvate is believed to result from a 
combination of uncontrolled proliferation and stress response of the cancer cells.  The 
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uncontrolled proliferation requires a large energy supply for cell replication, but more 
importantly, the quantity change was achieved by comparing the control and the drug 
treated samples, and these changes were induced by FY12.  When cancer cells are 
present under a stressful condition/environment or dying, they would adapt and undergo 
more replication/reproduction, as a secondary response. 
 
Figure 5.5 Effects of FY12 on the level of proteins associated with the glycolysis 
pathway in A2780 ovarian cancer cells.  Nine proteins highlighted in yellow were 
identified by nLC-CAD MS/MS, with the magnitude of the fold-change indicated 
in green (up-regulated) or red (down-regulated). 
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Key: PGM: Phosphoglucomutase; EIIGlc: D-glucose Npi-phosphotransferase; HXK: 
Hexokinase; GCK: Glucokinase; ADPGK: ADP dependent glucokinase; G6PT: D-
glucose-6-phosphotransferase; G6P-1-E: D-glucose-6-phosphate 1-epimerase; GPI: 
Glucose-6-phosphate isomerase; BgIA-2: 6-phospho-beta-D-glucosyl-D-glucose 
glycohydrolase; FBP: Fructose-bisphosphatase; PFK: Phosphofructokinase; PFP: D-
fructose-6-Phosphate 1-phosphotransferase; FBA: Fructose-bisphosphate aldolase; TPI: 
Triosephosphate isomerase; GAPDH: Glyceraldehyde-3-phosphate dehydrogenase; 
GAPOR: D-glyceraldehyde-3-phosphate: NADP+ oxidoreductase; BPGM: 
Bisphosphoglycerate mutase; PGK: Phosphoglycerate kinase; PGPM: D-
phosphoglycerate 2,3-phosphomutase; MINPP: Multiple inositol-polyphosphate 
phosphatase; AE: Alpha-enolase; PCK: Phosphoenolpyruvate carboxykinase; PCK 
(ATP): ATP Oxaloacetate carboxy-lyase; PK: pyruvate kinase; PFOR: Pyruvate 
ferredoxin-2-oxidoreductase; OFOR: 2-oxocarboxylate: ferredoxin-2-oxidoreductase; 
ACSL: Acyl-CoA-synthetase; DLAT: Dihydrolipoamide S-acetyltransferase; DLD: 
Dihydrolipoamide dehydrogenase; PD: Pyruvate dehydrogenase; PDC: 2-oxo-acid-
carboxyl-lyase; L-LDH: Lactate dehydrogenase; ALDH: Aldehyde dehydrogenase; 
ADH: Alcohol dehydrogenase; AOR: Alcohol cytochrome c oxidoreductase; MOR: 
Methanol cytochrome c oxidoreductase; AKR: Aldo-keto reductase. 
 As the same protein can be involved in more than one pathway, the quantified 
proteins were also imported onto the String database for clustering purposes.  This 
allows a clearer observation of how these proteins are related to each other and how are 
they contributing in the cells. 
 25 proteins were imported onto String database, and they were grouped into 4 
major clusters according to their cellular functions, including: (1) signalling 
pathway/cell division, (2) stress response, (3) amino acid synthesis/repair, and (4) 
energy production (Figure 5.6). 
 When A2780 ovarian cancer cells were treated with FY12, the cancer cells were 
under a stressful environment, which stimulated a lot of primary and secondary 
responses.  Three of the four 14-3-3 protein isoforms were down-regulated and they 
have been reported to be closely related to cancers and play important roles in many 
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signalling pathways.29  14-3-3 protein epsilon (14-3-3 ε) is one of the mammalian 14-3-
3 protein family members that is highly conserved in eukaryotes and has been reported 
as an oncogene activator, with the potential to cause cancer.  In tumour cells, oncogenes 
are often overexpressed and cause the tumour cells designated for apoptosis to survive 
and proliferate instead.30  A down-regulation (0.78-fold) of 14-3-3 ε is believed to leave 
the tumour cells scheduled to apoptosis/programmed cell death. 14-3-3 protein gamma 
(14-3-3 γ) was found to be involved in cancerous processes, and is consistently up-
regulated in other cancers such as human lung cancer.31  The observation of down-
regulation (0.75-fold) of this protein may suggest FY12 has a positive impact in killing 
the ovarian cancer cells.  Overexpression of 14-3-3 protein zeta (14-3-3 ζ) was 
previously reported as contributing apoptosis resistance, cancer recurrence and 
chemoresistance.32  14-3-3 ζ can therefore be used as a target or biomarker for cancer 
therapeutic resistance.  The down-regulation of 14-3-3 ζ by 0.69-fold shows FY12 is 
effectively targeting an important metabolic pathway and blocks the function of 14-3-3 ζ 
in human cancers, lowering the opportunity of having cancer recurrence and 
chemoresistance, increasing the survival rate of patients.  Actin and tubulin were found 
up-regulated by 2.1-fold and 3.04-fold respectively, the two largest quantity changes 
observed.  These two proteins are heavily involved in the cell division stages/cell 
proliferation.  Actin contributes to cell motility/invasivity of cells and cell division.  
When the ovarian cancer cells were “attacked” by the FY12 osmium-based anticancer 
drug, the cancer cells were under a vast amount of stress and appear to have stimulated a 
secondary response of triggering more cell division/replication.  Tubulin is heavily 
involved in mitosis, especially for migrating chromosomes to the opposite poles of a 
mitosing cells during the anaphase.  Similar to actin, the up-regulation of tubulin is also 
believed to be a secondary response of from the stimulated cancer cell division. 
 Heat shock proteins are a family of proteins that are produced by cells in 
response to exposure to stressful conditions, such as heat,33 and UV light.34  They are 
chaperone proteins that assist other proteins to fold properly and possess specific 
functionality.  Endoplasmin (HSP90B1) and heat shock protein HSP 90-alpha 
(HSP90AA1) were found up-regulated by 2.01-fold and 2.39-fold, respectively, which 
indicates that FY12 induced stress onto the ovarian cancer cells, and the heat shock 
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proteins were responding by up-regulating these proteins to cope with the stressful 
environment, possibly by altering the folding of proteins.  This is supported by the up-
regulation of the protein disulfide-isomerase, which is an enzyme that catalyses the 
formation and cleavage of cystine disulfide bonds within proteins as they fold.35  
Healthy biological systems have stable amino acid synthesis, in order to achieve a 
sustainable protein production with correct folding and functionalities.  However, once 
the delicate balance of amino acid synthesis is broken, proteins can be folded differently 
causing destructive effects.  S-Adenosylmethionine synthase isoform (MAT2A) and 
adenosylhomocysteinase (AHCY) were down-regulated by 0.53-fold and 0.65-fold, 
respectively.  The synthesis of S-adenosylmethionine is often referred to as the rate-
determining step of the methionine synthesis cycle.36  The decrease in quantity limits the 
production of methionine and possibly disrupts important cellular functions such as the 
growth of new blood vessels (angiogenesis).  ACHY is an enzyme that converts 
adensylhomocysteine to homocysteine and adenosine.  Similar to the decreased quantity 
of MAT2A, the decreased quantity of ACHY leads to less cysteine production, which 
affects protein folding greatly, as the cystine disulfide bonds contribute significantly to 
protein folding.37 
 
Figure 5.6 FY12-A2780 ovarian cancer cell experiment.  Protein clustering 
according to their cellular functions, achieved with String v11.0. 
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CF281-Staphylococcus aureus Bacterial Cells 
 The same proteomics approach was performed to study the effect of the iridium-
based antimicrobial complex on S. aureus bacterial cells.  Each of the two samples 
(control and dosed with 1 MIC of iridium) were repeated five times for reproducibility 
and reliability purposes.  These data sets were searched against the S. aureus proteome 
database using the Mascot search engine with the oxidation of amino acid side chains 
(histidine, tryptophan, and methionine), deamidation of asparagine and glutamine, 
phosphorylation of serine, threonine, and tyrosine as variable modification and 
carbamidomethyl (from cysteine alkylation) as a fixed modification.  With 1% false 
discovery rate (FDR), all identified peptides were manually checked for false positives.  
Only peptides which were detected three times or more out of the five replicates under 
the two different reaction conditions were quantified.  81 unique proteins and ~ 300 
peptides met these requirements and quantified (Figure 5.7). 
 
Figure 5.7 Venn diagram of proteins identified by Mascot under two different 
reaction conditions (control and 1 MIC). 
The difference in the number of proteins detected in the two reaction conditions 
was significantly different (~ 3.6 times more compared to the control sample).  The 
overall protein content after the cell lysis was quantified using Bradford reagent and 
measurement of the light absorbance at 600 nm.  Proteins turn the Bradford reagent 
from brown to blue, the more concentrated the protein is, the darker blue.  However, 
sodium dodecyl sulphate (SDS) which was used as a detergent to break down the 
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bacterial cell wall, will turns the Bradford reagent from brown to a greenish blue colour.  
In theory, all SDS should have been removed using acetone precipitation, however the 
residual SDS could induce artefacts into the protein quantification using light 
absorbance measurements by absorbing the 600 nm wavelength irradiation too.  In order 
to obtain a measurable absorbance difference, the colour change of Bradford reagent 
must be significantly high enough.  However, compared to the drug-treated sample, 
which required only 1 µL of the sample to cause a significant change, the control sample 
required 5 µL.  Therefore, the apparent protein quantity of the control sample may have 
appeared to be larger while a proportion of the light absorbance was contributed by the 
SDS, causing a low efficiency extraction for the Bradford assay calibration using bovine 
serum albumin (BSA).  The experiment could be improved by increasing the initial 
number of bacterial cells, in order to overcome the concentration of residual SDS from 
the cell lysis procedures.  The increase in number of cells could also avoid any scaling 
during sample preparation or quantification stages, yielding a more reliable protein 
quantity. 
 All the peptides were quantified using the label-free quantification method with 
the lysozyme peptide (NTDGSTDYGILQINSR, 877.4212 m/z) as an internal control.  A 
t-test was performed on the internal control, to ensure the detected abundances are 
statistically similar between the control and the drug treated sample (1 MIC).  The p 
value was calculated to be 0.12 (> 0.05), which shows the detected abundances were 
similar and can be used as an internal control for quantification purposes (Table S5.4).  
Peptides were quantified using the same method as mentioned above and only peptides 
with p values from t-test lower than 0.05 when compared between the two reaction 
conditions were selected for protein clustering (Table S5.5).  26 unique proteins met the 
requirements and were imported into the String database v11.0 for protein clustering.  
The proteins were separated into 6 groups according to their cellular functions (Figure 
8), including: (1) stress response, (2) energy production, (3) bacteria self-defence, (4) 
stress/repair, (5) replication, and (6) stress and removal of drugs. 
  




Figure 5.8 CF281-S. aureus bacterial cell experiment.  Protein clustering according 
to their cellular functions, achieved with String v11.0. 
 Analysis of the data suggest that when S. aureus bacterial cells were treated with 
CF281, a lot of stress was induced as a secondary response.  Different subunits of 30S 
ribosomal protein and 50S ribosomal protein were found up-regulated, ranging from 
2.1-fold to 12.4-fold, with the quantity of the 50S ribosomal protein L25 subunit 
increased the most.  These ribosomal subunits are heavily involved in the translation 
process, synthesising proteins after the transcription of DNA to RNA.38  When the 
bacterial cells are under a stressful environment, they are likely to be stimulated to 
produce more proteins for different purposes, such as enzymes for energy production, or 
for cell replication.  Apart from the ribosomal proteins, two elongation factors, G and 
Ts, were up-regulated by 7.9-fold and 2.6-fold, respectively.  They are mainly involved 
in protein translation, by catalysing the movement of translation RNA (tRNA) and 
messenger RNA (mRNA) through ribosome.  Alkyl hydroperoxide reductase C (ahpC) 
and thiol peroxidase (tpx) were also up-regulated by 8.4-fold and 2.4-fold, respectively.  
Bacteria, like cancer cells, are constantly under high oxidative stress,39 therefore, as an 
evolution, bacterial cells have developed a strong antioxidant response to reactive 
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oxygen species (ROS).40  Proteins ahpC and tpx both play important roles in cell 
protection against oxidative stress.  The observation of up-regulation between the 
control and drug-treated samples suggest that the iridium-based antimicrobial complex 
induced even more oxidative stress into the bacteria and triggered the oxidative stress 
defence system.  Therefore, inducing a vast amount of oxidative stress could be 
important to the MoA of CF281 (Figure 5.8, highlighted in red). 
Eight proteins were found involved in the energy production process, and they 
were all up-regulated, ranging from 2.8-fold to 8.6-fold, with the highest increase for 
enolase (Figure 8, highlighted in purple).  Enolase is responsible for the conversion of 
glycerate-2P to phosphoenol pyruvate (PEP), the ninth and penultimate step of 
glycolysis.  Formate acetyltransferase (pflB) helps regulate anaerobic glucose 
metabolism,41 and was also up-regulated, by 7.6-fold.  S. aureus are facultative 
anaerobes, which means they generate adenosine triphosphate (ATP) by aerobic 
respiration if oxygen is present, but are also capable of switching to fermentation or 
anaerobic respiration if they are in a hypoxia environment.  These observations support 
the secondary responses after the drug treatment, such as extra protein production and 
cell replication. 
Immunodominant staphylococcal antigen A (IsaA) is a non-covalently cell wall-
bound lytic transglycosylase, and involved in cell wall growth and division.42  
Immunoglobulin-binding protein sbi (sbi) has been reported to protect the bacterial cell 
against the host immune response.43  IsaA and sbi were both up-regulated by 11.9-fold 
and 3.8-fold, respectively.  This is believed to be a secondary response from the 
bacterial cells, responding to the “threat” introduced by CF281, as a self-defence system 
(Figure 5.8, highlighted in grey). 
Acyl carrier protein (AcpP) is an important component in both fatty acid and 
polyketide biosynthesis, many polyketides have been reported to possess antimicrobial 
properties, such as erythromycin A.44  RNA polymerase (rpoE) is involved heavily in 
the DNA transcription process.  RNA polymerase unzips the DNA double strand into 
single strand and copy them into RNA sequences.  They were up-regulated by 10.2-fold 
and 6.2-fold (Figure 5.8, highlighted in green), as a secondary response from the drug 
Chapter 5 Metallodrug-Proteomics Pathway Analysis using nLC-FT-ICR MS 
219 
 
treatment.  Pyrimidine-nucleoside phosphorylase was also found up-regulated by 2.5-
fold and it is responsible to synthesise pyrimidine bases for DNA replication.  Succinyl-
diaminopimelate desuccinylase (dapE) is closely related to the multidrug export 
system.45  Multiple drug resistance (MDR) is antimicrobial resistance shown by a 
species of microorganism to multiple antimicrobial drugs.  dapE also catalyses the 
hydrolysis of N-succinyl-L,L-diaminopimelic acid (SDAP), forming succinate and L,L-
2,6-diaminoheptanedioate (DAP), which is an intermediate involved in the biosynthesis 
of meso-diaminopimelic acid, an essential component of bacterial cell wall in gram-
positive bacteria.  The up-regulation of dapE (8.6-fold) is believed to also be a 
secondary response from the antimicrobial treatment. 
Conclusions 
Pathway analysis of an osmium-based metallodrug on A2780 ovarian cancer 
cells was achieved by nLC-FT-ICR CAD MS/MS.  The protein identities were achieved 
by matching the fragmentation patterns against the Mascot database and quantification 
of these proteins achieved using a label-free approach with lysozyme tryptic digested 
peptides.  FY12 has shown promising effects on multiple metabolic pathways and 
different cellular functions, such as energy production from the glycolysis pathway.  
Nine unique proteins showed a significant change in quantity (up-regulated) and 
pyruvate was selectively accumulated for extra energy production.  Other than the 
production of energy, the quantity of 14-3-3 protein isoforms were also influenced when 
the cancer cells were treated with FY12, which is believed to be the primary MoA 
against cancer cells.  Different stress responses, including up-regulation of heat shock 
proteins and the down-regulation of amino acid synthesis were believed to be a 
secondary response from the cancer cells.  Previous studies on the MoA’s of FY12 and 
other osmium-based complexes suggested oxidative stress was induced near the 
mitochondria of the target cells by high superoxide concentration, causing mitochondrial 
dysfunction and DNA damage.3,4  The results reported here not only supported these 
previous studies but also provided a more in-depth investigation in the quantity change 
of specific proteins. 
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 The mechanism of action (MoA) of the iridium-based antimicrobial complex 
CF281 was investigated using a similar methodology.  81 unique proteins were detected 
three times or more out of the replicates, and 26 of those were shown to have significant 
up-regulated quantity change with p values less than 0.05 in t-tests.  These proteins were 
clustered together according to their cellular functions.  The bacterial cells were shown 
to be in a very stressful environment when they were treated with CF281 and triggered a 
series of secondary responses, including extra protein/DNA biosynthesis and energy 
production.  Proteins responsible for coping with oxidative stress were also found vastly 
up-regulated, suggesting CF281 is capable to induce extra oxidative stress inside the 
bacteria cells and trigger cell death, different MoA from traditional treatments, such as 
penicillin, which focus on the disruption of cell wall formation by inhibiting the 
formation of peptidoglycan cross linkages that provide rigidity and strength of the cell 
wall.  The difference in MoA to traditional antimicrobial treatments will provide a 
possibility to improve the multiple drug resistance problem. 
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Figure S5.1 Example of base peak chromatogram of A2780 ovarian cancer cell 
control nLC-FT-ICR CAD MS/MS. 
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Figure S5.2 Example of base peak chromatogram of FY12-A2780 ovarian cancer 
cell nLC-FT-ICR CAD MS/MS. 
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Table S5.1 T-test result for the lysozyme reference peptide (FESNFNTQATNR, 
714.8365 m/z). 
T Test between P value 
Control and Drug treated 0.34 
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Table S5.2 Quantification of all detected peptides in the FY12-A2780 ovarian 
cancer cell experiment, using the label-free approach. 
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Carbon Metabolism SAVENCQDSWR 7.10E-04 0.76 0.76 
Alpha-enolase 
Carbon Metabolism SGKYDLDFK 2.27E-02 0.80 
0.77 
Carbon Metabolism LMIEMDGTENK 2.76E-02 0.76 
D-3-phosphoglycerate 
dehydrogenase 
Carbon Metabolism QIPQATASMK 1.35E-03 1.76 
1.11 
Carbon Metabolism AGTGVDNVDLEAATR 3.47E-02 0.61 
Fructose-bisphosphate 
aldolase 
Carbon Metabolism ALANSLACQGK 3.97E-03 1.44 
1.37 Carbon Metabolism PYQYPALTPEQK 5.04E-04 1.37 
Carbon Metabolism LQSIGTENTEENR 3.60E-05 0.30 
Glucose-6-phosphate 
isomerase 
Carbon Metabolism HFVALSTNTTK 8.13E-03 0.67 
0.68 
Carbon Metabolism TFTTQETITNAETAK 4.50E-06 0.69 
Malate dehydrogenase 
Carbon Metabolism LGVTANDVK 4.66E-02 0.71 
0.80 
Carbon Metabolism MISDAIPELK 2.66E-02 0.87 
Phosphoglycerate kinase 
Carbon Metabolism VDFNVPMK 1.96E-02 0.75 
0.83 
Carbon Metabolism AHSSMVGVNLPQK 4.55E-03 0.84 
Phosphoglycerate mutase 
Carbon Metabolism HYGGLTGLNK 6.42E-04 1.69 
1.66 
Carbon Metabolism VLIAAHGNSLR 1.33E-03 1.56 
Pyruvate kinase Carbon Metabolism ITLDNAYMEK 2.27E-02 1.34 1.34 
Triosephosphate isomerase 
Carbon Metabolism IAVAAQNCYK 1.49E-06 7.62 
2.68 
Carbon Metabolism SNVSDAVAQSTR 8.78E-03 0.52 
14-3-3 protein epsilon Cell Cycle YLAEFATGNDRK 1.98E-04 0.78 0.78 
14-3-3 protein gamma Cell Cycle YLAEVATGEK 7.84E-03 0.75 0.75 
14-3-3 protein theta 
Cell Cycle SICTTVLELLDK 2.56E-03 1.76 
1.04 
Cell Cycle AVTEQGAELSNEER 4.47E-03 0.67 
14-3-3 protein zeta/delta 
Cell Cycle GIVDQSQQAYQEAFEISKK 3.04E-03 0.64 
0.69 
Cell Cycle SVTEQGAELSNEER 7.67E-04 0.70 
Proliferating cell nuclear 
antigen 
Cell Cycle FSASGELGNGNIK 1.57E-02 1.18 1.18 
Adenosylhomocysteinase 
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Cys and Met 
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1.58 Glycolysis VTLTSEEEAR 1.57E-03 0.65 
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Phosphoenolpyruvate 
carboxykinase 
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Phosphoglycerate mutase 
Glycolysis HYGGLTGLNK 6.42E-04 1.69 
1.66 
Glycolysis VLIAAHGNSLR 1.33E-03 1.56 
Pyruvate kinase Glycolysis ITLDNAYMEK 2.27E-02 1.34 1.34 
Triosephosphate isomerase 
Glycolysis IAVAAQNCYK 1.49E-06 7.62 
2.68 
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LKDDEVAQLK 6.16E-04 0.76 
Pyruvate 
Metabolism 

















ITLDNAYMEK 2.27E-02 1.34 1.34 
14-3-3 protein epsilon Signalling Pathway YLAEFATGNDRK 1.98E-04 0.78 0.78 
14-3-3 protein gamma Signalling Pathway YLAEVATGEK 7.84E-03 0.75 0.75 
14-3-3 protein theta 
Signalling Pathway SICTTVLELLDK 2.56E-03 1.76 
1.04 
Signalling Pathway AVTEQGAELSNEER 4.47E-03 0.67 
14-3-3 protein zeta/delta 
Signalling Pathway GIVDQSQQAYQEAFEISKK 3.04E-03 0.64 
0.69 
Signalling Pathway SVTEQGAELSNEER 7.67E-04 0.70 
Actin 
Signalling Pathway GYSFTTTAER 2.51E-03 1.67 
2.10 
Signalling Pathway HQGVMVGMGQK 4.11E-02 2.26 
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Table S5.3 Summary of the quantified proteins in metabolic pathways of FY12-
A2780 ovarian cancer cell experiment.  Up-regulated proteins are shown in green 
and down-regulated proteins are shown in red. 
Glycolysis 
Protein Description Average Fold of Change Standard Deviation 
Alpha-enolase 0.77 0.005 
Fructose-bisphosphate aldolase 1.37 0.007 
Glucose-6-phosphate isomerase 0.68 0.003 
L-lactate dehydrogenase 1.58 0.010 
Phosphoenolpyruvate carboxykinase 2.46 0.002 
Phosphoglycerate kinase 0.83 0.002 
Phosphoglycerate mutase 1.66 0.004 
Pyruvate kinase 1.34 0.006 
Triosephosphate isomerase 2.68 0.035 
 
Carbon Metabolism 
Protein Description Average Fold of Change Standard Deviation 
6-phosphogluconate dehydrogenase 0.76 0.001 
Alpha-enolase 0.77 0.005 
D-3-phosphoglycerate dehydrogenase 1.11 0.007 
Fructose-bisphosphate aldolase 1.37 0.007 
Glucose-6-phosphate isomerase 0.68 0.003 
Malate dehydrogenase 0.80 0.002 
Phosphoglycerate kinase 0.83 0.002 
Phosphoglycerate mutase 1.66 0.004 
Pyruvate kinase 1.34 0.006 
Triosephosphate isomerase 2.68 0.035 
 
Signalling Pathway 
Protein Description Average Fold of Change Standard Deviation 
14-3-3 protein epsilon 0.78 0.001 
14-3-3 protein gamma 0.75 0.001 
14-3-3 protein theta 1.04 0.001 
14-3-3 protein zeta/delta 0.69 0.002 
Actin 2.10 0.079 
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Cys and Met Metabolism 
Protein Description Average Fold of Change Standard Deviation 
Adenosylhomocysteinase 0.65 0.001 
L-lactate dehydrogenase 1.58 0.010 
Malate dehydrogenase 0.80 0.002 
S-adenosylmethionine synthase isoform 0.53 0.003 
Antigen Processing and Presentation 
Protein Description Average Fold of Change Standard Deviation 
Heat shock 70 kDa protein family 0.93 0.008 
Heat shock protein HSP 90-alpha 2.39 0.019 
Protein disulfide-isomerase 1.57 0.002 
 
Pentose Phosphate Metabolism 
Protein Description Average Fold of Change Standard Deviation 
6-phosphogluconate dehydrogenase 0.76 0.001 
Fructose-bisphosphate aldolase 1.37 0.007 
Glucose-6-phosphate isomerase 0.68 0.003 
 
Biosynthesis of Amino Acids 
Protein Description Average Fold of Change Standard Deviation 
Alpha-enolase 0.77 0.005 
D-3-phosphoglycerate dehydrogenase 1.11 0.007 
Fructose-bisphosphate aldolase 1.37 0.007 
Phosphoglycerate kinase 0.83 0.002 
Phosphoglycerate mutase 1.66 0.004 
Pyruvate kinase 1.34 0.006 
S-adenosylmethionine synthase isoform 0.53 0.003 
Triosephosphate isomerase 2.68 0.035 
 
Protein Processing in Endoplasmic Reticulum 
Protein Description Average Fold of Change Standard Deviation 
Endoplasmin 2.01 0.009 
Heat shock 70 kDa protein family 0.93 0.008 
Heat shock protein HSP 90-alpha 2.39 0.019 
Protein disulfide-isomerase 1.57 0.002 




Protein Description Average Fold of Change Standard Deviation 
14-3-3 protein epsilon 0.78 0.001 
14-3-3 protein gamma 0.75 0.001 
14-3-3 protein theta 1.04 0.001 
14-3-3 protein zeta/delta 0.69 0.002 
Proliferating cell nuclear antigen 1.18 0.001 
 
Pyruvate Metabolism 
Protein Description Average Fold of Change Standard Deviation 
L-lactate dehydrogenase 1.58 0.010 
Malate dehydrogenase 0.80 0.002 
Phosphoenolpyruvate carboxykinase 2.46 0.002 
Pyruvate kinase 1.34 0.006 
 
Phagosome 
Protein Description Average Fold of Change Standard Deviation 
Actin 2.10 0.079 
Tubulin 3.04 0.010 
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Figure S5.3 Example of base peak chromatogram of S. aureus bacterial cell control 
nLC-FT-ICR CAD MS/MS. 
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Figure S5.4 Example of base peak chromatogram of CF281-S. aureus bacterial cell 
nLC-FT-ICR CAD MS/MS. 
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Table S5.4 T-test result for the lysozyme reference peptide 
(NTDGSTDYGILQINSR, 877.4212 m/z). 
T Test between P value 
Control and Drug Treated (1 MIC) 0.12 
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Table S5.5 Quantification of all detected peptides for the CF281-S. aureus bacterial 
cell experiment using the label-free approach. 






30S ribosomal protein S2 WLGGILTNYK 1.43E-02 2.10 2.10 
30S ribosomal protein S7 TMEDRLANEILDAANNTGGAVK 9.95E-04 3.57 3.57 
50S ribosomal protein L13 LFVYGGAEHPHAAQQPENYELRG 2.44E-05 2.33 2.33 
50S ribosomal protein L14 KTANIGDVIVCTVK 7.59E-04 2.73 2.73 
50S ribosomal protein L2 NMTSLDFAEITK 1.86E-03 3.96 3.96 
50S ribosomal protein L25 TVEVPVQLVGEAVGAK 7.74E-05 12.42 12.42 
50S ribosomal protein L5 VLDNAVEELELITGQKPLVTK 9.47E-04 4.91 4.91 
Acyl carrier protein MENFDKVKDIIVDR 7.56E-03 6.18 6.18 
Alcohol dehydrogenase 
IVAFDINDDKLAFAK 3.93E-04 10.02 
6.52 VVAVGLPVDKMNLDIPR 1.05E-03 4.18 
LVLDGIEVVGSLVGTR 2.91E-02 7.11 
Alkyl hydroperoxide 
reductase protein C 
NFDVLDEATGLAQR 1.56E-04 8.44 8.44 
ATP synthase subunit b QQQEQIIHEANVR 5.52E-03 2.40 2.40 
Elongation factor G VMTDPYVGKLTFFR 1.42E-04 7.89 7.89 
Elongation factor Ts ALTETDGDIDKAIDYLREK 3.16E-02 2.57 2.57 
Enolase AAADLLGQPLYK 1.10E-05 8.55 8.55 
Formate acetyltransferase 
ETLIDAMEHPEEYPQLTIR 2.42E-04 9.52 
7.63 AACEAYGYELDEETEKIFTDYR 4.94E-03 3.55 
ETLLDAMEHPEEYPQLTIR 2.42E-04 9.52 
Immunodominant 
staphylococcal antigen A 
LSNGNTAGATGSSAAQIMAQR 6.92E-04 11.85 11.85 
Immunoglobulin-binding 
protein sbi 
GAIDQTVLTVLGSGSK 7.64E-04 3.78 3.78 
L-lactate dehydrogenase TLKDIMAEAEELK 3.69E-03 2.83 2.83 
L-threonine dehydratase 
catabolic TdcB 
LLGIDATIVMPETAPIAK 3.17E-04 7.09 7.09 
Probable DNA-directed 
RNA polymerase subunit 
delta 
FLNVGENLWGLRDWYSVDDIEEK 4.76E-04 10.24 10.24 
Pyrimidine-nucleoside 
phosphorylase 
TLEDAEALAHAMVR 1.51E-02 2.24 
2.50 
NTMAIISDMNQPLGR 3.48E-03 2.71 
Pyruvate dehydrogenase 
E1 component beta 
subunit 
TVQPLDVDTIVASVEK 5.38E-04 6.53 
6.53 
TVQPIDVDTIVASVEK 5.03E-04 7.09 
Pyruvate kinase 
STDALLNNAVATAVETGR 6.71E-05 7.92 
7.55 
AEASDVANAIYDGTDAVMLSGETAAGLYPEEAVK 1.02E-02 5.07 
Succinyl-diaminopimelate 
desuccinylase 
IATVENPELSFASK 9.97E-06 8.56 8.56 
Thiol peroxidase LISVVPSIDTGVCDQQTR 2.44E-02 2.43 2.43 
Triosephosphate 
isomerase 
SSTSEDANEMCAFVR 5.96E-06 8.32 
7.16 SVVIAYEPIWAIGTGK 6.71E-04 7.18 
QTIADLSSKEVSEATR 1.40E-04 3.21 
 




Conclusions and Future Work 
 The work presented in this thesis has illustrated new progress in studies of 
metallodrugs and their interaction with biomolecules using Fourier Transform-Ion 
Cyclotron Resonance Mass Spectrometry.  This chapter aims to introduce, summarise, 
and outline the achievements and conclusions of each of the previous chapters. 
Chapter 2 Metallodrug-Peptide Interactions 
 
Figure 6.1 Summarising graphic for Chapter 2 
 The novel osmium-(II)-based anticancer complex, [(η6-bip)Os(en)Cl]PF6 (Os1-
Cl), was shown to interact with DNA with a different mechanism of action to cisplatin, 
which could lead to new ways of potentially attacking/killing cancerous cells more 
effectively with less undesired side effects.  Interactions between Os1-Cl and 
proteins/peptides were also studied to discover the possibility of possessing bimodal 
mechanisms of action.   
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Tryptic digested bovine serum albumin (BSA) was used as a model protein and a 
series of osmiated BSA peptides were observed.  The osmium complex was found to 
dissociate readily with low collision energy of 5 V, producing the unmodified peptide, 
suggesting the binding interaction between the osmium complex and the target peptide 
is weaker than the protein backbone.  Electron capture dissociation tandem mass 
spectrometry (ECD MS/MS) successfully preserved the osmium modification upon 
fragmentation and more binding information was revealed.  Os1-Cl was found to 
interact with the side chain of a lysine residue on the peptide KFWGK as well as a weak 
π-π interaction between the biphenyl ligand and the aromatic side chain of tryptophan. 
 nLC-MS and nLC-MS/MS using a reversed-phase (RP) column were also 
attempted to provide more separation between the unmodified and osmiated peptides.  
An isotopic prediction algorithm (SNAP-LC algorithm) was used to pick out species 
containing a characteristic osmium isotope pattern and generate a prefer/inclusion list 
for targeted nLC-ECD MS/MS analysis.  Side chains of glutamic acid and lysine, as 
well as the N- and C- termini were revealed to be possible osmium binding sites. 
 This work shows FT-ICR MS is particularly suitable for studying metallodrug-
biomolecule interactions with the wide array of possible fragmentation techniques and 
capable of coupling to different hyphenated techniques.  The ultra-high resolution and 
mass accuracy provided by FT-ICR MS not only allow confident characterisations but 
also provide important knowledge for new anticancer metallodrug designs.  The 
methodology developed can effectively identify metal-bound species by SNAP-LC peak 
picking algorithm, accurately identify the characteristic isotope pattern of the transition 
metals.  Together with a wide variety of fragmentation techniques, this workflow can be 
applied to more complex systems, e.g. metallodrug-intact protein interaction analysis, or 
even metallodrug-whole cell interaction analysis, in order to fully characterise the 
properties of these novel metallodrug complexes. 
  
Chapter 6 Conclusions 
243 
 
Chapter 3 Reduction of Disulfide Bonds in Proteins for Enhanced MS and MS/MS 
Capabilities 
 
Figure 6.2 Summarising graphic for Chapter 3 
 Chapter 3 focuses on alternative methods for disulfide bond reduction. 
Traditional reduction methods use chemical reducing reagents, such as dithiothreitol 
(DTT) to reduce disulfide bonds.  However, use of chemical-based reducing reagents 
often requires harsh reaction conditions, such as an excessive amount of concentrated 
reagents and specific pH adjustments.  Labile modifications, such as metallodrug 
binding can easily be lost/altered during the chemical reduction, results in misleading 
conclusions.  Therefore, the alternative reduction methods; electrochemical reduction 
and radical-induced reduction were investigated in this chapter. 
 The electrochemical reduction process was monitored using human lysozyme, 
bovine ribonuclease A and human insulin.  The reduction process was shown to be a 
sequential process and could be used to selectively reduced certain disulfide bond in 
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stages.  The reduced protein species were shown to be more effectively ionised during 
the electrospray ionisation (ESI) process and attained higher charge states than non-
reduced species.  It is believed that reduced species have more open protein structure 
with more sites exposed to charge carriers, such as protons.  The electrochemical 
voltage to reduce fully a disulfide-bonded protein was also found to be protein-
dependent, which can be measured using a statistical approach, especially with large 
intra-disulfide bonded proteins, where the change in mass is often minimal compared to 
the mass of the protein.  Insulin was used as a model inter-disulfide bonded protein, two 
separated polypeptide chains were observed upon reduction.  The ion abundance of the 
polypeptide chains was found to be the dominant peaks in the ESI-MS, overtaking the 
intact insulin species.  The reduced species were shown to undergo fragmentation more 
readily in subsequent MS/MS experiments.  An increase in cleavage coverage of over 7-
fold was observed with human lysozyme compared to the non-reduced species upon 
ECD MS/MS. 
 The performance of radical-induced reduction was monitored using human 
insulin as a model protein.  The two separated polypeptide chains were observed to 
increase in intensity with the irradiation time, suggesting the reduction process was 
occurring in the solution phase.  However, different to electrochemical reduction, the 
intact protein species remained the dominant species in the MS spectrum.  Limited 
fragmentation of intact insulin was achieved using collisionally activated dissociation 
tandem mass spectrometry (CAD MS/MS), cleavage coverage of only 39% was 
observed, while ECD MS/MS provided a coverage of 51%, an increase believed to be 
contributed by the disulfide bond preferentiality of ECD MS/MS.  Upon radical-induced 
reduction, a promising 79% cleavage coverage with ECD MS/MS of the chain B of 
insulin was observed. 
 Both alternative reduction methods have proved to be effective tools for top-
down analysis and can greatly assist protein identification and characterisation, which is 
a key research area in proteomics studies, especially those containing chemically 
sensitive modifications, such as metallodrugs.  These alternative reduction methods can 
be applied to the metallodrug-biomolecules system, to avoid the use of chemical 
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reducing reagents like DTT that could disrupt the labile metallodrug-modifications in 
the future to achieve a more comprehensive characterisation of these novel metal 
complexes.  
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Chapter 4 Organoiridium Photosensitisers Induce Specific Oxidative Attack on 
Proteins within Cancer Cells 
 
Figure 6.3 Summarising graphic for Chapter 4 (Reproduced from Zhang et. al. 
2017 with permission).1,2 
 Six iridium (III)-based photosensitisers were designed to release cytotoxic 
singlet oxygen when irradiated with visible blue light (463 nm).  The mechanisms of 
action of these novel photosensitisers on a model peptide, [Lys3]-Bombesin were studied 
using FT-ICR MS and ECD MS/MS.  Four of the six photosensitisers showed the ability 
to not only oxidise, but also chemically bind to the target peptide, which displayed the 
possibility of a dual mechanisms of action against target biomolecules.  A series of 
oxidation products were observed, and by employing ECD MS/MS, oxidation sites were 
found to be methionine, histidine, and tryptophan.  A specific form of tryptophan, 3-
hydroxykynurenine, was identified and provided solid evidence for the production of 
singlet oxygen.  Histidine was found to oxidise to 2-oxo-histidine, which is also a 
common oxidation product of histidine upon singlet oxygen oxidation. 
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 Iridium complex PZ6 showed no toxicity towards A549 3D multicellular tumour 
spheroids (MCTSs) in the dark, and no toxicity towards MRC-5 MCTSs in either the 
dark or upon irradiation.  However, the IC50  values for PZ6 towards A549 spheroids 
upon 1P and 2P irradiation were extremely low, 1.0 µM and 0.23 µM respectively, 
showing that PZ6 is a potent anticancer metallodrug with high selectivity to cancerous 
cells. 
 The effect of PZ6 on A549 lung cancer cells was studied by nLC-FT-ICR CAD 
MS/MS and the proteins were quantified using a label-free approach.  Specific histidine 
residues in the proteins heat shock protein 70 kDa and aldose reductase were found to be 
oxidised and potentially disrupt their cellular functions in cancer cells.  The combination 
of oxidative stress induced by photoactivation of PZ6 together with the malfunction of 
mitochondria in cancer cells leads to the increased use of glucose to generate energy and 
is consistent with the observation of the increase in quantity of the nine unique enzymes 
involved in the glycolytic pathway. 
 Most of the protein identified were the abundant proteins in cells, that could be 
due to the single-dimensional liquid chromatography experimental setup, causing co-
elution of species.  Ions with lower intensities were supressed by the ions with higher 
intensities.  The low intensity species often could not be identified because of the lack of 
fragmentation/effective fragmentation of these species.  To improve with the 
experimental setup, a multi-dimensional liquid chromatography system could be used, 
with the extra dimensional of separation (orthogonal to the first dimension, e.g. reverse 
phase column followed by strong cation exchange column), the co-eluting species have 
a higher probability to be separated and effectively fragmented. 
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Chapter 5 Metallodrug-Proteomics Pathway Analysis using nLC-FT-ICR MS 
 
Figure 6.4 Summarising graphic for Chapter 5 
 Quantitative nLC-FT-ICR MS/MS was employed to study the proteomic effects 
of an osmium-based anticancer drug (FY12) against A2780 ovarian cancer cells and an 
iridium-based antimicrobial complex (CF281) against Staphylococcus aureus (S. 
aureus). 
 nLC-FT-ICR CAD MS/MS was used to conduct pathway analysis of FY12 on 
A2780 ovarian cancer cells.  The proteins were identified by matching the fragmentation 
pattern against the Mascot database and quantification of the identified proteins was 
measured using a label-free approach with a lysozyme tryptic digested peptide 
(FESNFNTQATNR, 714.8365 m/z).  FY12 has shown significant effects on multiple 
metabolic pathways and different cellular functions. Nine unique proteins along the 
glycolysis pathway showed a significant change in quantity and pyruvate was 
selectively accumulated for extra energy production. In addition, quantities of 14-3-3 
isoforms were also perturbed and believed to be the primary MoA against the ovarian 
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cancer cells.  Different stress responses, including the up-regulation of heat shock 
proteins and the down-regulation of amino acid synthesis which are believed to be a 
secondary response from the cancer cells, were observed. 
 The MoA of the iridium metalloantibiotic CF281 in S. aureus was investigated 
using a similar methodology and quantified with another lysozyme tryptic digested 
peptide (NTDGSTDYGILQINSR, 877.4212 m/z).  81 unique proteins were detected 
three times or more out of the replicates, and 26 of those were shown to have significant 
up-regulated quantity change with p value less than 0.05 in a two-tailed t-test.  The 
bacterial cells were shown to be in a very stressful chemical environment when they 
were treated with CF281 and triggered a series of secondary responses, including extra 
protein/DNA biosynthesis and energy production.  CF281 also found to be capable of 
inducing oxidative stress inside the bacteria and trigger cell death, different to the 
traditional treatments for S. aureus, which focus on the disruption of cell wall formation 
by inhibiting the formation of peptidoglycan cross linkages that provide rigidity and 
strength for the cell wall. 
 FT-ICR MS has proved to be a very versatile analytical technique to study the 
interactions between biomolecules and metallodrugs in this thesis.  The ultra-high 
resolution and mass accuracy of FT-ICR MS allow unambiguous assignments in mass 
spectra and provide important information about the mechanisms of action of the 
metallodrugs.  FT-ICR MS together with hyphenated techniques allow a more detailed 
analysis in complex systems, such as cell lysate.  SNAP-LC has also been shown to pick 
out metal-modified species effectively and precisely in mass spectra, and localisation of 
the metallodrug can be achieved via various fragmentation techniques.  Constant 
improvement in MS techniques and instrumentations will help with the speed of data 
acquisition and accuracy of acquired data.  A truly data independent acquisition method, 
two-dimensional mass spectrometry (2DMS) is currently under rapid development and 
allow full characterisation of metallodrug-biomolecules interaction.  Analytical 
procedures mentioned in the thesis will hopefully become more automatic and high 
throughput in the future, which can help inform better drug designs, elucidate their 
mechanisms of actions and application to different types of life-threatening diseases. 
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